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The development of better analgesic drugs for the treatment of chronic
inflammatory conditions such as rheumatoid arthritis (RA) would be greatly
facilitated by extending knowledge of the underlying mechanisms involved in
generating pain in diseased tissue and developing new models for testing candidate
compounds. In this thesis behavioural and electrophysiological techniques in both
the rat and the mouse were used to determine the effect of a number of mediators
and/or pharmacological receptors reported to be involved in chronic inflammation
and nociception. The specific aims of the thesis centred on testing the following
hypotheses: a) The neuropeptide somatostatin inhibits sensory nerve function in both
normal and arthritic knee joints, b) the endocannabinoid anandamide activates
peripheral nociceptors via its reported action at the vanilloid receptor (VRi), c)
chronic unilateral inflammation of the knee joint can be induced in mice using
Freund's Complete Adjuvant (FCA), and d) the purinoceptor P2X7 plays a role in the
induction of inflammation and hyperalgesia associated with experimental arthritis in
mice. An additional aim of the thesis was in vivo neural recording from nociceptors
innervating the mouse knee joint with a view to examining transgenic mice in future
studies.
Somatostatin or its long lasting analogue octreotide, and anandamide were
administered by close intra-arterial injection to both normal and FCA-induced
arthritic rat knee joints and their ability to inhibit and/or excite articular nociceptors
was recorded under pentobarbitone anaesthesia. Furthermore, the ability of these
agents to modulate afferent discharge caused by known algogens (capsaicin (VR|
receptor), bradykinin (Bi/B2 receptor), and a,|3-methylene adenosine 5' triphospate
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(aPmeATP; P2X1/P2X3 receptor)) was also investigated. Neither somatostatin nor
octreotide directly activated peripheral nociceptors in normal or arthritic rat knee
joints. Furthermore, neither compound inhibited either basal firing or discharge
evoked by capsaicin, bradykinin or aPmeATP. Anandamide caused a rapid onset,
short duration increase in afferent discharge in both normal and arthritic rat knee
joints. This was via the VRi receptor because the response was blocked by the VRi
antagonist capsazepine.
Chronic unilateral inflammation induced by intra-articular injection of FCA
was characterised in two mouse strains, DBA/1 and C57 Black 6 (C57BL6). The
developed model was used to examine the role of the purinoceptor P2X7 (ATP
nucleotide receptor) in the induction of experimental arthritis by using a transgenic
mouse line lacking the P2X7 receptor. To enable the use of transgenic mice for
studying chemically or mechanically evoked responses in peripheral nociception, a
technique was developed for recording afferent discharge from the saphenous nerve
of the anaesthetised mouse in vivo.
Behavioural studies in mice showed that repeated intra-articular injections of
FCA produced a persistent and local inflammation in the knee joint that was
associated with hyperalgesia to mildly noxious pressure. Histology of the joints
showed changes characteristic of a mild, unilateral arthritis present in all treated
animals. The inflammation induced was consistent between animals and between
both DBA/1 and C57BL6 strains. Validation of the model was shown by the
effective attenuation of the induced inflammation by treatment with prednisolone and
indomethacin. The P2X7 receptor appeared not to play a role in the inflammation or
associated hyperalgesia produced in the mouse model of arthritis, as there was no
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difference between knock out mice and wild-type controls in the arthritis and
hyperalgesia induced by FCA. Finally, for the first time it has been possible to
record chemically and mechanically evoked responses from nociceptors innervating
normal and arthritic mouse knee joints under urethane anaesthesia.
In summary, in relation to the hypotheses being tested, the results showed
that: a) the reported anti-nociceptive effect of somatostatin is not mediated by action
on peripheral nociceptors or the inhibition of tested algogens, b) anandamide is able
to directly activate sensory afferents via VRi receptors, c) chronic, unilateral arthritis
can be induced in mice by repeated intra-articular injections of FCA, and d) P2X7
purinoceptors do not play a role in the induction of inflammation and hyperalgesia
associated with the FCA model of unilateral arthritis. Innovation in this thesis
included a novel model of murine unilateral arthritis and the development of a new
technique for direct measurement of evoked discharge from peripheral nociceptors
innervating the mouse knee joint. These advances in knowledge provide information































































m (prefix) milli (10~3)
MAN medial articular nerve
Min minute
MmHg milimeters of mercury
Mol mole
n number





PBS phosphate buffered saline
PG prostaglandin
PLC phospholipase C
PNS peripheral nervous system
S second
sew Streptococcal cell walls
SEM standard error of the mean
TG trigeminal ganglion
TX thromboxane
v/v volume per volume
w/v weight per volume
Most abbreviations, other than commonly used expressions, are also defined at the
first point of occurrence in the text.
vii
Associated Publications
GAULDIE, S.D., MCQUEEN, D.S., PERTWEE, R. & CHESSELL, LP. (2001).
Anandamide activates peripheral nociceptors in normal and arthritic
rat knee joints. British Journal of Pharmacology, 132, 617-21.
GAULDIE, S.D., MCQUEEN, D.S., & CHESSELL, I.P. (2002). Unilateral
chronic arthritis induced in the mouse knee joint using Freund's








1. General Introduction 16
Pain and nociception 17
Discovery and classification of nociceptors 18




Sensitisation of nociceptors 22
Arthritis 24
Knee joint articular afferents 26
Anatomy of articular afferents 27
Inflammatory mediators in nociception 32
Directly acting algogenic mediators 32
Indirectly acting algogenic mediators 38
Aims of the studies 41
2. Methods 43
2.1 Models of experimental arthritis 44
Rat model of unilateral arthritis 44
Induction of unilateral arthritis 44
Assessment of arthritis 45
ix
Murine model of unilateral arthritis 47
2.2 In vivo recording from afferent nerves 47
Recording from afferent nerves in the rat knee joint 47
Anaesthesia and surgical procedures 47
Dissection of the medial articular nerve 48
Recording from the medial articular nerve 48
Recording from afferent nerves in the mouse knee joint 49









Tables and Figures 55




Afferent nerve recording in vivo 61
3.3 Results 62
Afferent nerve recordings in vivo 62
x
Characterisation of afferent nerve fibres 62
Spontaneous discharge in nociceptors innervating normal and arthritic rat
knee joints 63
Evoked responses to known algogens capsaicin, bradykinin and aPmeATP 64
3.4 Discussion 67
Tables and Figures 75
4. Effect of somatostatin on knee joint nociceptors 83
4.1 Introduction 84
4.2 Methods 88
Afferent nerve recording in vivo 88
4.3 Results 88
Characterisation of afferent nerve fibres 88
Neither octreotide nor somatostain-14 excited peripheral nociceptors 89
Effect of octreotide on spontaneous afferent discharge from normal and arthritic
knee joints 90
Effect of octreotide on responses from knee joint afferents evoked by capsaicin,
bradykinin and aPmeATP 91
4.4 Discussion 93
Tables and Figures 97
5. Effect of anandamide on knee joint nociceptors 101
5.1 Introduction 102
Anandamide as a neuromodulator in nociception 103
5.2 Methods 105
Afferent Nerve Recording In Vivo 105
xi
5.3 Results 105
Characterisation of afferent nerve fibres 105
Anandamide-evoked activation of knee joint afferents 106
Proportion of afferents activated by anandamide 106
Dose-related increase in the nociceptor action potential discharge evoked by
anandamide 107
Features of the anandamide-evoked response 107
Effect of anandamide on excitatory responses evoked by ATP, bradykinin and
capsaicin 109
Comparison of the capsaicin and anandamide-evoked responses in normal knee
joints 110
Response to anandamide is abolished by the VRi antagonist, capsazepine Ill
5.4 Discussion 112
Tables and Figures 115
6. FCA-induced unilateral arthritis in the mouse knee joint 125
6.1 Introduction 126
Murine models of arthritis 127
Transgenic mouse strains and arthritis 128
Aims of the study 130
6.2 Methods 131
Induction of unilateral arthritis 131




Hyperalgesia/weight bearing allodynia 132
Drug treatment 133
Histopathology 133
Electrophysiological recording from the saphenous nerve 135
6.3 Results 136
Induction of unilateral arthritis in mice 136
Sub-cutaneous injection of FCA around the mouse ankle joint 136
Sub-cutaneous injection of FCA around the mouse knee joint 137
Antigen induced arthritis with methylated bovine serum albumin 138
Unilateral arthritis with repeated injections of FCA in DBA/1 mice 139
Unilateral arthritis with repeated injections of FCA in C57BL6 mice 143
Comparison of unilateral arthritis development in different strains of mice.... 148
Knee joint diameter 148
Hyperalgesia/allodynia 148
Histopathology 149
Effect of the steroid prednisolone on established FCA-induced unilateral
arthritis DBA/1 mice 150




Effect of NSAID indomethacin on established FCA-induced unilateral arthritis
in C57BL6 mice 154





Induction of FCA unilateral arthritis in P2X7 knock out mice 159
Background 159




Recording from the saphenous nerve in normal and arthritic knee joints of
C57BL6 mice 164
Basal discharge of nociceptors innervating normal and arthritic knee joints
165
Dose-related increase in the action potential discharge evoked by capsaicin
and bradykinin 166
Features of the capsaicin and bradykinin evoked responses 166
6.4 Discussion 167
Tables and Figures 180
7. General Discussion and Future Directions 227
7.1 Properites of nociceptors innervating normal and arthirtic rat knee joint 228
Future directions 231
7.2 Modulation of nociceptors by inflammatory mediators 232
Future directions 234
xiv
7.3 Murine unilateral arthritis and electrophysiological recording from afferents
innervating the mouse knee joint 235
FCA-induced unilateral arthritis in the mouse knee joint 235
Future directions 236
Electrophysiological recording from mouse knee joint afferents in vivo 237
Future directions 237
7.4 General conclusions 238
References 240
Index of Figures and Tables 261
Appendix I - Drugs and Solutions 266




Arthritic conditions, including rheumatoid and osteoarthritis (RA and OA
respectively) affect a large number of people worldwide, with over 8 million people
in the UK suffering from arthritis, including up to 3 million who are severely
disabled by the condition (Arthritis-Research-Foundation, 2002). "Arthritis" simply
means an inflammation of the joint and the primary clinical feature of the disease is
chronic inflammation that is capable of affecting all joints in the body, but most
commonly affects the toes, ankles, knees, shoulders, wrists, and knuckles (Kelley et
al., 1997). Inflammation within the joint causes the accumulation of inflammatory
cells in the synovial space, the release of lysosomal enzymes resulting in bone and
cartilage erosion, oedema and deformation, and bone formation that can fuse the
joint together and impair normal mobility. The chief complaint of patients
presenting with an arthritic condition is severe chronic pain. Current therapies for
arthritis involve reducing the chronic inflammation in the hopes of decreasing the
associated pain.
PAIN AND NOCICEPTION
One of the vital roles of the sensory (afferent) nervous system is to provide
information about our external surroundings and the state of various internal tissues
for the purpose of homeostasis. This includes information about things in our
surroundings that have the potential to cause injury. The sensation of pain is
emotive, and as such strongly reinforces our reaction to painful stimuli. This
contributes to our ability to avoid the same or related stimuli when we come across
them in the future, thereby preventing injury. Additionally, if an injury is sustained
the perception of pain causes a reflex protective action that prevents further injury.
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Pain, although an important consideration in conditions such as RA, especially for
those who suffer from it, is merely the subjective perception of sensory input arising
from a noxious stimulus.
DISCOVERY AND CLASSIFICATION OF NOCICEPTORS
Psychophysicists such as (Blix, 1884) and (von Frey, 1894; von Frey, 1922)
provided the first evidence that pain was a sense distinct from touch and was
mediated by specialised sensory organs. Von Frey was able to describe different
sensitivities to stimuli such as touch, pain, warmth and cold at precise points on the
skin. Further more he was able to show that at spots producing pain the area was
exclusively innervated by unspecialised or "free" endings - so called because the
afferents do not terminate at a specific sensory structure or endplate. These "free"
endings were termed "noci-receptors" by Sherrington and it was proposed that they
existed to detect external stimuli that was potentially harmful (Sherrington, 1906).
Later, work using electrophysiological recording techniques from sensory
nerves innervating peripheral tissues, showed that there were several kinds of fibres
responsible for the transmission of sensory information (Clarke et al., 1935; Gasser
& Erlanger, 1927). The classification of these afferent fibres divides the afferents
according to the morphology and conduction velocity of the axon and fall into three
main categories (Erlanger & Gasser, 1937): C-fibres, are small diameter,
unmyelinated fibres with conduction velocities of <2 ms"1; A5-fibres, are myelinated
fibres of a slightly larger diameter and conduction velocities of between 3 and 30 ms"
'; and Ap-fibres that are large diameter myelinated afferents with conduction
velocities of 35-100 ms"1. These studies also proposed that innocuous stimuli was
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transmitted by the larger Ap fibres and painful sensation from noxious stimuli was
transmitted by thinly or non-myelinated A8 and C-fibres (Erlanger & Gasser, 1937;
Heinbecker et ah, 1932; Zotterman, 1933). However, the hypothesis that A5 and C-
fibres played a role in the transmission of nociceptive signals from peripheral tissue
was not shown conclusively until the late 1960s by Perl and colleagues.
Using electrophysiological recordings from thinly myelinated AS fibres
innervating cat skin it was found that a small proportion had response thresholds to
thermal and mechanical stimuli many times higher than that seen in other AS fibres.
These fibres, termed nociceptors, only responded to noxious thermal stimulation or
intense mechanical stimulation through pinching of the skin (Burgess & Perl, 1967).
Furthermore, in studies carried out on thin, unmyelinated C-fibres innervating the
hind limb of the cat approximately half the afferents responded only to innocuous
mechanical stimulation, with the rest responding only when the stimuli imposed were
noxious and were therefore deemed nociceptors. The 50% of C-fibre nociceptors
could be further divided with 80% responding to intense mechanical stimulation,
noxious heat, and chemical irritants (these were named polymodal nociceptors), and
20% responding to high threshold mechanical stimulation alone (termed
mechanonociceptors) (Heppelmann, 1997; Heppelmann et al., 1988; Hildebrand et
ah, 1991; Bessou & Perl, 1969). Polymodal nociceptors, because they make up the
largest proportion of nociceptors and possess many unique properties including a
high degree of plasticity, have been the subject of the most research.
There are two important peripheral mechanisms by which nociceptors can be
activated, excitation and sensitisation. Excitation is the induction or increase of
afferent neural discharge following stimulation (e.g. electrical, mechanical, thermal,
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or chemical stimuli). Sensitisation or hyperalgesia produces a decrease in the
threshold required to activate the nociceptor and an increase in the response to
stimulation.
EXCITATION OF NOCICEPTORS
Activation of nociceptors results from depolarisation of peripheral terminals
through activation of specific receptors. These receptors mediate the membrane
permeability to a number of ionic species such as sodium (Na+), calcium (Ca2+), and
potassium (K+). An influx of Na+ or Ca2+ into the cell in response to receptor
activation cause a depolarisation of the cell memebrane and triggers an action
potential that is transferred to the CNS where it can be perceived as pain (Belmonte
& Cervero, 1996).
Mechanical excitation
Afferents that respond to low intensity mechanical stimulation
(mechanoreceptors) in the joint have conduction velocities in the A(3 range and
respond to normal movements. They have proprioceptive functions to determine the
position of the joint in space as well as vibration within the structure (Schaible &
Schmidt, 1988). Movements that are beyond the normal range, or applied force
above a certain threshold are perceived as painful and these stimuli activate a
separate population of A8 fibres known as mechanonociceptors. Very little is known
about the specific mechanisms involved in the depolarisation of the nociceptor due to
high-intensity mechanical stimulation. Work in non-mammalian systems such as the
mechanosensitive channel of large conductance (MscL) in Eschericia coli, a channel
that opens in response to a deformation of the lipid bi-layer (reviewed in Sukharev et
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al., 1997), or the genetic manipulation of the nematode Caenorhabditis elegans,
possessing a mechanosensitive sodium channel that can be blocked by amiloride
(reviewed in Tavernarakis & Driscoll, 1997), point to the possibility of a specific
mechanosensitive channel present on peripheral nociceptors, however to date this
remains unknown.
Thermal excitation
There are two types of receptors in the skin that will respond to mild changes
in temperature. Cold receptors have conduction velocities in the AS to C-fibre range
and discharge spontaneously at normal skin temperatures; discharge increases with
cooling by as little as 0.5°C (Darian-Smith et al., 1973). As with mechanoreceptors
under normal conditions, these afferents appear to be insensitive to chemical
stimulation, including capsaicin (Szolcsanyi et al., 1988). Warm receptors conduct
almost exclusively in the C-fibre range and are also spontaneously active at normal
skin temperature (~30°C) and show linear increase in discharge as skin temperature
increases, up to 46°C. Outside these constraints the afferents become silent (Darian-
Smith & Johnson, 1977a; Darian-Smith & Johnson, 1977b).
Although mechanoreceptors can be excited by normally innocuous stimuli
during injury or inflammation, cold and warm receptors do not appear to become
sensitised. During inflammation, an increase in sensitivity to temperature is not the
result of a recruitment of normally silent afferents but is instead mediated by
alterations to nociceptive afferents in which their threshold to activation becomes
lower (Meyer et al., 1996).
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Temperatures outside the normal physiological distribution are perceived as
painful and these signals are transmitted by thermonociceptors. Very little is known
about the mechanisms for the transduction of noxious cold stimuli, however in recent
years the mechanism by which high temperatures stimulate nociceptors has begun to
be explained. Capsaicin (8-methyl-N-vanillyl-6-noneamide) is present in chilli
peppers and is the compound responsible for making them taste hot. With the
discovery and cloning of the first vanilloid receptor (VRi) a channel has been found
that is gated by capsaicin and which is also sensitive to high temperature - that
greater than 42 °C (Caterina et al., 1997). A second channel, also found to be gated
by noxious heat, the vanilloid receptor like channel (VRL-1) was cloned soon after.
This channel, although from the same receptor family, is not sensitive to capsaicin
and is not activated until temperatures exceed 53°C (Caterina et al., 1999). For a
detailed review of the properties of the vanilloid receptors see Szallasi & Blumberg
(1999).
Chemical excitation
Peripheral nociceptors are capable of being activated by some chemical
irritants acting through specific receptors to produce an acute painful response.
However, during inflammation, a large number of chemical mediators are released
that are able to directly activate, or in some cases, sensitise peripheral nociceptors
producing a long lasting, chronic pain. The mechanisms for chemical activation
and/or sensitisation of nociceptors will be examined in more detail below.
SENSITISATION OF NOCICEPTORS
In order to study changes that occur in nociceptor sensitivity it is easiest to
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examine the changes in afferents innervating the skin, in response to damage done to
tissue through injury or inflammation induced by noxious heat, local electrical
stimulation or chemical irritants. There are two distinct zones that surround the site
of injury in which the sensitivity of nociceptive afferents is altered. The first zone
immediately surrounds the site of injury or inflammation. Sensitisation in this area is
known as primary hyperalgesia. Hyperalgesia is defined as a state of increased pain
sensation where a normally noxious stimulus is perceived as being more painful, and
is characterised by spontaneous pain and an increased sensitivity to thermal or
mechanical (and in the joint, chemical) stimuli (Hardy et al., 1952). The second
zone arises in the surrounding area and shows an increased sensitivity to mechanical
but not thermal stimulation. The increased sensitivity means that normally non-
noxious stimuli are now capable of producing pain - known as allodynia (Meyer et
al., 1996).
Increased sensitivity is not limited to the skin as similar responses are seen in
other nociceptors, including those that innervate the rat knee joint (Heppelmann &
Pawlak, 1997a; Heppelmann & Pawlak, 1997b; Kelly et al., 1995a; Mapp et al.,
1996). The basis of this afferent sensitisation arises from the release of a number of
pro-nociceptive mediators during inflammation that are capable of lowering the
activation threshold of peripheral nociceptors.
Sensitisation is not restricted to the periphery. Neurons in the dorsal horn
that receive projections from the DRG can also be sensitised producing a "wind-up"
effect, which acts to increase the gain of the afferent inputs (Kress & Reeh, 1996).
However, this thesis will focus on peripheral afferents and in particular the terminals
of afferent nociceptors under inflammatory conditions.
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ARTHRITIS
Arthritis can be divided according to primary pathology into two major
categories, osteoarthritis and rheumatoid arthritis. Osteoarthritis (OA) is a slowly
progressing degenerative disease that affects the major synovial joints primarily, but
not exclusively, through non-immune processes. The condition comprises a number
of vague clinical syndromes and is primarily defined by its associated symptoms,
which include joint enlargement, deformity, stiffness, reduced function and a general
decrease in the quality of life due to chronic pain. OA is typically associated with a
particular joint and is usually the result of "wear and tear". Joint instability as a
result of a specific injury or a series of small insults can lead to a local inflammation
in the joint. The inflammation is self-perpetuating and can lead to further joint
destruction including the erosion of articular cartilage, and bone erosion and
formation. The chronic inflammation and oedema in the synovial space can lead to
severe pain through stimulation of peripheral nociceptors present in and around the
joint (Schaible & Schmidt, 1996).
Rheumatoid arthritis (RA) is a systemic condition of unknown aetiology
whose primary clinical feature is a chronic inflammation present in multiple joints
(polyarthritis). In synovial joints the inflammation is symmetrical with joints on both
the left and the right sides of the body being affected. One of the hallmarks ofRA is
the progressive destruction of the articular cartilage and erosion of bone due to the
chronic inflammation present in the joint (Figure 1.1). RA is considered to be an
autoimmune condition with the possibility of a number of different primary stimuli.
One particular stimulus is the loss of tolerance to self-antigens existing on articular




























Figure 1.1 - Comparison of normal and arthritic knee joints
A schematic representation of A) normal and B) arthritic (rheumatoid) knee
joint. The normal joint shows a thin synovial lining and smooth surfaces on
the bone and overlying cartilage. The arthritic joint displays thickening of the
synovial membrane (hypertrophy) due to invasion of inflammatory cells,
which also infiltrate the joint space and surrounding tissues, including
ligaments, tendons, and muscle (peri-articular inflammation). A combination
of synoviocytes and polymorphonuclear leukocytes (PMN) overgrow the joint
surface (pannus) and erode the cartilage and bone through the release of
metalloproteinases and components of the complement system. Adapted
from (Arthritis-Research-Foundation, 2002)
causing a localised and chronic inflammatory condition in the synovial space (Kelley
et al., 1997). In a normal joint the synovial lining consists of a very thin membrane
only a couple of cells thick, isolating the largely acellular joint space. During arthritis
the synovial inflammation, or synovitis, involves a very significant thickening of the
synovial membrane as well as the invasion of inflammatory cells (consisting mostly
of polymorphonuclear (PMN) leukocytes) into the synovial membrane and the joint
space. One of the characteristic features ofRA is the formation of pannus. Pannus is
the tissue formed at the boundary of the cartilage and the synovial lining and consists
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of both synoviocytes and inflammatory cells. The pannus overgrows the healthy
cartilage starting from the border with the synovium. Within the pannus tissue a
number of mediators are released including neuropeptides and cytokines that
perpetuate the inflammation, and oxygen radicals, and lysosomal and
metalloproteinase enzymes, that cause cartilage destruction and bone erosion (Kelley
et al., 1997). Standard treatments for chronic inflammatory conditions, such as RA,
still focus on reducing inflammation, in an attempt to treat the associated pain.
In order to examine RA in an experimental setting a number of animal
models of the condition have been developed. Although no one model provides
perfect mimicry of the clinical condition they can provide valuable insight into the
disease process. In this thesis two models of induced experimental arthritis in the
knee joint, one in the rat (Chapter 3) and one in mouse (Chapter 6), will be discussed
and used. The knee joint provides a well-characterised environment in which to
study the responses of peripheral nociceptors under normal conditions, and during
chronic joint inflammation.
KNEE JOINT ARTICULAR AFFERENTS
There is an extensive literature on sensory nerve innervation in a wide variety
of tissues throughout the body including skin (Bessou & Perl, 1969; Burgess & Perl,
1967; Torebjork & Hallin, 1974), joints (Heppelmann, 1997; Mapp, 1995; Schaible
& Schmidt, 1983b; Schepelmann et al., 1992), cornea (Belmonte et al., 1991;
Belmonte & Giraldez, 1981; Giraldez et al., 1979), skeletal muscle (Mense & Meyer,
1985), airways (Fox et al., 1993), viscera (Cervero, 1994), and teeth (Greenwood et
al., 1972). Only knee joint sensory nerves will be described due to their relevance to
the experimental work undertaken. Furthermore, although the knee joint is
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innervated by both myelinated and unmyelinated afferents as well as unmyelinated
sympathetic efferents (Freeman & Wyke, 1967; Polacek, 1966; Skoglund, 1956) it is
the articular afferents and in particular articular nociceptors that are the focus of this
thesis.
Anatomy of articular afferents
Early anatomical looking at the innervation of the knee joint were done in the
knee joint of the cat (Freeman & Wyke, 1967; Gardner, 1944; Skoglund, 1956). To
date the cat knee joint has been the most extensively examined, however, studies in
other species including rats (Hildebrand et ah, 1991) and humans (Biedert et al.,
1992; Halata et ah, 1985; Wojtys et ah, 1990) have shown that the pattern of
innervation, types of fibres, and ratio of myelinated to unmyelinated fibres are
broadly similar between species with differences found only in the absolute number
of fibres innervating the joint, which is dependent on the size of the animal.
The articular branches that exit the saphenous nerve on the medial aspect of
the limb supply the knee joint - see Figure 1.2. The innervation arises primarily
from two articular nerves, the posterior articular nerve (PAN) and the medial
articular nerve (MAN). In this thesis, electrical recordings of sensory nerve activity
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The MAN branches from the saphenous nerve and traverses the antero-medial aspect
of the thigh and runs alongside the descending genicular artery and vein. At the
medial aspect of the knee joint the nerve divides into two branches and spreads out to
innervate the medial and antero-medial areas of the fibrous joint capsule including
the articular ligaments, menisci and adjacent periosteum, and adipose tissue
(Freeman & Wyke, 1967; Heppelmann et al., 1990; Johansson et al., 1991; Polacek,
1966). These studies, using both light and electron microscopy, were unable to find
sensory innervation in the synovium. However, recent studies have shown that the
release of inflammatory mediators including substance-P, somatostatin, and
calcitonin gene related peptide (CGRP) in the synovium is from afferent terminals
leading to the supposition that terminals are present (Ferrell & Russell, 1985; Imai et
al, 1997).
Much of the literature on knee joint afferents utilises a classification system
dividing the fibres into four types (Group I-IV) based on their morphology (for
review see Schaible & Grubb (1993). However, to avoid confusion the Erlanger and
Gasser classification system (Ap fibres, A5 fibres, and C fibres) will be used for the
remainder of this thesis.
The MAN of the cat contains approximately 630 afferent fibres and the
majority of these fibres are AS fibres and C-fibres with only approximately 20% of
the fibres being classified as AP fibres (Heppelmann, 1997; Heppelmann et al., 1988;
Hildebrand et al., 1991; Langford & Schmidt, 1983). Although a small proportion of
afferent fibres innervating the knee joint respond to low threshold mechanical
stimulation (AS 35%, C 10%) the vast majority of C-fibres and approximately 30%
of AS fibres are only excited by noxious movements of the joint or are insensitive to
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mechanical stimulation under normal conditions (Schaible & Grubb, 1993).
From their peripheral terminals, articular afferents extend long axons up to
the cell bodies in the dorsal root ganglia (DRG). The size of the cell body of
neurons within the DRG is correlated with the type of afferent fibre, with C-fibres
having small diameter cell bodies (0.4-2.0 pm), A5 fibres having a medium diameter
somas (2-6 pm), and A(3 fibres having the largest diameter cell bodies (>10 pm)
(Millan, 1999). Since the majority of cutaneous and articular afferents are C-fibre
polymodal nociceptors, it is assumed that the properties of small diameter neurons
relates to nociceptors.
In addition to sending axons to the periphery, articular nociceptors project
axons from the DRG into the dorsal horn of the spinal cord. Using retrograde
transport of horseradish peroxidase (HRP) as a tracer it has been shown in the cat
knee joint the afferents of the MAN enter the spinal cord via L5 and L6 (Craig et al.,
1988; Skoglund, 1956). Once in the dorsal horn these afferents have projection
fields that are limited to the cap of laminae I, laminae V-VI, and the dorsal part of
laminae VII (Craig et al., 1988).
The anatomy of articular nociceptors is such that compounds that modulate
their function can act a number of different sites both centrally, in the dorsal horn,
and peripherally, in the DRG and at peripheral terminals. The focus of this thesis is
the peripheral terminals of articular nociceptors. The terminal is the point at which a
nociceptive signal is initiated and as such interference at this point would eliminate
the central processing of the input and the perception of pain. Furthermore, the wide
array of pharmacological targets at the peripheral terminal allows for many different
therapeutic approaches to be used (Figure 1.3). Finally, by focusing on the periphery
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Figure 1.3 - Mediators activating peripheral nociceptors
Simplified scheme of the local mediators, and potential therapeutic targets,
that may act on peripheral nociceptors at the A) dorsal horn or B) nerve
terminal under conditions of tissue damage or inflammation. Adapted from
(Lundberg, 1996).
it reduces the possibility of unwanted side effects cause by central actions.
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INFLAMMATORY MEDIATORS IN NOCICEPTION
A normal joint is painful only when exposed to extreme external stimuli such
as over-rotation or a strong external pressure. In the diseased state nociceptive
afferents innervating the joint become sensitised and the joint can be painful during
normal movement, or even while resting. The normal responses of nociceptors are
altered during chronic inflammation by the release of a large number of mediators
that originate from neural and non-neural sources. Neural sources involve the release
of substances from the peripheral terminals of both postganglionic sympathetic
efferents and sensory afferents. Additionally, as with all inflammations, a large
number of immune cells are recruited to the site such as macrophages,
polymorphonuclear leukocytes, and mast cells, all of which release mediators into
the surrounding tissue.
Regardless of whether substances released during inflammation originate
from the nervous or immune systems there are two mechanisms through which
mediators can affect peripheral nociceptor function, directly on the sensory nerve
terminal to excite it, or indirectly by triggering the release of another algogenic
mediators and/or sensitising the afferent to activation by another stimulus.
Directly acting algogenic mediators
Algogenic chemicals that directly activate nociceptors do so by activating
specific receptors on the afferent terminals. Some compounds such as capsaicin, and
adenosine 5' triphosphate (ATP) produce a rapid depolarisation of the nerve by
activating specific ligand-gated ion channel linked receptors causing a rapid influx of
ionic species. Other compounds bind to receptors that are linked to guanyl-
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nucleotide-binding proteins (G-proteins) that cause depolarisation via intra-cellular
second messenger systems. The algogens bradykinin, ATP, and capsaicin are of
particular relevance to this thesis and as such will be discussed in detail below.
Bradykinin (BK)
Tissue damage, inflammation, and an acidic environment will trigger the
activation of a group of proteolytic enzymes, one present in the plasma, the other
widely distributed in a number of different tissues, known as kallikreins, that are
responsible for the production of the nonapeptide bradykinin (BK: Arg-Pro-Pro-
Gly-Phe-Ser-Pro-Phe-Arg) from its precursor (Marceau, 1995). Bradykinin, in
addition to its role in mediating vascular permeability, has long been shown to be a
potent activator of peripheral nociceptors (Keele & Armstrong, 1964). The effects of
bradykinin are mediated through two G-protein coupled receptors, namely
bradykinin receptor B1 and B2. The use of specific receptor antagonists has
established that the B2 receptor is constitutively expressed in both the DRG
(Steranka et al., 1988) and peripheral terminals (Kelly et al., 1995a). The bradykinin
B2 receptor plays a more critical role in acute inflammation - including inducing
oedema and pain, whereas the inducible B1 receptor is up-regulated during
conditions of persistent inflammation and is likely to play a role in chronic pain
(Hall, 1997).
Bradykinin is released in response to the pro-inflammatory cytokines IL-1(3
and TNF-a (Dray & Perkins, 1993; Dray & Urban, 1996) and it acts both as a pro¬
inflammatory mediator and an algogen. Injection of bradykinin induces
inflammation in both animals and humans by acting at the B2 receptor (Marceau et
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al., 1983), and circulating levels of bradykinin have been shown to be 3-fold higher
in patients with RA (Hargreaves et al., 1988). In addition, bradykinin is able to
activate C and AS nociceptors and can induce pain in humans when applied to blister
bases where it was shown to be one of the most potent algesics known (Whalley et
al., 1987). Bradykinin activates peripheral nociceptors innervating the knee (Kanaka
et al., 1985; Kelly, 1998; Kelly et al., 1995a) and the ankle joint in the rat (Asghar et
al., 1997). Furthermore, a specific B2 receptor antagonist blocks the hyperalgesia
associated with inflammation (Perkins et al., 1993; Perkins et al., 1995) and
transgenic mice lacking the B2 receptor showed no response to an intra-plantar
injection of carrageenan (Rupniak et al., 1997) demonstrating a crucial role for
bradykinin in peripheral nociceptor sensitisation.
Adenosine 5 '-triphosphate
Adenosine 5'-triphosphate (ATP; Figure 1.4) is a ubiquitous cytoplasmic
constiuetent and is present at high levels when released from damaged cells at an
injured on inflamed site, as is confirmed by the increased concentration of ATP in
the synovial fluid of patients with rheumatoid arthritis (Park et al., 1996; Ryan et al.,
1996). Since ATP was able to evoke pain when applied to blister bases it was
proposed that the nucleotide could act as a neuronal activator and play an important
role in pain signalling (Bleehen et al., 1976; Bleehen & Keele, 1977). For
extracellular ATP to behave as an activator of peripheral nociceptors it needs to act
directly and have a mechanism for breakdown or reuptake. As there exists a well-
described mechanism for the breakdown of ATP to adenosine via nucleotidases
present in almost every tissue (Figueroa et al., 1989; Nustad et al., 1975) all that
remained was to determine if activation of sensory nociceptors was non-specific, or
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Figure 1.4 - ATP and its stable
analog a,p-methylene ATP
Structure of ATP and a,p-
methylene ATP (apmeATP).
apmeATP is a stable analog that
specifically activates P2X1 and
P2X3 receptor subtypes.
receptor mediated.
The existence of an ATP receptor was first suggested by (Burnstock et al.,
1970) after proposing that it (and its metabolite, adenosine) was the substance
released from autonomic nerves innervating intestinal smooth muscle, something
previously shown in sensory nerves (Holton, 1959). It was proposed that these purine
receptors be classified as P1-purinergic receptors for adenosine and P2-purinergic
receptors for ATP (Burnstock et al., 1978). Further research showed that ATP
activates two types of receptors; ATP-gated ion channels (P2X receptors) and G-
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Table 1.1 - Pharmacological profile of P2X receptors
Functional characteristics of cloned P2X receptor subtypes expressed in
Xenopus oocytes or mammalian cells. Modified from (Collo et at., 1997).
Abbreviations: apmeATP, a,p-methylene ATP; 2meSATP, 2-methylthio ATP;
ATPyS, adenosine 5'-0-(3-thiotriphosphate; BzATP, 3'-0-(4-benzoyl)benzoyl
ATP.
1997). In addition to the role of ATP in nociception it has also been proposed that
activation of the P2X7 receptor on mast cells and macrophages may be responsible
for releasing of the pro-inflammatory cytokine IL-1 p which subsequently produces
sensitisation of peripheral nociceptors - this is addressed in detail in Chapter 6.3.
Capsaicin
Capsaicin (8-methyl-vanillyl-6-nonenamide; Figure 1.5) is the active,
pungent ingredient in chilli peppers. The topical application of capsaicin to the skin
or to mucous membranes produces a painful, burning sensation (Keele & Armstrong,
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1964). With prolonged exposure there is desensitisation of the response, and
analgesia results (Szallasi & Blumberg, 1999). Capsaicin selectively activates a
nociceptive population of C-fibres and causes depolarisation of small diameter
sensory neurons in the DRG (Wood et al., 1988). As capsaicin can specifically
activate some nociceptors, the mechanism of action is likely to be an important target
for the development of novel analgesics.
Caterina et al. (1997) took the first step towards the elucidation of the action
of capsaicin by cloning the receptor on afferent nociceptors that responds to
capsaicin. As capsaicin and its active analogs contain the vanillyl chemical moiety
the receptor was designated the vanilloid receptor (VRi). In addition to being
activated by capsaicin, the VRi receptor is an ion channel that is gated by noxious
heat, i.e. is activated by temperatures above 42°C (Caterina et al., 1997). As
capsaicin specifically activates noxious heat sensitive C-fibres, it is likely that the
Figure 1.5 - Structure of VRi agonists and
antagonists
Structure of VRi agonists capsaicin and




VRi receptor plays an important role in nociceptive processing. For that reason a lot
of effort has been put into finding an endogenous compound that chemically
activates peripheral nociceptors via the VRi receptor. One potential endogenous
ligand, anandamide, and its interaction with the VRi receptor will be addressed in
this thesis (see Chapter 5).
Indirectly acting algogenic mediators
The presence of inflammatory mediators during chronic inflammation can
drastically affect the responses of nociceptors innervating inflamed tissue.
Nociceptors are silent under normal conditions however during inflammation
afferents have an increased spontaneous discharge rate, a decreased threshold for
activation, and a greater response to noxious stimuli than that seen in normal tissue.
Furthermore, under inflammatory conditions afferents can show changes in the type
of stimulus required to activate them, becoming susceptible to a much broader
spectrum of stimuli (Coggeshall et al., 1983; Guilbaud et al., 1985a; Schaible &
Schmidt, 1985) and in some cases afferents that are normally non-responsive, even to
acute noxious input (silent nociceptors), start generating noxious signals (Schaible &
Schmidt, 1996). For example, although there is no evidence that mechanoreceptors in
the skin can be activated by thermal or chemical stimulation under normal
conditions, during inflammation both skin and joint afferents become responsive and
spontaneously active (Belmonte & Cervero, 1996).
Mediators releasedfrom immune cells
As stated above, the peripheral terminals of articular nociceptors are
embedded into a wide variety of tissues and are open to stimulation by the immediate
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environment. Therefore the terminal is the point at which the peripheral nervous
system and the immune system readily come in contact. Immune cells drawn to the
site of inflammation release a wide variety of pro- and anti-inflammatory cytokines,
prostaglandins, thromboxanes and other molecules, all of which affect the
surrounding tissue, and some of which are capable of altering the sensitivity of
peripheral nociceptors. Joint afferents, under normal conditions can be sensitised
and become spontaneously active or show an increased response to noxious stimuli
after the local injection of prostaglandin 12 (prostacyclin) (Birrell et al., 1993;
Schepelmann et al., 1992), prostaglandin E2 (Birrell et al., 1990b; Grubb et al.,
1991), and interleukin ip (Kelly et al., 1997).
Mediators releasedfrom sensory terminals
In addition to transferring information from the periphery, sensory afferents
are also able mediate their own function or the local environment by the release of
active neuropeptides from peripheral terminals and into the circulation. The
compounds produced in the neurons are neuropeptides and they are synthesised both
in the cell body and transported to the terminal or at the terminal itself (for example
(Heppelmann et al., 1997) and are released upon stimulation. Using
immunohistochemical techniques it has been shown that peptides are expressed in
the small diameter neurons (primarily C-fibres) of the DRG under normal conditions
and include substance-P, calcitonin-gene-related peptide (CGRP), preprotachykinin
(PPT) and somatostatin (Donaldson et al., 1995; Hanesch et al., 1991; Ju et al., 1987;
Smith et al., 1993).
Only a proportion of C-fibre afferents are polymodal nociceptors containing
neuropeptides, which leads to a further division into peptidergic and non-peptidergic
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afferents. In the rat DRG approximately 50% of small diameter neurons exhibit
some sort of peptide immuno-reactivity (Hunt & Rossi, 1985). However as the DRG
contains the cell bodies of all C-fibres innervating a wide variety of tissues it is
difficult to determine if there is differential innervation of peptidergic fibres in
specific tissues. Therefore, although the majority of fibres innervating the knee joint
are polymodal C-fibre nociceptors, it is not currently known whether all C-fibres are
peptidergic or whether there is a proportion that are non-peptidergic (Lawson, 1996).
The classification of whether or not a neuron is peptidergic is based on the type of
trophic factor that maintains its survival. Neurons that require nerve growth factor
(NGF) express neuropeptides whereas those that require brain derived neurotrophic
factor (BDNF) or glial cell line-derived neurotrophic factor (GDNF) do not express
neuropeptides, but will bind the plant lectin, isolectin B4 (IB4) (Snider & McMahon,
1998). Recent findings by Guo et al (1999) examining the expression of the receptor
for the potent C-fibre activator capsaicin (see below) in the rat DRG found that the
receptor was only colocalised with a proportion of CGRP and SP positive cells.
Instead the capsaicin receptor colocalised with the binding of IB4, placing it on non-
peptidergic neurons (Guo et al., 1999).
For the purpose of this study, two indirect mediators of nociceptor function
studied. Both compounds are released from sensory terminals during inflammation
however details of their specific actions are not detailed here but instead are
reviewed in subsequent chapters dedicated to the individual mediators: the
neuropeptide, somatostatin (see Chapter 4), and the endogenous cannabinoid,
anandamide (see Chapter 5). In addition to investigating the effect of these
compounds on nociceptive afferents, their ability to modulate the effects of potent,
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known activators of peripheral nociceptors, including the algogens bradykinin, ATP,
and capsaicin was also examined.
AIMS OF THE STUDIES
In this thesis predominantly electrophysiological techniques were used to
examine the role of a number of mediators in the induction of chronic inflammation
and activation of peripheral nociceptors in normal and arthritic knee joints in the rat
and the mouse. The hypotheses that were tested are as follows:
• FCA-induced chronic inflammation increases the sensitivity of nociceptive
afferents to responses evoked by the algogens capsaicin, bradykinin, and
ATP.
• The neuropeptide somatostatin inhibits spontaneous and evoked excitation in
afferents innervating the normal and arthritic rat knee joint.
• Anandamide, an endogenous cannabinoid-like substance, can activate
peripheral nociceptors through its reported action at the vanilloid receptor
(VR,).
In recent years there have been enormous developments in the manipulation of the
mouse genome. The manipulation of specific genes in the mouse means that
targeting of a specific receptor is greatly facilitated and does not require the
development of specific agonists and antagonists. To study transgenic mice with
mutations of receptor types relevant to nociception and chronic inflammation, it was
necessary to determine the feasibility of inducing a chronic inflammation in the
mouse knee joint. Furthermore, to determine the role of the target gene in peripheral
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nociceptive transmission the feasibility of electrophysiological recording of knee
joint afferents was also examined. The aims of this thesis are:
• Develop a murine model of chronic unilateral joint inflammation that is
consistent across a number of different mouse strains.
• Determine the role of the purinoceptor P2X7 in the establishment and
maintenance of chronic joint inflammation.
• Develop a method for the electrophysiological recording of evoked responses





The experiments detailed in this thesis were performed in accord with the
regulations and guidelines of the Scientific Procedures Act (1986) under the Personal
Licence number (PIL): 60/7128 and Project Licence number (PPL): 60/2750.
Animals used in this study were housed in a licensed animal facility within the
Faculty ofMedicine and experiments were performed in licensed premises within the
Department of Neuroscience (formerly Department of Pharmacology) at the
University ofEdinburgh.
In this present study a total of 154 male Wistar rats, 104 male DBA-1 mice,
12 female DBA-1 mice, and 76 male C57BL6 mice were used. All animals were
purchased from Charles River (UK), with the exception of the DBA-1 mice which
were purchased from Harlan (UK). Also included in this study were 12 transgenic
male DBA-1 mice and 12 wild type littermates received from GlaxoSmithKline
(UK). Histological studies on tissue taken and fixed at the University of Edinburgh
were performed at GlaxoSmithKline (Ware, UK). Animals were kept on a 12-hour
light/dark cycle and maintained on standard animals feed and water ad libitum for the
duration of all experiments. All in vivo experiments were performed between 9.00
and 17.00.
2.1 MODELS OF EXPERIMENTAL ARTHRITIS
RAT MODEL OF UNILATERAL ARTHRITIS
Induction of unilateral arthritis
A localised chronic inflammation was induced in rats (180-200 g) by intra¬
articular (i. art.) injection of Freund's Complete Adjuvant (FCA, 1 mg ml"1 heat
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killed Mycobacterium tuberculosis suspended in heavy liquid paraffin oil) into the
left knee (stifle) joint under transient halothane anaesthesia (3% in oxygen). The
knee was swabbed with 70% ethanol and the FCA (150 pi) was injected using a
sterile 26-gauge needle (Microlance, UK) inserted into the joint space through the
patella tendon just below the patella. Once the animals had recovered from
anaesthesia they were housed up to four in a cage until they were used. Control
animals were injected with heavy liquid paraffin oil (HLP).
Assessment of arthritis
The single intra-articular injection of FCA produces a mild to moderate
chronic inflammation that reaches its peak after approximately 14 days and persists
for up to 100 days, which is the time limit on our Project Licence. During this time
the general health of the animals remains good as shown by their ability to gain
weight, groom and move around as normal (Donaldson et al., 1993). Animals were
used for electrophysiological studies 14-35 days following the induction of arthritis.
The general condition of the animals was monitored for discomfort and mobility
throughout this time by observation (either by myself or the Named Animal Care
Worker). The level of inflammation and allodynia associated with the experimental
arthritis was determined prior to their being used in neural experiments. Within the
laboratory the induction of unilateral arthritis has been shown to produce a mild
inflammation, however procedures were in place for animals experiencing severe





The extent of joint inflammation was established by measuring the width of
the joint at the middle of the joint capsule (diameter) of both the injected and
uninjected joint using microcalipers (Mitutoyo, Japan). The induced inflammation
was restricted to the injected joint, showing no spread to the contralateral joint,
therefore the uninjected joint acted as an internal control and inflammation could be
expressed as the increase in joint diameter of the arthritic (left, injected) versus the
normal (right, uninjected) knee.
Allodynia
The inflammation-associated allodynia was determined by comparing the
distribution of body weight between the normal and arthritic limbs using a dual
channel weight averager (GlaxoSmithKline/Linton Instruments; (Clayton et al.,
1997). Briefly, the instrument consists of a pair of force transducers that were
capable ofmeasuring the weight applied on each limb over a fixed time (7 seconds).
The rats were restrained for a short period of time, in a clear Perspex box, which
required them to stand with each hind limb on a plate connected to the transducer.
The force on each transducer was measured over the fixed time and given as a digital
readout in grams applied by each limb. Given the internal control, the result could be
expressed as the decrease in weight applied to the arthritic versus the normal limb i.e.
the rat will distribute the body weight such that the inflamed limb bears less weight
than the normal limb.
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MURINE MODEL OF UNILATERAL ARTHRITIS
As the development of this novel model comprised a significant proportion of
the overall project, it makes up a separate chapter in this thesis. Full details on the
methods are provided in chapter 6.
2.2 IN VIVO RECORDING FROM AFFERENT NERVES
RECORDING FROM AFFERENT NERVES IN THE RAT KNEE JOINT
Anaesthesia and surgical procedures
Rats were initially anaesthetised with an intra-peritoneal (i.p.) injection of
pentobarbitone (60 mg kg"1). Once fully anaesthetised the rat was laid on its back
and its core body temperature maintained at 38 °C using an automated heating
blanket (Harvard Apparatus Limited, UK) attached to a thermistor probe inserted
into the rectum. A small midline incision was made in the neck to expose the trachea
which was cannulated (cannula outer diameter (OD): 2.0 mm, Portex, UK) to allow
for the spontaneous breathing of room air or, if required, artificial respiration using a
ventilator (Harvard Apparatus Limited, UK). The right carotid artery was cannulated
(OD: 0.75 mm) to allow for the continual monitoring and recording of arterial blood
pressure through a pressure transducer (Bell and Howell, UK) attached to computer
(Maclab/8 linked with a Macintosh LC475). Deep anaesthesia and fluid levels were
maintained throughout the experiment with an intravenous (i.v.) infusion of
pentobarbitone (0.4-0.5 mg kg"1 min"1) diluted 50:50 in saline administered through
a cannula (OD: 0.63 mm) inserted into the right femoral vein exposed after opening
the medial aspect of the right hind limb. An additional cannula (OD: 0.70 mm) was
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inserted into the right femoral artery with its tip positioned in the lower abdominal
aorta to allow for the close intra-arterial (i.a.) of drugs to the left knee joint.
Experiments could last upwards of 6 hours therefore changes in blood chemistry (pH,
pC02, and p02) were periodically monitored.
Dissection of the medial articular nerve
Extracellular recordings were performed on a portion (filament) of the medial
articular nerve (MAN) innervating the left knee joint. The left hind limb was fixed
to a support using plaster of Paris and a small incision was made on the medial
aspect in order to expose the MAN where it leaves the saphenous nerve. The skin
was secured to a small brass ring to form a pouch that was filled with heavy liquid
paraffin oil (HLP) to create an electrically isolated system. The saphenous nerve was
then cut centrally to prevent interference from efferent neural activity. Furthermore,
input from skin afferents was restricted by separating as much of the skin as possible
from the knee joint, thereby rupturing any afferents innervating the skin. The MAN
was dissected from the surrounding tissue and was split using fine forceps until a
small filament, typically containing 1 - 4 functional afferent fibres was isolated.
Once isolated, electrical activity was recorded using a bipolar platinum/iridium
(Pt/Ir) that is placed half way between the saphenous nerve and the joint capsule (see
Figure 2.IB).
Recording from the medial articular nerve
Afferent activity was recorded by laying the dissected MAN fibres over
bipolar Pt/Ir wire electrodes (Figure 2.1). The raw nerve signal was passed through
both a pre-amplifier and an amplifier (Neurolog NL 103 and NL 105 respectively;
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signal amplified x 10 000). It was then displayed on an oscilloscope (Gould 1604),
digitised (Sony, Digital Audio Processor PCM-701ES), and stored on videotape
(Sony, Hi8 Recorder EV-C2000E PAL). The signal was then filtered - 100Hz low
pass and 1000 Hz high pass (Neurolog, NL 115), and passed through a voltage
discriminator (Digitimer D.130) connected to a loud speaker, before being displayed
on the oscilloscope. For the purpose of off-line data analysis, both the filtered and
the voltage discriminated signal passed through a Micro 1401 interface (Cambridge
Electronic Design, UK) connected to a personal computer (Research Machines,
Pentium III/500 MHz) running Spike2 software (Cambridge Electronic Design,
version 3.20). Electrical events were recorded on-line by setting both positive and
negative trigger levels. These were saved as data files for off-line analysis. In
addition keyboard markers were written into the file while recording to show the
exact point at which the drugs were injected. Figure 2.2 illustrates the experimental
set-up.
RECORDING FROM AFFERENT NERVES IN THE MOUSE KNEE JOINT
As with the development of the unilateral arthritis model mouse, the
techniques developed for the recording from the mouse knee joint represent a
significant component of the work undertaken for this thesis, and full details on the
final procedures involved are provided in Chapter 6.2
IDENTIFICATION OF FIBRES
To determine the types of afferent fibres recorded within the whole filament,
individual fibres were characterised according to their mechanosensitivity,




Probing the knee joint using a hand held plastic probe identified the receptive
field being recorded as well as the receptive field of the individual fibres and their
mechano-sensitivity. The tip of the probe was approximately 1 mm in diameter. The
receptive field was only identified for the medial aspect because of the restricted
access to the whole knee joint, and consequently the mechanosensitivity of some
afferents showing spontaneous activity could not be confirmed.
Conduction velocity
Conduction velocities were not done routinely to prevent the sensitisation of
the preparation following repeated electrical stimulation. However, where possible
conduction velocities of afferents were determined using a stimulating electrode
made up of a silver wire core insulated within a metal tube (external diameter: 1mm).
This electrode was placed onto receptive field of a particular afferent as identified
using the plastic probe. Supra-threshold 1 ms (0.3 - 5 V) pulses were delivered at a
frequency of 1 Hz in order to trigger firing in the afferent, and by measuring (ruler)
the distance between the recording electrode and the stimulating electrode, an
estimate of the conduction velocity (CV) was made:
CV(m/s) =^^
t(ms)




Data was collected and analysed off-line using Spike2 software. Within the
software is the capability of measuring the duration of action potentials produced by
individual fibres. Action potentials of short spike duration (<1.5 ms) were taken to
be A5 mechanonociceptors and those with a longer duration (>2 ms) were
characterised as C-fibre polymodal nociceptors (Gee et al., 1999; Iggo, 1978).
Chemosensitivity
The afferents innervating the knee joint show a heterogeneous response to a
number of algogens (Dowd, 1999). Therefore where possible the chemosensitivity to
the algogens capsaicin (9 nmol), bradykinin (9 nmol), and aPmeATP (60 nmol) were
administered (see below) to establish a pharmacological profile of these afferent
terminals.
DRUG ADMINISTRATION
Drugs were administered by a close intra-arterial (i.a.) bolus injection via the
femoral, arterial cannula over 2s. Drugs were injected in a total volume of 0.1 ml
and washed in with 0.2 ml saline (0.9% w/v NaCl in distilled water) as the catheter
dead space was 0.1 ml. As the cannula tip had been positioned in the abdominal
aorta, the injected compound was rapidly (within 2s) carried by the circulation into
the (uncannulated) contralateral hind limb from which neural recordings were made.
To prevent desensitisation of the preparation or a particular receptor 20 minutes was
left between drug injections.
With this method it is not possible to get an exact measurement of the local
drug concentration at the peripheral terminals. Therefore, the amount of drug is
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stated as moles injected and, although it is appreciated that the entire amount is
unlikely to reach the site of action. The drugs used in this study, including molecular
mass, and suppliers are given in Appendix I.
DATA SORTING
Once the experiment was recorded on the computer it was analysed using
Spike2 software. The recorded waveform was scanned and the program templates
used to represent the individual spikes that make up the recorded response. Once this
had been done the waveform was rescanned and the response of each fibre displayed
on separate channels. These were generally displayed in histogram format, showing
the total number of impulses in 1 s bins to provide both the absolute discharge
(impulses) and the frequency (impulses s"1).
DATA ANALYSIS
Drug effects were determined by comparing the action potential discharge
frequency or the absolute number of action potentials recorded immediately
following injection (test period) for the whole duration of the response with that of
the discharge recorded in the 15 s period immediately prior to injection. The 15 s
pre-injection period was taken as the control period. Data are expressed as either the
change in the mean action potential frequency (Ax; impulses s"1; Equation 1) or the
change in the absolute number of action potentials evoked over the duration of the
response (AEx; impulses; Equation 2) according to the formula below. If no clear




4x = x test Xcontrol Equation 1
A = ?!test ^X,control Equation 2
Definitions
Zx : The total number of action potentials counted in either the control (15 s) or
test (duration of response) periods, Zx control or Zx test respectively (expressed
as impulses).
X : The frequency of action potential discharge in either the control (15 s) or test
(duration of response) periods (expressed as impulses s"1).





% test ~ '
test
We are interested in the primary events at the local site of action on the
afferents in the knee joint therefore delayed effects are not examined as they may
possibly be the result of the injected drug circulating to additional sites to produce
secondary effects on afferent discharge.
STATISTICAL ANALYSIS
Data was collected and analysed using Microsoft Excel, GraphPad Prism and
GraphPad Instat software. Unpaired t-tests were used to analyse differences between
the means of two normally distributed groups. When the sample size for each group
was too small or the data was not normally distributed then the non-parametric
Mann-Whitney U-Test was used. For paired data the Student's paired t-test
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(parametric) or Wilcoxon U-Test (non-parametric) tests were used. To determine
differences between the means of more than two normally distributed groups a one¬
way analysis of variance (ANOVA) was done and a post-hoc test (Tukey's multiple
comparison) performed if the result was deemed to be significant. The medians of
two or more groups of non-parametric data were analysed with a Kruskal-Wallis test
and post-hoc analysis done using Dunn's multiple comparison. Correlations between
normally distributed groups were determined using a Linear (Pearson) Correlation
and non-parametric data were compared using a Spearman Rank Correlation. To
compare the relative proportions in a population between two groups the Fisher's
Exact test was used. In all cases the null-hypothesis that the variance between
groups could arrive from chance was rejected at the 0.05 level. Therefore a P value
of less than 0.05 was considered significant and where possible the actual P value






Figure 2.1 - Experimental set-up for neuronal recording from rat MAN
Photographs of the experimental set-up for recording neural activity from
sensory afferents in the MAN innervating the rat knee joint. A) The left knee
joint was fixed to a support and the skin tied to a small brass ring to form a
cavity. The cavity was filled with heavy liquid paraffin to produce an
electrically isolated system. B) Close up photograph of the MAN being laid
across the bipolar platinum-iridium electrode. S is the saphenous nerve. For
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Chapter 3 -Normal and Arthritic Knee Joint Nociceptors
3. Characterisation of nociceptors in normal
and arthritic rat knee joints
58
Chapter 3 -Normal and Arthritic Knee Joint Nociceptors
3.1 INTRODUCTION
Adjuvant arthritis is one of the most well characterised models of
experimental chronic inflammation. The systemic injection of bacterial cell walls or
their components induces an inflammation that is thought to possess many of the
characteristics seen in human rheumatoid arthritis and as such is widely used for the
investigation of anti-inflammatory and anti-rheumatic drugs (Greenwald & Diamond,
1988). Polyarthritis (inflammation in multiple joints) can be produced by the
injection of Freund's Complete Adjuvant (FCA) containing heat killed
Mycobacterium tuberculosis into the footpad or tail base (Billingham, 1983;
Rainsford, 1982). The inflammation produced in adjuvant arthritis is very severe and
can lead to gross deformation of the joints, irreversible ankylosis, considerable
discomfort, diminished weight gain or actual weight loss and spontaneous bleeding
from the nose and eyes (Greenwald & Diamond, 1988). The severity of the
inflammation has led some investigators to develop less invasive methods for
examining arthritic joints.
A unilateral model of arthritis was previously developed in this laboratory by
the sub-cutaneous injection of low doses of FCA (100-200 pg) around the ankle joint
in the rat (Grubb et al., 1988). The inflammation is restricted to the injected joint
and allows comparison between the inflamed joint and the corresponding joint in the
contralateral limb as an intra-animal control. Using this model the neural responses
of articular nociceptors evoked by a number of mediators of nociception and
inflammation were examined in normal and arthritic joints. The mediators
investigated include 5-hydroxytryptamine (Birrell et al., 1990a; Grubb et al., 1988),
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prostaglandins E2 and 12 (Birrell et al., 1990b; Birrell et al., 1991; Birrell et al.,
1993; Grubb et al., 1991), bradykinin (Asghar et al., 1997), and paracetamol and
aspirin (McQueen et al., 1991). Although these studies show that the model is
effective for the examination of nociceptor function, it has been argued that the
inflammation induced by sub-cutaneous injection of FCA is largely peri-articular and
the more appropriate method of inducing arthritis was by introduction of the FCA
directly into the synovial space (Butler et al., 1992). Intra-articular injections into
the rat ankle joint did not prove feasible, the small size and anatomical complexity
meant that the injection process resulted in trauma to the joint
Previously it had been shown that it was possible to record action potential
discharge from sensory afferents contained in the medial articular nerve (MAN)
innervating the cat knee joint (Coggeshall et al., 1983; Fleppelmann et al., 1986;
Kanaka et al., 1985; Schaible & Schmidt, 1983a; Schaible & Schmidt, 1986;
Schaible & Schmidt, 1985; Schaible & Schmidt, 1983b). A method was subsequently
developed in this laboratory for the induction of a unilateral arthritis in the rat knee
joint by intra-articular injection of FCA and neural recordings from the MAN
(Dowd, 1999). A number of groups have examined peripheral nociceptors
innervating the rat knee joint (Davis & Perkins, 1993; Davis & Perkins, 1994; Davis
& Perkins, 1996; McDougall et al., 1994; McDougall et al., 1995; Perkins et al.,
1995). However, these studies only examine the effect of inflammatory mediators on
mechanical or thermal hyperalgesia and therefore very little is known about the
pharmacological profde of chemically evoked responses from articular nociceptors.
Previous work in this laboratory has examined the evoked response of
nociceptor afferents by ATP (Dowd et al., 1998a; Dowd et al., 1998b) and IL-1
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(Kelly et al., 1995a; Kelly et al., 1997). The aim of this section of the studies was to
examine responses evoked by known activators of peripheral nociceptors, namely
capsaicin (VRi receptor), bradykinin (B1 and B2 receptors) and the stable ATP
analog a,p-methylene-ATP (P2X], P2X3 and P2X2/3 (heteropolymeric combination)
receptors) and to determine whether these responses are altered during FCA-induced
arthritis.
3.2 METHODS
AFFERENT NERVE RECORDING IN VIVO
Induction of arthritis and the recording of neural activity were carried out as
described in Section 2.2. Experiments were conducted in a total of 154 male Wistar
rats (body weight range 220-520 g; mean ± sem. 374 ± 9 g). Successful neural
recordings were made in 114 (74%) of the experiments and can be further divided
into 76 normal and 38 arthritic animals. Arthritis was induced 14-35 days before the
animals were used in electrophysiological studies. All animals displayed mild but
persistent unilateral arthritis as characterised by a significant increase in the diameter
of the injected joint (injected 10.7 ± 0.1 mm; uninjected 10.0 ± 0.1 mm; n=36;
P=0.0001, paired t-test). Animals were anaesthetised with pentobarbitone (60 mg kg"
1
i.p and deep anaesthesia maintained via a slow i.v. infusion at 0.5 mg kg"1 min"1
pentobarbitone) then prepared surgically as detailed in Section 2.2. Extracellular
neural activity in the MAN was recorded using bipolar platinum-iridium electrodes -
for detailed description of electrode placement see Section 2.2 and Figure 2.IB.
Collected data were analysed off-line using Spike2 software. Drugs were
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administered by close arterial injection into the right femoral cannula in a total
volume of 0.1 ml.
3.3 RESULTS
AFFERENT NERVE RECORDINGS IN VIVO
Characterisation of afferent nerve fibres
Afferent neural discharge was recorded from 167 fibres from 76 normal knee
joints and 67 fibres from 38 arthritic knee joints. Afferent fibres were characterised
as either C-fibre polymodal nociceptors or AS mechanonociceptors based on their
conduction velocities, spike duration, mechanosensitivity, and their ability to be
activated by capsaicin. Several low threshold mechano-sensitive A(3 fibres were
identified during the studies, however they were not examined in detail and are not
included in this thesis.
Initial experiments tried to characterise the fibres being recorded from in full
using mechanical stimulation, electrical stimulation to determine conduction velocity
and chemical characterisation using capsaicin, bradykinin, and aPmeATP (for
sample data see Table 3.1). As stated in the general introduction, a number of
inflammatory and nociceptive mediators can be released anti-dromically through
electrical stimulation of the nerve and by mechanical stimulation of peripheral
terminals. Therefore, characterising the afferent fibres required procedures that
caused the preparation in some cases to become sensitised or in other cases non-
responsive. After discussions with my supervisor it was decided that the chemical
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responses of the afferents should be the primary concern and therefore in the
majority of experiments the determination of fibre type was based on responsiveness
to the VRi agonist capsaicin (1-10 nmol). Fibres sensitive to capsaicin were denoted
C-fibres. Fibres not responding to capsaicin but showing activation by another
algogen or mechanical stimulation were denoted A5 mechanonociceptors.
When possible, to confirm capsaicin sensitive afferents as C-fibres,
conduction velocities were determined using electrical stimulation. All C-fibre
polymodal nociceptors tested showed slow conduction velocities (<1.5 ms"1) whereas
A5 mechanonociceptors had a faster conduction (> 4 ms"1; see Table 3.1). The speed
of conduction was also reflected in the duration of the action potential. Slow
conducting C-fibres had significantly longer spike durations (4.1 ± 0.5 ms; n=10)
when compared to the myelinated, faster conducting A5 mechanonociceptors (1.3 ±
0.1 ms; n=7; P = 0.02, unpaired t-test). Probing the joint capsule with a small hand¬
held plastic probe also activated afferent fibres.
In normal joints, of the total of 167 afferent fibres, 126/167 (75%) were
classified as C-fibres and 41/167 (25%) as A5 mechanonociceptors. 61/67 (91%)
afferents innervating arthritic knee joints were classified as C-fibres and 6/67 (9%)
were found to be A5 mechanonociceptors.
Spontaneous discharge in nociceptors innervating normal and arthritic rat knee
joints
Previous studies have shown that in adjuvant induced arthritis there is an
increased proportion of spontaneous afferent discharge in the inflamed joint (Dowd,
1999; Guilbaud et al., 1984). In this study spontaneous afferent firing was noted in
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28/76 (37%) normal joints and in 23/38 (67%) arthritic knee joints (Figure 3.1). In
joints that showed spontaneous discharge the mean action potential discharge
frequency was 1.09 ± 0.55 impulses s"1 in normal joints and 0.87 ± 0.61 impulses s"1
in arthritic joints (Figure 3.2). There was no significant difference between normal
and arthritic joints when comparing the frequency of the spontaneous discharge (P =
0.43; Mann-Whitney).
Evoked responses to known algogens capsaicin, bradykinin and aPmeATP
Peripheral nociceptors innervating the rat knee joint are heterogeneous and
often respond to a number of different algogens (see General Introduction; Chapter
1). In this study the afferents were characterised by determining whether there was a
response to capsaicin, bradykinin, and aPmeATP (Figure 3.3). Furthermore, the
pooled response was analysed for the latency to onset, duration, and magnitude in
terms of both the discharge frequency and the total number of action potentials
evoked. The mean for each of these variables was compared in data obtained from
normal and arthritic knee joints.
Capsaicin
Capsaicin (1-10 nmol, close i.a.) was used as one of the tools to distinguish
between C and A5 nociceptors. However, even in fibres characterised by conduction
velocity capsaicin excited all C-fibres and did not produce excitation in any of the
A8 mechanonociceptors. Capsaicin (1-10 nmol, close i.a.) excited a total of 126 C-
fibres and 0 A8 fibres innervating 55 normal knee joints and 61 C-fibres and 0 AS
fibres innervating 31 arthritic knee joints.
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The excitation evoked by close arterial injection of capsaicin (3 nmol) was
examined in detail in normal (n=32) and arthritic (n=20) knee joints (Figure 3.4).
The response onset latency was 3.0 ± 0.1 s in normal knee joints and this was not
significantly different in arthritic knee joints, in which delay to onset was 2.9 ± 0.2 s
(P = 0.72; unpaired t-test; Figure 3.4A). There was also no significant difference in
the duration of the evoked response to capsaicin (P = 0.43; Mann-Whitney) with a
mean response duration of 9.2 ± 2.9 s (2.8 s) in normal joints and 4.1 ± 0.8 s (2.7 s)
in arthritic knee joints (the median is shown in brackets as the duration was not
normally distributed) - Figure 3.4B. Differences between normal and arthritic knee
joints were seen in the magnitude of the response to capsaicin. The increase in the
discharge frequency evoked by capsaicin (3 nmol) in normal knee joints (36.9 ± 3.3
impulses s"1) was greater than that evoked in arthritic knee joints (26.8 ± 3.0
impulses s"1; P = 0.04; unpaired t-test; Figure 3.4C). Similarly, the mean total
number of action potentials generated was greater in normal knee joints (295 ± 85
impulses, median: 119) when compared to inflamed knee joints (88 ±15 impulses,
median: 62; P = 0.02; Mann-Whitney; Figure 3.4D).
Bradykinin
Bradykinin (1-28 nmol) administration was examined in a total of 99 C-fibres
and 27 A5 fibres innervating 34 normal knee joints and 37 C-fibres and 4 A5 fibres
innervating 18 arthritic knee joints. Bradykinin activated 36/99 (37%) and 25/37
(68%) of C-fibres in normal and arthritic knee joints respectively; this difference was
statistically significant (P = 0.002, Fisher's Exact test). All these fibres were also
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activated by capsaicin. None of the A5 fibres, in either normal (0/27) or arthritic
joints (0/4), were activated by bradykinin
Components of the excitation produced by close arterial injection of
bradykinin (9 nmol) were investigated in recordings from 15 normal and 9 arthritic
knee joints (Figure 3.5). There was no significant difference in the response latency
between normal (6.8 ± 0.7 s) and arthritic knee joints (7.5 ± 1.5 s; P = 0.62; unpaired
t-test; Figure 3.5A). Similarly, there was no difference in the discharge frequency
with 3.6 ± 0.5 impulses s"1 in normal joints and 2.2 ± 0.7 impulses s"1 in inflamed
joints (P = 0.15; unpaired t-test; Figure 3.5C). The duration of the response was
significantly increased in arthritic animals when compared to normal animals (153.6
± 24.5 s and 35.4 ± 6.4 s respectively; P = 0.0001, unpaired t-test; Figure 3.5B). As
the discharge frequency was similar between normal and arthritic animals the change
in duration meant that the total number of action potentials generated was also
significantly increased in arthritic knee joints (normal: 129 ± 35 impulses, arthritic:
284 ± 77 impulses; P = 0.048; unpaired t-test; Figure 3.5D)
a,P -methylene A TP
aPmeATP (19 - 190 nmol) elicited a fast onset, high frequency response
from a total of 11/80 (14%) of C-fibres and 28/28 (100%) of AS fibres in normal
joints (n=38) and 4/33 (12%) of C-fibres and 7/7 (100%) of AS fibres in arthritic
joints (n=17). There was no significant difference between the proportion of either
C-fibre or A-fibre afferents (P = 0.77 and P = 1.23 respectively; Fisher's Exact test)
excited in normal and arthritic knee joints. All the C-fibres activated by aPmeATP
were also activated by capsaicin in both normal and arthritic joints and bradykinin
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activated 3/11 (27%) of a|3meATP sensitive C-fibres in normal joints and 1/4 (25%)
in arthritic joints; this was not significant (P = 1.00, Fisher's Exact test). The AS
mechanonociceptors activated by aPmeATP were not activated by either capsaicin
or bradykinin.
Close arterial injection of aPmeATP (60 nmol) elicited an excitation of rapid
onset, and short duration that was similar in normal and arthritic knee joints (Figure
3.6). There were no significant differences in the mean response latency (normal:
2.6 ± 0.3 s, arthritic: 2.8 ± 0.1s; P = 0.56; unpaired t-test), the mean duration of the
response (normal: 1.6 ± 0.2 s, arthritic: 1.5 ± 0.5 s; P = 0.89; unpaired t-test), the
mean discharge frequency (normal: 9.0 ± 2.4 impulses s"1, arthritic: 9.6 ± 2.0
impulses s"1; P = 0.88; unpaired t-test), or the mean number of action potentials
evoked (normal: 12 ± 3, arthritic: 17 ± 9; P = 0.56; unpaired t-test).
3.4 DISCUSSION
This section of the thesis examined changes in both spontaneous and
chemically evoked primary afferent discharge in arthritic rat knee joints and
compared these with responses from normal joints. The MAN in the cat knee joint
has been shown to consist primarily of afferents arising from the joint capsule of
which approximately 80% were unmyelinated C-fibres and 20% were myelinated
fibres of which the majority were A5 fibres (Heppelmann et al., 1988; Langford &
Schmidt, 1983). The innervation of the rat knee joint has also been examined,
however much of the work focuses on the posterior articular artery (PAN) and not
the MAN (Hildebrand et al., 1991). What is known of the innervation of the MAN
into the rat knee joint is that approximately 1/3 of the fibres present in the bundle are
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afferents (Hildebrand et al., 1991). To ensure that we were recording only afferent
activity the saphenous nerve was cut centrally. Assuming that the proportion of
afferents being recorded is similar to the overall proportion of afferents in the nerve
bundle, the results of this study for the proportion of myelinated to unmyelinated
fibres was consistent with those seen in the cat with 75% of recorded afferents being
classified as C-fibres and 25% classified as A5 fibres. Furthermore, this was also
consistent with earlier findings from this laboratory in the rat knee joint (Dowd,
1999).
As efferent activity was not being recorded, all C-fibres were deemed to be
nociceptors as their firing was induced by capsaicin, which is known to produce pain
in both animals and humans (Szallasi & Blumberg, 1999). It was not possible to
characterise specifically the A5 fibres into either mechanoreceptors or high threshold
mechanonociceptors, as it was not technically feasible to move the joint to produce
noxious mechanical stimulation, such as over rotation of the joint, as is used in other
experimental models (Heppelmann & Pawlak, 1997a; Heppelmann & Pawlak, 1999).
In addition the excessive use of direct mechanical stimulation of the joint causes
desensitisation in our preparation and as such when tested, mechanical thresholds
were left until the end of an experiment.
Determination of A-fibre type was not permitted by noxious mechanical
stimulus. However, it has previously been shown that although AS
mechanonociceptors are insensitive to excitation by capsaicin under normal
conditions, AS mechanoreceptors, for non-nociceptive sensory input and
proprioception, do respond to capsaicin after a long latency (Szolcsanyi, 1987). As
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this was not seen in any of the myelinated fibres we recorded from, it is assumed that
all fibres tested were transmitting nociceptive information.
Although the proportion of C to A5 fibres was consistent with that seen in the
cat and previously shown in the rat in normal joints, there was a difference in the
relative number of each fibre in the arthritic knee joints of rats. In the arthritic joint
the vast majority of fibres recorded from were C-fibre polymodal nociceptors (91%)
with only a small number of A5 mechanonociceptors (9%). The first explanation of
this finding is simply a skew in the sampling of afferents in these arthritic joints. It
would be very interesting for future work to examine changes in number and fibre
type of afferents in the MAN of chronically inflamed joints. However, recent reports
point to the fact that primary sensory afferents may change under conditions of
neuropathy or chronic inflammation producing alterations in their central projections
into the dorsal horn. In addition, neuropathy and inflammation are capable of
inducing the production of neuropeptides in medium and large diameter sensory
neurons (A5 and A|3 myelinated fibres respectively). This as been shown in the rat
DRG after sciatic nerve lesion and FCA induced inflammation with the production of
brain-derived neurotrophic factor (BDNF) (Zhou et al., 1999), and calcitonin gene
related peptide (CGRP) (Bulling et al., 2001; Ohtori et al., 2001), and in sensory
nerves innervating the guinea pig airway, where exposure to NGF produced
expression of substance P (Hunter et al., 2000). In combination, these results show
that under severe conditions such as chronic inflammation, it is possible for the A8
fibres to change their phenotype causing A5 mechanonociceptors, normally
insensitive to capsaicin, to become C-fibre-like nociceptors capable of being
activated by capsaicin. Recent reports show that in response to partial nerve injury
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the level of VRi receptor mRNA increases in the cell bodies of A-fibres in the rat
DRG (Hudson et ah, 2001). Since one of the criteria for classification of AS fibres is
insensitivity to capsaicin, it would be necessary to determine under conditions of
chronic inflammation whether A-fibres will begin to express the VRi receptor, and
also whether changes in VRi receptor expression in the cell body equates to receptor
expression at the peripheral terminal. If this were the case it would begin to explain
the apparent lack of AS fibres in the arthritic joint in our model. Further work will
be required to isolate myelinated fibres using conduction velocities to determine
whether in our model the induction of chronic arthritis is capable of directing A-
fibres to become activated by stimuli that previously only activated C-fibre
polymodal nociceptors.
It has been previously been shown in the rat ankle joint (Asghar et ah, 1997;
Guilbaud et ah, 1985b) and the cat knee joint (Schaible & Schmidt, 1985) that in
chronic inflammation induced by FCA there is an increase in both the number of
afferents showing spontaneous activity and, in addition, those afferents that are
spontaneously active produced higher action potential discharge frequencies than that
seen in normal joints. The present study in the rat knee joint does show a
significantly higher proportion of afferent fibres with spontaneous firing in arthritic
joints, however, there was no significant difference between normal and arthritic
joints in terms of the frequency of the discharge.
If it is assumed that signalling from peripheral sensory afferents provides
continual information on both the external and internal environment to the central
nervous system, then changes in any of the features of the response may be capable
of changing the perception of the input centrally. For this reason future experiments
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will need to examine, in more detail, different components of the afferent responses
generated and look for differences between normal and arthritic joints. Using recent
developments in processing software, it will be possible to examine the nature of
both the spontaneous and evoked response to determine changes in the coding of the
sensory information. For example, in addition to the absolute discharge or the
frequency it will be possible to examine the grouping of the spikes and the inter-
spike interval to determine if these are altered in chronically inflamed joints.
As there was no alteration in spontaneous discharge frequency recorded from
afferents innervating normal and arthritic joints, changes in the evoked responses to
known algogens (including capsaicin, bradykinin and apmeATP) were studied to
determine whether their response characteristics were altered under conditions of
chronic inflammation.
ATP and capsaicin activate ligand-gated ion channels, namely the
purinoceptor (P2X) and the vanilloid receptor (VRi) respectively. It was confirmed
that a|3meATP does activate sensory afferents in the rat knee joint (Dowd et al.,
1997) presumably through its selective activation of P2X|, P2X3 and/or P2X2/3
receptors. The localisation of the P2X3 receptor to small diameter sensory neurons in
the DRG (Novakovic et al., 1999; Rae et al., 1998) and to the peripheral terminals of
these afferents (Vulchanova et al., 1997) indicates that it is most likely the receptor
being activated. There was however no significant difference in the excitation
evoked by apmeATP in afferents innervating normal and arthritic joints - meaning
that chronic inflammation did not sensitise the afferents to stimulation by apmeATP.
This result conflicts with recent reports showing that currents mediated by the P2X3
receptor were potentiated by substance P and bradykinin (Paukert et al., 2001).
71
Chapter 3 -Normal and Arthritic Knee Joint Nociceptors
Furthermore, following FCA-induced peripheral inflammation, recordings from
dissociated rat DRG neurons showed a threefold increase in P2X3 mediated ATP
currents and the expression of P2X3 receptor was significantly increased (Xu &
Huang, 2002).
The response evoked by capsaicin was significantly different when
comparing afferents innervating normal and arthritic joints, however in the
chronically inflamed joints the excitation evoked was less than that seen in normal
animals, implying a desensitisation of the afferents. There is no information of the
expression of the VRi receptor following chronic inflammation and furthermore
recent reports are conflicted in the expression and sensitivity of the VR] receptor
following acute (48 hours) inflammation. In the rat DRG it has been shown that
FCA-induced peripheral inflammation did not alter the level of VRi expression
(Sanchez et ai, 2001). However, work by Carlton and Coggeshall (2001) suggests
that peripheral sensitisation following inflammation is a result of an increase in the
number of VRi receptors present at the peripheral terminal. One potential
mechanism for an increase in receptor levels comes from the fact that activation of
phospholipase C (PLC) by nerve growth factor (NGF) or bradykinin triggers
expression ofVRi (Chuang et al., 2001).
Although chronic inflammation did not appear to sensitise the ion-channel
receptors, bradykinin, acting through a G-protein coupled receptor, did show a
significantly greater excitation in afferents innervating the arthritic joint. Both the
duration of the response and the absolute number of impulses generated in the
arthritic rat joint were increased when compared to normal joints. One potential
explanation for this finding lies in the fact that in chronically inflamed joints the pH
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of the tissue is lower than usual (Wall & Melzack, 1999). Under these conditions the
enzymes responsible for the breakdown and elimination of bradykinin are likely
inhibited (Edery & Lewis, 1962) leaving the molecule free to act for a longer time.
Similarly, it has been shown that bradykinin modulates ionic channels particularly at
low pH to prolong activation in isolated, small diameter, rat DRG neurons (Kress et
al., 1997).
Another possible explanation involves the activation of both of the
bradykinin receptors. Bradykinin acts on two receptors, B1 and B2. The B2 receptor
is constitutively expressed and the B1 receptor is inducible and shows a significant
increase in expression following tissue injury or inflammation (for reviews see
Calixto et al., 2000; Couture et al., 2001). It is possible that in normal animals
bradykinin is acting on the B2 receptor to produce its effect and then during chronic
inflammation the B1 receptor is also expressed at high levels producing a combined
response. The hypothesis that B2 may be involved in acute pain and B1 in the more
chronic phase was strengthened by the report that chronic constriction injury caused
an upregulation of both receptors in the rat lumbar DRG (Ma et al., 2000) and work
from this laboratory showing excitation by the B1 agonist desArg9-bradykinin in
afferents innervating arthritic but not normal rat knee joints (Kelly, 1998).
Furthermore, following chronic constriction injury in the rat, B2 antagonists were
able to produce anti-nociception at all time points whereas the B1 antagonist was
only effective after 14 days, therefore in a more chronic phase (Levy & Zochodne,
2000).
Further work using specific agonists and antagonists for the two bradykinin
receptors would determine whether the increased response to bradykinin during
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chronic inflammation is due to the presence of B1 receptors. Although it is known
that levels of B1 receptor are greatly increased during inflammation there has been
recent debate in the literature as to whether or not the B1 receptor is constitutively
expressed in sensory afferents. Several studies showed immunohistological evidence
for its presence in small diameter, peptidergic neurons in the DRG (Ma, 2001; Ma et
al., 2000; Wotherspoon & Winter, 2000). Others were not able to elicit a B1 agonist
dependent excitation from peripheral nociceptors in the rat knee (Kelly, 1998) or find
B1 mRNA in rat DRG (Brand et al., 2001). Probably the most conclusive proof of
constitutive B1 receptor expression comes from the finding that mice lacking the
receptor display hypoalgesia under normal conditions (Pesquero et al., 2000).
The further understanding of differential response patterns and
chemosensitivity of sensory afferents innervating arthritic joints could lead to new
targets for drugs specific to a chronic inflammatory condition such as rheumatoid
arthritis.
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TABLES AND FIGURES
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AS X 5.3 1.2
AS 5.8 1.3 X
AS X 3.1 1.6
AS 3.4 1.1 X
AS X 3.6 0.9
AS X 5.6 1.5 X
AS X 3.2 1.6 X
C X 0.4 6.1 X
C X 0.6 3.0 X X
C 0.5 7.5 X X
C 0.7 2.6 X X
C 0.7 3.0 X J
C X 1.2 3.6 X
C X 1.1 2.9 X
C X 0.5 5.6 X
C X 0.8 5.0 X X
c X 1.7 3.2 x
Table 3.1 - Characteristics of nociceptors innervating the normal rat
knee joint
Sample table of data collected to characterise AS and C fibres innervating the
rat knee joint. AS fibres had conduction velocities of 4.3 ± 0.5 m s"1 (n=7) and
spike durations of 1.3 ± 0.1 ms (n=7). None of the AS fibres were sensitive to
capsaicin but some were sensitive to ATP or its stable analogue apmeATP.
C fibres had conduction velocities of 0.8 ± 0.1 m s~1 (n=10) and spike
durations of 4.1 ± 0.5 ms (n=10). C fibres showed responses to capsaicin,
bradykinin and ATP or apmeATP. It was not always possible to determine if
the fibre could be mechanically stimulated due to restricted access to the
joint surface.
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Figure 3.1 - Proportion of afferent nerves showing spontaneous firing
in recordings from normal and arthritic rat knee joints
Proportion of afferent fibres contained in a portion of the MAN that showed
spontaneous activity in recordings made from A) normal and B) arthritic rat
knee joints. Fibres characterised as non-active (silent) showed no
spontaneous (on-going) basal discharge, but were activated by either direct
chemical or mechanical stimulation.
A greater proportion of afferents showed spontaneous activity in arthritic
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Figure 3.2 - Basal spontaneous activity in fibres of the MAN in normal
and arthritic rat knee joints
The action potential discharge frequency (impulses s~1) of spontaneously
active fibres recorded from a portion of the MAN innervating normal and
arthritic rat knee joints. Data shown represents the mean basal discharge ±
sem for responses from normal (n=28) and chronically arthritic (n=23) joints.
There was no significant difference in the frequency of the spontaneous
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Figure 3.3 - Typical responses evoked by capsaicin, bradykinin and
ATP in a multi-fibre recording from the MAN in a normal rat knee joint
Multi-fibre neural discharge (left panel) showing the evoked response from a
portion of the MAN innervating a normal rat knee joint by a close arterial
injection of A) capsaicin (9 nmol, activated fibres 1, 3-6), B) bradykinin (9
nmol, activated fibres 3 and 4), and C) a(3meATP (60 nmol, activated fibres 2
and 6). Filters were set to allow only discharge above noise level to be
captured. Individual fibres are shown on the right panel
Typical responses showing high frequency, transient responses for the ion
channels gated by receptors for capsaicin and apmeATP and the longer-
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Figure 3.4 - Comparison of the capsaicin-evoked response obtained
from afferent nerves innervating normal and arthritic rat knee joints.
Comparison of the A) latency to onset, B) response duration, C) change in
action potential discharge frequency and D) change in total action potential
discharge following a close arterial injection of capsaicin (9 nmol). Data
shown represents the mean ± sem for pooled responses from normal (n=32)
and arthritic (n=20) joints. * P<0.05.
There was a significant decrease in the magnitude of the response in arthritic
joints when compared to normal joints.
Normal Arthritic Normal Arthritic
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Figure 3.5 - Comparison of the bradykinin-evoked response obtained
from afferent nerves innervating normal and arthritic rat knee joints.
Comparison of the A) latency to onset, B) response duration, C) change in
action potential discharge frequency and D) change in total action potential
discharge following a close arterial injection of bradykinin (9 nmol). Data
shown represents the mean ± sem for pooled responses from normal (n=15)
and chronically arthritic (n=9) joints. *** P<0.001, * P<0.05.
There was a significant increase in the duration of the response in arthritic
joints when compared to normal joints. This increase in duration resulted in
an overall increase in the number or action potentials generated.
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Figure 3.6 - Comparison of the aPmeATP-evoked response obtained
from afferent nerves innervating normal and arthritic rat knee joints.
Comparison of the A) latency to onset, B) response duration, C) change in
action potential discharge frequency and D) change in total action potential
discharge following a close arterial injection of apmeATP (60 nmol). Data
shown represents the mean ± sem for pooled responses from normal (n=13)
and chronically arthritic (n=6) joints.
There was no significant difference in any of the elements of the response
evoked by apmeATP between normal and arthritic joints.
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4. Effect of somatostatin on knee joint
nociceptors
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4.1 INTRODUCTION
Somatostatin (SOM) is a neuropeptide that is widely distributed throughout
the body. It was first discovered in 1968 as a hypothalamic extract that had an
endocrine function in its ability to inhibit the release of growth hormone from the
pituitary (Krulich et al., 1968). It has since been shown that in addition to its
endocrine role SOM displays a wide variety of effects both centrally and
peripherally, including acting as a neuromodulator and as a mediator of
inflammation, with the vast majority of its actions being inhibitory (for reviews see
Reichlin, 1983; Reichlin, 1995 and Schindler et al., 1996).
The peptide occurs naturally in two forms in mammals, a fourteen amino acid
peptide (SOM-14) and a twenty-eight amino acid peptide (SOM-28). Both isoforms
are derived from a precursor protein preprosomatostatin and they become active once
cleaved from the parent protein, which occurs in response to inflammatory mediators
such as LPS, IFN-y, TNF-a, and prostaglandin E2 (Elliott et al., 1998). The diverse
effects of SOM are mediated by five specific somatostatin receptors (SSTRi_5),
which were identified by molecular cloning. The receptors can be divided into two
classes according to their pharmacological characteristics. The first class (SSTR2,
SSTR3 and SSTR5) exhibits a high affinity for smaller peptide analogs of
somatostatin, including octreotide, and a second class (SSTRi and SSTR4) that do
not (Schindler et al., 1996). The SSTR2 receptor has also been further subdivided
into SSTR2a and SSTR2B as splice variants differ in the intracellular C-terminal, and
therefore may be capable of activating alternative signal pathways. All the receptors
are closely related, and all produce their effects through G-protein coupled
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mechanisms (reviewed in Patel, 1997; Patel, 1999). SOM-14 and SOM-28 show
equal activity at SST 1.4, however the SST5 receptor shows a 10-15-fold selectivity for
SOM-28 over SOM-14. In vivo the peptides have a short half-life of 1-3 minutes and
are rapidly degraded by tissue and serum peptidases, therefore to facilitate studies a
number of long lasting synthetic analogs have been developed, including octreotide
(Sandostatin) that increases the half-life to 1.5-2 hours and prolongs the duration of
action to approximately 12 hours (Brown, 1990). Octreotide shows highest affinity
for the SSTR2 and SSTR5 receptors. The amino acid structures of SOM-14, SOM-
28, and octreotide are shown in Figure 4.1.
SOM-28 Lys- Aitq -G1 u-Ax'jj- Px'o -A-l-s-Met -A_<a - Sex -Asri - Ala - £e r - H.H
Aid—G ly-Cys-Ly - As n - Phe - Phe-Trp
l
Cya -Sex-Thr-Phe-Thr-Lyn
SOM-14 11 H - A1 a - G1y - Cy a -Lya - As: t - Phe- ?J1e - 'T'rp
I
Cys Ser Thr Phe-Thr-Lya
sks-201-995 1octreotide) c ?he c(Cys Phe n Trp-Lye-Thr-CysJ-Thr-o1
Figure 4.1 - Structure of somatostatin and synthetic analog octreotide
Amino acid structure of the two naturally occurring somatostatin analogs,
somatostatin-28 (SOM-28) and somatostatin-14 (SOM-14) and the long-
lasting analog octreotide (Sandostatin). Adapted from Schindler et al. (1996).
SOM has been shown to possess both anti-inflammatory and anti-nociceptive
activity. Its anti-inflammatory properties have been demonstrated in animal models
of both acute and chronic inflammation (Corsi et al., 1997; Karalis et al., 1994;
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Matucci-Cerinic et al., 1995) and in human chronic inflammatory conditions such as
osteo- and rheumatoid arthritis (Ciocci et al., 1994; Coari et al., 1995; Fioravanti et
al., 1993; Fioravanti et al., 1995; Russo et al., 1997; Silveri et al., 1994). SOM is
released from many immune cells including macrophages and T-cells in response to
cytokines or other inflammatory mediators (Bjorling et al., 1997; Elliott et al., 1998).
Once released, activation of the SSTR2A receptor, also present on the majority of
immune cells, inhibits the release of other pro-inflammatory mediators including
INF-y (Elliott et al., 1999), TNF-a, IE-1 (3, and IL-6 (Grimaldi et al., 1997; Peluso et
al., 1996). Furthermore, there is a substance P (SP)/SOM immunoregulatory circuit
where increased levels of one neuropeptide inhibits the expression of the other (Blum
et al., 1998; Campbell & Scanes, 1995). SOM and SP have opposite effects on
different aspects of the inflammatory response such as neutrophil migration (Partsch
& Matucci-Cerinic, 1992) and activation (Kolasinski et al., 1992) and the production
of metalloproteinases in RA (Sakane & Suzuki, 1998). In addition to being present
in immune cells, SOM is also produced in peripheral sensory neurons and is released
from the peripheral terminals where it can act locally on adjacent terminals or
immune cells (Hokfelt et al., 2000; Szolcsanyi et al., 1998a), and is also capable of
acting systemically (Szolcsanyi et al., 1998b). Under conditions of chronic
inflammation the levels of SOM and its receptors are increased. In human RA
patients it has been shown that not only is there an increase in SOM levels in the
synovium of arthritic joints but there is also a corresponding increase in the level of
the SSTR2A receptor which becomes localised to the synovium, suggesting a
prominent role in the condition (ten Bokum et al., 1999; van Elagen et al., 1999).
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In addition to producing anti-inflammatory effects, both animal and human
studies have shown that SOM is also capable of causing analgesia. Presumably, one
mechanism for SOM-mediated analgesia is simply through its action to reduce
inflammation, and thereby reducing nociceptor sensitisation/activity by inflammatory
mediators. However it has been shown that SOM also acts directly on sensory
afferents to inhibit nociception (Heppelmann & Pawlak, 1999). Anatomical studies
of the rat DRG show the presence of both SSTR2 splice variants (Schulz et al., 1998;
Selmer et al., 2000) and the SSTR3 receptor (Senaris et al., 1995). Targeting these
receptors on peripheral afferents using SOM or its analogs inhibited activation of
mechanonociceptors in both the normal and the inflamed knee joint of the rat
(Heppelmann & Pawlak, 1997a). Furthermore, somatostatin is involved in the
control of normal tissue and joint homeostasis as there is tonic expression of
somatostatin, as evidenced by treatment with the specific antagonist cyclo-
somatostatin, which was able to increase the sensitivity of articular
mechanonociceptors to noxious movements (Heppelmann & Pawlak, 1999).
The present investigation used electrophysiological methods to examine the
hypothesis that SOM, or its long lasting analog octreotide, will inhibit the function of
polymodal nociceptors innervating the rat knee joint. It has already been shown that
somatostatin can decrease mechanonociceptor function in rat articular afferents, so
the present study examined the effect of SOM or octreotide on the spontaneous and
chemically evoked discharge from C-fibre polymodal nociceptors innervating both
normal and arthritic rat knee joints.
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4.2 METHODS
AFFERENT NERVE RECORDING IN VIVO
Induction of arthritis and subsequent neural recordings from afferent nerves
innervating the knee joint were carried out as described in Section 2.2. Experiments
were conducted in a total of 23 normal and 6 arthritic Wistar rats (body weight range
220-520 g; mean ± sem. 372 ± 14 g). Arthritis was induced 14-35 days before the
animals were used in electrophysiological studies. Animals displayed mild but
persistent unilateral arthritis as characterised by a significant increase in the diameter
of the injected joint (injected 11.0 ± 0.2 mm; uninjected 10.2 ± 0.2 mm; n=6;
P=0.008, paired t-test). Animals were anaesthetised with pentobarbitone (60 mg kg"1
i.p and deep anaesthesia maintained via a slow i.v. infusion at 0.5 mg kg"1 min"1) then
prepared surgically as detailed in Chapter 2.2. Extracellular neural activity in the
MAN was recorded using bipolar platinum-iridium electrodes. Collected data was
analysed off-line using Spike2 software. Drugs were administered by close arterial
injection into the right femoral cannula in a total volume of 0.1 ml. For the majority
of experiments the stable analog octreotide was used due to the rapid metabolism of
SOM-14 in vivo.
4.3 RESULTS
CHARACTERISATION OF AFFERENT NERVE FIBRES
Afferent neural discharge was recorded from a total of 52 individual fibres
from 23 normal knee joints and 11 individual fibres innervating 6 arthritic knee
joints. The afferents were classified as either C-fibre polymodal nociceptors or AS
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mechanonociceptors based on their conduction velocities, spike duration,
mechanosensitivity and excitation by capsaicin, as described in Chapter 2.2. In
normal joints, 43/52 (83%) of fibres were C-fibre polymodal nociceptors and 9/52
(17%) were A5 mechanonociceptors. In arthritic joints, 10/11 (91%) of afferents
were C-fibres and 1/11 (9%) was an A8 fibre. There was no significant difference in
the proportion of C-fibres or A5-fibres (P = 0.68 and P = 0.68 respectively, Fisher's
exact test) innervating normal and arthritic joints. Spontaneous discharge in these
fibres was present in 9/52 fibres (17%) in normal joints, with a mean frequency of
0.47 ± 0.31 impulses s"1, and in arthritic joints 6/11 (55%) afferents showed
spontaneous activity with a mean frequency of 0.31 ± 0.07 impulses s"1. There was a
significant increase in the number of afferents showing spontaneous discharge in
nociceptors innervating arthritic joints (P = 0.02, Fisher's exact test), however there
was no statistical difference in the mean discharge frequency (P = 0.67; unpaired t-
test) in recordings from normal and arthritic knee joints.
NEITHER OCTREOTIDE NOR SOMATOSTAIN-14 EXCITED PERIPHERAL
NOCICEPTORS
The reported inhibitory nature of somatostatin would lead one to expect that
somatostatin would not directly activate peripheral nociceptors. However, one report
has shown that SOM causes excitation of spinal neurons purportedly via C-fibre
activation (Wiesenfeld-Hallin, 1985).
A single close-arterial injection of octreotide (1-98 nmol) did not excite C-
fibre polymodal nociceptors (0/36; 0%) or A5 mechanonociceptors in normal joints.
Similar results were found in arthritic joints: no C-fibres (0/8 ;0%) or AS fibres (0/4;
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0%) were activted. As octreotide is only an agonist at SSTR2 and SSTR5 receptors,
the native protein SOM-14 was also tested in a few animals. The same results were
obtained: SOM-14 (0.6-60 nmol) was inactive in afferents innervating normal (C-
fibres: 0/7; 0% activated, and A5 fibres: 0/1; 0% activated) and arthritic joints (C-
fibres: 0/2; 0% activated, and A8 fibres: 0/1; 0% activated).
EFFECT OF OCTREOTIDE ON SPONTANEOUS AFFERENT DISCHARGE
FROM NORMAL AND ARTHRITIC KNEE JOINTS
In recordings that showed spontaneous afferent discharge we examined the
change in action potential discharge frequency for 60 s following the injection of
octreotide (10 nmol i.a.; Figure 4.2). In normal joints there was no significant
change in the afferent discharge frequency of 2.19 ± 0.73 impulses s"1 before and
2.57 ± 0.99 impulses s"1 after close arterial injection of octreotide (P = 0.28; paired t-
test; n=5 for both; Figure 4.2A). The same response was seen in arthritic joints with
a frequency of 2.51 ± 0.53 impulses s"1 before and 2.72 ±1.12 following octreotide
(P = 0.85; paired t-test; n=3 Figure 4.2B). The afferent discharge was also measured
5 minutes following the injection of octreotide, and again there was no change in the
frequency (data not shown).
Single experiments in a normal and an arthritic animal were also undertaken
using higher doses of octreotide (29 and 98 nmol) and somatostatin-14 (6 - 60 nmol),
but again there was no change in spontaneous discharge up to 5 min after drug
administration.
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EFFECT OF OCTREOTIDE ON RESPONSES FROM KNEE JOINT
AFFERENTS EVOKED BY CAPSAICIN, BRADYKININ AND apmeATP
The ability of octreotide to act as a neuromodulator was examined by
investigating excitation evoked by known algogens before and after the injection of
the neuropeptide. Responses to capsaicin, bradykinin and a|3meATP were measured
before, and 5 minutes following, close arterial injection of octreotide (10 nmol;
Figure 4.2). A minimum of 20 minutes was allowed between successive injections
of algogen in order to minimise desensitisation.
Capsaicin
The excitation of knee joint afferents evoked by capsaicin (3 nmol) before
and after octreotide (10 nmol) was examined in a total of 12 afferent fibres from 5
normal knee joints (Figure 4.3A). The mean action potential discharge frequency
evoked by caps before the injection of octreotide was 27.5 ± 6.2 impulses s"1 and the
mean number of action potentials generated was 60 ± 8 impulses. Five minutes after
the administration of octreotide the response to the same dose of capsaicin averaged
39.5 ± 12.2 impulses s"1 and the mean number of action potentials was 83 ± 22
impulses. There was no significant difference in the response obtained before and
after octreotide, either in terms of the mean discharge frequency (P = 0.29; paired t-
test), or the mean total number ofpotentials evoked (P = 0.25; paired t-test).
The native peptide was also tested to see whether it could modulate the
response to capsaicin (3 nmol). SOM-14 (6 nmol) in 3 fibres from 2 normal knee
joints had no significant effect on capsaicin-evoked discharge frequency: mean
responses to capsaicin were 24.9 ± 14.8 impulses s"1 before, and 23.9 ± 5.8 after
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SOM-14. Therefore, neither the peptide, nor the synthetic analog octreotide,
modulated the excitatory response to capsaicin.
Bradykinin
The excitation of nociceptive afferents innervating the rat knee joint evoked
by bradykinin (9 nmol) in the presence of octreotide (10 nmol) was examined in 6
fibres from 3 normal knee joints (Figure 4.3B). The mean response evoked by
bradykinin before octreotide was 5.6 ± 1.9 impulses s"1 and the total number of
action potentials evoked was 128 ± 38 impulses. Five minutes after close arterial
injection of octreotide the excitation evoked by bradykinin (9 nmol) was not
significantly different, with a mean discharge frequency of 6.4 ±3.0 impulses s"1 (P =
0.51; paired t-test) and a mean action potential discharge of 128 ± 70 (P = 0.99;
paired t-test).
a,p - methylene ATP
The rapid excitation evoked by aPmeATP (60 nmol) was examined before
and after octreotide (10 nmol) in 6 fibres from 3 normal knee joints (Figure 4.3C).
Before octreotide there was a mean increase in the discharge of 22.5 ± 14.1 impulses
s"1 and the mean number of action potentials generated was 28 ± 14 impulses. When
the same dose of aPmeATP was repeated 5 minutes after close-arterial injection of
octreotide (10 nmol) the response was not significantly different; the discharge
frequency was 14.5 ± 9.2 impulses s"1 (P = 0.29; paired t-test) and a mean absolute
discharge of 23 ± 18 impulses (P = 0.59; paired t-test).
Although octreotide and somatostatin-14 appeared not to influence either
spontaneous firing or evoked responses of peripheral nociceptors, both were
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biologically active, as demonstrated by their ability to reduce blood pressure. A
typical vasodepressor response to octreotide (10 nmol) and somatostatin-14 (6 nmol)
is shown in Figure 4.4.
4.4 DISCUSSION
This section of the thesis examined the ability of SOM and its analog
octreotide to modulate nociceptive afferents innervating the normal and arthritic rat
knee joint. Results show that neither SOM nor octreotide inhibited spontaneous
discharge arising from normal or arthritic joints. Similarly, evoked responses to
known algogens capsaicin, bradykinin, and aPmeATP were not altered after close-
arterial injection of SOM and octreotide.
Receptors for the neuropeptide SOM have been found in the rat DRG and
therefore may play a role in the modulation of peripheral nociceptor signalling (see
Introduction). In the vast majority of tissues the effect of SOM receptor activation is
inhibitory, however several reports of excitatory effects of the neuropeptide have
been noted (Randic & Miletic, 1978; Wiesenfeld-Hallin, 1985). Wiesenfeld-Hallin et
al. (1985) in particular, attributed spinal cord excitability to SOM released from
primary afferent C-fibres acting either locally on adjacent fibres or systemically once
released into the circulation. In our model similar doses of SOM-14 or octreotide
were unable to directly activate sensory afferents innervating either the normal or
arthritic rat knee joint.
It is has been reported that SOM, either exogenously applied or released from
sensory terminals by anti-dromic stimulation, is able to inhibit the activation of
mechanonociceptors innervating the rat knee joint (Heppelmann & Pawlak, 1997a;
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Heppelmann & Pawlak, 1999). In our model we examined the effect of close arterial
injection of SOM-14 and octreotide on spontaneously active afferents innervating the
rat knee joint. There was no effect on the spontaneous discharge from afferents in
either normal or arthritic knee joints. Additionally we found no effect on responses
evoked by capsaicin, bradykinin or aPmeATP after the close arterial injection of
either SOM-14 or octreotide. Although there was no effect on spontaneous or evoked
responses from nociceptors innervating the knee joint both SOM and octreotide were
capable of producing a biological effect, detected as a vasodepressor response in the
arterial blood pressure.
Although SOM-14 and octreotide do not appear to modulate spontaneous or
chemically evoked discharge from primary afferents, recent reports have shown that
SOM may still play a role in peripheral nociception. It has been shown that the
SSTR2a receptor is expressed on the peripheral terminals of primary afferents
innervating rat skin (Carlton et al., 2001a). Furthermore, in vivo following intra-
plantar injection of formalin, octreotide was able to diminish nociceptive behaviour
such as licking and chewing of the injected limb. In vitro, octreotide was also able to
inhibit bradykinin-mediated sensitisation to a noxious thermal stimulus (Carlton et
al., 2001a). In the present study the lack of effect of SOM-14 or octreotide could be
due to the fact that the neurons expressing SSTR2a receptors in the DRG are actually
associated with medium to large diameter cells (Schulz et al., 1998). Medium to
large diameter cell bodies in the DRG are characteristic of myelinated fibres of the
A5 and Ap range. As the majority of afferents recorded in the present study were C-
fibre polymodal nociceptors that arise from small diameter cells in the DRG it is
possible that the SSTR receptor is not expressed on these fibres.
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Even if SOM is not capable of modulating evoked C-fibre discharge, its
release from the peripheral terminals of these same fibres plays an important role as
both an anti-inflammatory and neuromodulator of peripheral nociceptors during
acute inflammation. SOM released from peptidergic neurons is able to inhibit
plasma extravasation at a remote site (Than et al., 2000). Therefore it is likely that
during neurogenic inflammation SOM is released together with pro-inflammatory
neuropeptides such as substance P and CGRP. It is the relative levels of SOM and
substance P/CGRP that control the release of pro-inflammatory cytokines
(Weinstock & Elliott, 1998), such as interferon y (IFNy) and tumour necrosis factor
(TNFa), that are capable of sensitising nociceptors and subsequently determine the
nociceptive threshold of sensory afferents . Proof of this hypothesis has already been
shown for mechanonociceptors innervating the normal knee joint (Heppelmann &
Pawlak, 1999) and in peripheral cutaneous C-fibre polymodal nociceptors (Carlton et
al., 2001b) that become sensitised to activation by a noxious movement or thermal
stimulus in the presence of the SOM antagonist cyclo-somatostatin.
The lack of inhibition of the spontaneous and evoked excitations of articular
nociceptors may be due to the bolus injection used for SOM and the algogenic
mediators. The administration SOM or octreotide as a bolus injection may not
permit the peptide to be present at an adequate concentration over a period of time
suffcient to alter the balance in tonically expressed pro- and anti-inflammatory
neuropeptides. Similarly, all the models detailed above involved acute inflammation
to sensitise peripheral afferents, so it may be that under conditions of chronic
inflammation the equilibrium shifts so far towards pro-inflammatory peptides that a
single bolus injection of SOM is unable to produce a significant inhibition. This
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would fit with clinical trials in RA patients who require prolonged treatment with
SOM-14 to produce analgesia (Coari et al., 1995; Fioravanti et al., 1993; Fioravanti
et al., 1995; Russo et al., 1997). Further work could be undertaken to examine the
effect of prolonged treatment with SOM or octreotide on the increased number of
spontaneously active fibres or the increased response to bradykinin in C-fibre
polymodal nociceptors innervating arthritic joints. This could be accomplished by
the implantation of osmotic mini-pumps, administering SOM over a prolonged
period.
Once the distribution of all SSTR receptors in the periphery is known, the
targeting of these receptors with the aim of altering the balance of pro- and anti¬
inflammatory mediators during chronic inflammation may provide an effective
treatment for conditions such as osteo- and rheumatoid arthritis.
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Figure 4.2 - Effect of octreotide on spontaneous discharge in afferents
innervating normal and arthritic rat knee joints
Basal spontaneous activity in peripheral nociceptors innervating A) normal
(n=5) and B) arthritic (n=3) rat knee joints before and for 60 s following close
arterial injection of octreotide (10 nmol). Data represents the mean ± sem.
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Figure 4.3 - Evoked responses to capsaicin, bradykinin, and apmeATP
following octreotide in normal rat knee joints
Mean action potential discharge frequency and total number of action
potentials evoked by A) capsaicin (3 nmol; 12 fibres from n=5 animals) B)
bradykinin (9 nmol; 6 fibres from n=3 animals) and C) apmeATP (60 nmol; 6
fibres from n=3 animals) before and 5 minutes following close arterial
injection of octreotide (10 nmol). Data represent mean ± sem.
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Figure 4.4 - Blood pressure response evoked by octreotide and
somatostatin-14 in a normal rat.
The vasodepressor response evoked by the close arterial injection (at
arrows) of A) octreotide (10 nmol) and B) somatostatin-14 (6 nmol) in a
normal rat.
Both octreotide and somatostatin induce a fall in blood pressure within
seconds of injection confirming that they were biologically active.
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5. Effect of anandamide on knee joint
nociceptors
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5.1 INTRODUCTION
The cannabis sativa plant has been used therapeutically and recreationally for
thousands of years, but very little research was done on the properties of the plant
until the isolation of the main psychoactive constituent, A9(-) tetrahydrocannabinol
(THC) by Gaoni and Mechoulam in 1964 (see detailed review by Mechoulam &
Hanus, 2000). With the development of high affinity analogs of THC, a specific
cannabinoid receptor (CBj) in the CNS was characterised (Devane et al., 1988) and
cloned (Matsuda et al., 1990). This was followed by the characterisation of a second
receptor (CB2) present in the periphery (Munro et al., 1993). Recent reports have
shown that the CBi receptor is not restricted to the CNS and is also expressed in the
periphery (Ahluwalia et al., 2000) and furthermore, CBi receptors are produced in
the cell bodies of sensory neurons in the dorsal root ganglia and are transferred by
axonal transport to the peripheral terminals of primary nociceptors (Hohmann &
Herkenham, 1999). The majority of the properties attributed to cannabis, in particular
its antinociceptive and antihyperalgesic effects are mediated through its action at the
CBi receptor either centrally (Richardson et al., 1998a) or in the periphery
(Calignano et al., 1998; Richardson et al., 1998b).
With the discovery of a receptor for cannabinoid compounds it was assumed
that there must be an endogenous compound capable of activating the receptor and
producing similar effects to THC (Martin et al., 1999; Mechoulam et al., 1998). The
first endogenous cannabinoid or endocannabinoid, arachidonoyl ethanolamide, was
isolated from pig brain and was given the name anandamide - from the Sanskrit word
"ananda" meaning "bliss" (Devane et al., 1992). Anandamide binds with moderate
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affinity to the CBi receptor and low affinity at the CB2 receptor (Khanolkar &
Makriyannis, 1999) and it possesses many of the properties of THC including
antinociceptive (reviewed in Pertwee, 2001) and antihyperalgesic action (Richardson
et al., 1998a).
ANANDAMIDE AS A NEUROMODULATOR IN NOCICEPTION
An important putative role for anandamide is as a neuromodulator of
nociception. Anandamide behaves as a classic neurotransmitter in that it is
synthesised from membrane phospholipids and released on demand by neurons after
2+
being triggered by Ca influx or cell injury. Mechanisms exist for rapid enzymatic
degradation by fatty acid amide hydrolase (FAAH) and for re-uptake by a specific
anandamide membrane transporter (Di Marzo, 1999). Once bound to the G-protein-
coupled CBi receptor, anandamide is capable of modulating neuronal membrane
permeability to Ca2+ and K+ ions and inhibiting the activity of adenylate cyclase
(reviewed in Di Marzo et al., 1998b and Howlett & Mukhopadhyay, 2000).
A role of anandamide in nociception was suggested when it was shown that
nociceptive responses were increased in the presence of the specific CBi antagonist,
SR141716A (Chapman, 1999). However, this evidence is not in accord with
recent studies in CBi knockout mice, which showed hypoalgesia in the hot-plate test,
and in addition it was still possible to induce analgesia with cannabinoids (Zimmer et
al., 1999). Although it is known that endocannabinoids are capable of inducing
intra-cellular signalling via both receptor and non-receptor pathways (Felder et al.,
1993; Felder et al., 1992) it was proposed that anandamide might produce effects
through activation of an entirely different receptor population, namely vanilloid
receptors.
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Recent reports have linked anandamide with the recently cloned vanilloid
receptor subtype 1 (VRi) which is sensitive to capsaicin (Caterina et al., 1997) and is
antagonised by capsazepine (Bevan et al., 1992; Szallasi & Blumberg, 1999). Di
Marzo et al. (1998) used the structural similarity between synthetic agonists of
vanilloid receptors and anandamide to predict interactions between the cannabinoid
and vanilloid systems. They showed that the capsaicin analog olvanil, which
exhibits some analgesic properties, is able to bind to and inhibit the anandamide
membrane transporter thereby preventing the re-uptake of anandamide (Di Marzo et
al., 1998a). Conversely, it has also been shown that anandamide is a vasorelaxant
(Randall & Kendall, 1998a; Randall & Kendall, 1998b) and this vasodilatation
results from VRi-mediated release of calcitonin-gene-related peptide (CGRP) from
perivascular sensory nerves (Zygmunt et al., 1999).
The present investigation used electrophysiological methods to examine the
affect of anandamide on the function of peripheral nociceptors innervating normal
and chronically inflamed arthritic knee joints. Both CBi and VRi receptors are co-
localised in small diameter cell bodies in the DRG and therefore are likely present on
the peripheral terminals of jont afferents, a study was undertaken to test whether
anandamide affects spontaneous or chemically evoked discharge in normal knee
joints, or in the joints of rats with FCA-induced experimental arthritis, via activation
of peripheral CBi receptors. In addition the ability of anandamide to directly activate
peripheral nociceptors through activation of the VRi receptor was also examined.
The hypothesis was that since the VRi receptor is readily desensitised by stimulation
the analgesic effect of anandamide may be a result of its action on peripheral
nociceptors to diminish their responsiveness.
104
Chapter 5 - Anandamide and Peripheral Nociceptors
5.2 METHODS
AFFERENT NERVE RECORDING IN VIVO
Arthritis induction and neural recordings were carried out as described in
Chapter 2.2. Experiments were conducted in a total of 16 normal and 10 arthritic
Wistar rats (body weight range 230-470 g; mean ± sem. 375 ± 12 g). Arthritis was
induced 14-35 days before the animals were used in electrophysiological studies.
Animals displayed mild but persistent unilateral arthritis as characterised by a
significant increase in the diameter of the injected joint (injected 10.5 ± 0.1 mm;
uninjected 9.8 ± 0.1 mm; n=10; P=0.0001, paired t-test). Animals were
anaesthetised with pentobarbitone (60 mg kg"1 i.p; deep anaesthesia maintained by
infusing 0.5 mg kg"1 min"' i.v.) then prepared surgically as detailed in Chapter 2.2.
Extracellular neural activity in a filament of the MAN was recorded using bipolar
platinum-iridium electrodes. Collected data was analysed off-line using Spike2
software. Drugs were administered by close arterial injection into the right femoral
cannula in a total volume of 0.1 ml.
5.3 RESULTS
CHARACTERISATION OF AFFERENT NERVE FIBRES
Afferent neural discharge was recorded from a total of 48 individual fibres
from 16 normal knee joints and 24 individual fibres innervating 10 arthritic knee
joints. The afferents were classified as either C-fibre polymodal nociceptors or A5
mechanonociceptors based on their conduction velocities, spike duration,
mechanosensitivity and responsiveness to capsaicin as described in Chapter 2.2. In
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normal joints, 41/48 (85%) of fibres were classified as C-fibre polymodal
nociceptors and 7/48 (15%) were classified as A5 mechanonociceptors. In arthritic
joints, 21/24 (87%) of afferents were classified as C-fibres and 3/24 (13%) were
classified as A8 fibres. There was no significant difference in the proportion of C and
A5 between normal and arthritic joints ( P = 1.00 and P = 1.00 respectively, Fisher's
exact test). On-going (spontaneous) discharge occurred in 15/48 fibres (31%) in
normal joints, with a mean discharge frequency of 0.01 ± 0.01 impulses s"1 and in
arthritic joints 11/24 (46%) afferents showed spontaneous activity with a mean
discharge frequency of 0.04 ± 0.01 impulses s"1. There was no significant difference
in the mean discharge frequency recorded from normal and arthritic knee joints (P =
0.12; unpaired t-test).
ANANDAMIDE-EVOKED ACTIVATION OF KNEE JOINT AFFERENTS
Proportion of afferents activated by anandamide
A single close arterial injection of anandamide (8.6 nmol - 2900 nmol)
evoked an increase in afferent discharge that was rapid in onset and of a short
duration (Figure 5.1). The excitatory response to anandamide was present in 21/41
(51%) C-fibre polymodal nociceptors but was not seen in any of the A5-
mechanonociceptors studied (0/7; 0%) in normal knee joints. Similarly, in arthritic
joints anandamide evoked a response in 10/21 (48%) C-fibre polymodal nociceptors
but did not excite A5 mechanonociceptors (0/3; 0%), there was no significant
difference in the proportion of afferents innervating normal and arthritic joints (C-
fibres: P = 1.00, A-fibre: N/A; Fisher's exact test; Figure 5.2). Anandamide was
injected in a suspension of soya oil and water (1:4) and injection of vehicle (0.1 ml)
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had no effect in these fibres with a mean discharge frequency of -0.1 ± 0.1
impulses-s"1 (n=5).
Dose-related increase in the nociceptor action potential discharge evoked by
anandamide
The excitation evoked by anandamide in the C-fibre polymodal nociceptors
innervating the knee joint was dose-dependent for both the total action potential
discharge (Figure 5.3A) and the discharge frequency (Figure 5.3B). Due to the
limited solubility of anandamide, the maximum dose that could be administered was
2900 nmol - the stock solution supplied. For this reason the maximum response was
that evoked by 2900 nmol. As a result it was impossible to calculate exact ED5o
values and so apparent ED50 values were calculated, based on the response to 2900
nmol being "maximum". The mean apparent ED50 for the activation of C-fibres by
anandamide in normal joints (n=3) was 1.1 ± 0.7 pmol and 3.0 ± 0.9 pmol in arthritic
joints (n=3) - this difference was not statistically significant (P = 0.20, Mann-
Whitney)
Features of the anandamide-evoked response
The onset delay, duration, and magnitude of the response evoked by a sub-
maximal dose (860 nmol) of anandamide were determined in both normal (n=15
individual fibres from 5 animals) and arthritic knee joints (n=l 1 individual fibres
from 6 animals). The magnitude of the response was calculated both in terms of the
number of action potentials generated in an evoked discharge, and the discharge
frequency. Figure 5.4 shows a typical excitatory response to anandamide (860 nmol)
recorded from nociceptive afferents innervating normal and arthritic knee joints.
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Response latency
Anandamide rapidly excited afferents innervating the knee joint (Figure
5.5A). In normal joints the mean response latency to 860 nmol of anandamide was
4.5 ± 0.5 s and the corresponding figure for arthritic joints was 5.2 ± 0.4 s. There
was no significant difference in the response latency between normal and arthritic
joints (P = 0.28; unpaired t-test)
Response duration
The response to anandamide was short lasting in both normal (n=5) and
arthritic (n=6) joints with mean response durations of 4.8 ± 1.0 s and 3.9 ± 1.1 s
respectively. Figure 5.5B illustrates the response duration; there was no significant
difference between normal and arthritic animals (P = 0.54; unpaired t-test)
Magnitude of the response
The magnitude of the excitatory response elicted by anandamide was
examined in terms of the discharge frequency (Figure 5.5C) and total number of
action potentials generated (Figure 5.5D). In normal joints (n=5) the mean discharge
frequency was 7.2 ± 2.3 impulses-s"1 where the mean number of action potentials
generated was 67 ± 25. Arthritic joints (n=6) had a mean discharge frequency of 9.7
+ 3.0 impulses-s"1 and a mean action potential discharge of 50 ± 24 impulses. Once
again there was no significant difference between normal and arthritic joints for the
frequency of the response or the number of action potentials produced (P = 0.53 and
P = 0.65 respectively; unpaired t-test).
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EFFECT OF ANANDAMIDE ON EXCITATORY RESPONSES EVOKED BY
ATP, BRADYKININ AND CAPSAICIN
As part of the routine pharmacological characterisation of the joint afferents,
injections of algogens in doses capable of activating polymodal nociceptors were
administered during each experiment. These algogens included capsaicin,
bradykinin, and ATP or its stable analog, aPmeATP. They were given before and
after multiple, increasing doses of anandamide (8.6 nmol - 2900 nmol), thereby
permitting the examination of the effect of anandamide on the evoked responses -
results are shown in Table 5.1.
In normal joints the response to bradykinin (9 nmol) was 1.7 + 0.7
impulses-s"1, and after anandamide it was not significantly different with a response
of 1.3 ± 0.6 impulses-s"1 (n=8 individual fibres from 2 animals; P = 0.14, Wilcoxon).
The response to ATP (2000 nmol) was unchanged after the administration of
anandamide (P = 0.69, Mann-Whitney) with a response of 14.8 ± 6.0 impulses-s"1
prior to anandamide and 11.2 ± 4.7 impulses-s"1 following (n=5 individual fibres
from 2 animals). In arthritic joints after anandamide, there was no significant
difference in the response to bradykinin or ATP (P = 0.43 and P = 0.31 respectively;
Wilcoxon), with evoked discharge averaging 2.2 ± 0.6 impulses-s"1 and 1.3 ± 0.5
impulses-s"1 (n=6 individual fibres from 3 animals) before and after bradykinin
respectively, and 2.3 ± 1.5 impulses-s"1 and 6.5 ± 2.5 impulses-s"1 (n=4 individual
fibres from 3 animals) before and after ATP respectively.
The response to capsaicin (9 nmol) was also examined before and after
anandamide. In normal joints, the evoked discharge averaged 21.0 ± 7.6 impulses-s"1
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before, and 12.1 ± 3.5 impulses-s"1 after anandamide, and this difference was not
statistically significant (P = 0.46, Wilcoxon, n=12 from 4 animals). Similarly, no
difference was seen in the arthritic joints, with responses of 11.6 ± 2.0 impulses-s"1
before and 8.1 ± 2.2 impulses-s"1 after anandamide (n=l 1 from 6 animals; P — 0.28,
Wilcoxon).
COMPARISON OF THE CAPSAICIN AND ANANDAMIDE-EVOKED
RESPONSES IN NORMAL KNEE JOINTS
It was proposed that, in addition to the activation of CBi receptors, some of
the actions of anandamide might be attributable to the activation of vanilloid VRi
receptors (see Introduction). The afferent nociceptive excitation generated by a sub-
maximal dose of anandamide (860 nmol) was compared to that produced by a
standard dose of capsaicin (9 nmol). Figure 5.1 shows the typical responses evoked
by anandamide and capsaicin, and it can be seen that, generally speaking, the two
responses are similar. Furthermore all the afferents activated by anandamide (21
afferents from 16 animals) were also excited by capsaicin.
The examination of the components of the responses, in terms of the response
latency, duration, and magnitude, for capsaicin and anandamide are shown in Figure
5.6. The delay in onset of the response was longer following anandamide in
comparison with capsaicin (4.5 ± 0.5 s and 2.6 ± 0.3 s respectively), and this
difference was statically significant (P = 0.002; unpaired t-test; Figure 5.6A). Both
drugs produced excitations with short durations of 8.2 ± 4.5 s for capsaicin and 4.8 ±
1.0 s for anandamide and the difference was not significant (P = 0.37; unpaired t-test;
Figure 5.6B). The magnitude of the response is obviously dependent on the dose
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administered, and the doses were chosen to generate similar levels of afferent
excitation. There was no significant difference in the magnitude of the excitatory
responses when the total number of action potentials generated by either capsaicin or
anandamide (P = 0.11; unpaired t-test; Figure 5.6D) was measured. However, the
mean discharge frequency evoked by capsaicin was significantly larger than that seen
following anandamide (P = 0.02; unpaired t-test; Figure 5.6C).
RESPONSE TO ANANDAMIDE IS ABOLISHED BY THE VRi
ANTAGONIST, CAPSAZEPINE
In order to confirm the activation of polymodal nociceptors by anandamide
was attributable to activation of VRi receptors, the effects of both capsaicin (9nmol)
and anandamide (2900 nmol) were examined in the presence of the VRi antagonist
capsazepine (1 mg kg"1). In a normal rat knee joint, capsazepine completely
abolished the afferent response to both capsaicin and anandamide (Figure 5.7).
Capsazepine has a short half life in vivo and therefore the effect was short-lasting -
the excitatory response to both drugs recovered after 20 minutes. Furthermore the
effect was specific to capsaicin and anandamide, as responses to both bradykinin (9
nmol) and a(3meATP (60 nmol) were not affected by capsazepine (Table 5.2).
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5.4 DISCUSSION
The primary, and somewhat unexpected finding from this in vivo study is that
close intra-articular injection of anandamide causes a dose-dependent rapid onset,
short-lasting excitation in a sub-population of polymodal nociceptors in normal and
arthritic rat knee joints.
Anandamide is an agonist at CBi and CB2 receptors, and both types are
present in the periphery - CBi receptors are localised to sensory nerves and the CB2
receptors are expressed on immune cells, such as mast cells, B-cells and natural killer
cells. The ability of anandamide to activate nociceptors was unexpected and appears
to be inconsistent with previously reported anti-nociceptive actions associated with
CBi receptor activation. Cannabinoids act on the CBi receptor both centrally in the
brain and spinal cord, and peripherally in the dorsal root ganglion, to cause analgesia
(reviewed in Fuentes et al., 1999; Pertwee, 2001; Walker et al., 1999). In the present
study the focus was on determining what effect anandamide has on peripheral
nociceptive nerve terminals located in an articular joint. Analgesic effects of the CBi
receptor appear to result from relatively low doses of cannabinoids, and the high
doses of anandamide required to activate peripheral nociceptors in our study are
likely to result from actions on a different pharmacological receptor.
The rapid onset of the response to anandamide eliminates a number of
potential indirect mechanisms, such as activation of the CB2 receptor on immune
cells triggering the release of algogenic mediators. Furthermore, even allowing for
the rapid metabolism of anandamide to arachadonic acid and subsequently to
eicosanoids, the latency of onset of the response is too short to result from the action
of a metabolite. The rapid response is not characteristic of G-protein coupled
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receptor activation; rather it is more representative of the response of a ligand-gated
ion-channel, such as the VRi receptor channel (Szallasi & Blumberg, 1999).
It is now known that anandamide is a full agonist at the human VRi receptor
when expressed in HEK293 cells (Smart et al., 2000), and the vasodilatory action of
anandamide is a result of VRi mediated release of CGRP (Zygmunt et al., 1999).
The afferents activated by anandamide were all sensitive to capsaicin, but the
corollary did not apply as only 64% and 72% of capsaicin sensitive afferents were
activated by anandamide in normal and arthritic joints respectively. The VRi
receptor is expressed on approximately 88% of small to medium neurones in the
dorsal root ganglion (Michael & Priestley, 1999). These are the cell bodies for thinly
myelinated (AS) or unmyelinated (C) fibres running from the periphery. Although
the VRi receptor is not present on all sensory afferents, our study did not reveal
afferents that are sensitive to anandamide but insensitive to capsaicin. Furthermore,
the present work showed that activation of capsaicin sensitive sensory nerves in vivo
by anandamide can be abolished by the VRi antagonist capsazepine (1 mg kg"1).
Therefore, excitation of peripheral nociceptors by high doses of anandamide appears
to involve a VRi-dependent mechanism. In addition, it can be concluded that if
cannabinoid receptors are present on peripheral terminals they are not excitatory.
Capsaicin, even in small doses, desensitised the VRi receptor in our
preparation, whereas anandamide did not cause desensitisation either to capsaicin or
itself in the doses tested. Future experiments should examine the afferent response to
anandamide after a desensitising dose of capsaicin (>86 nmol).
Fow doses of cannabinoids can produce anti-hyperalgesia and anti-
nociception when acting both centrally and peripherally (Johanek et al., 2001). In
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the present study higher doses of anandamide were examined to determine the effect
on responses evoked by other algogens commonly used to characterise primary
nociceptive afferents. The results show that responses to three of these (capsaicin,
bradykinin, and ATP) were not significantly different after anandamide (860, 2900
nmol). Therefore anandamide did not reduce the chemosensitivity of primary
sensory afferents. More detailed experiments are required to determine whether the
high threshold mechanosensitivity or thermo-sensitivity of these afferents is affected
by high doses of anandamide.
Recently there has been debate in the literature that the concentrations of
anandamide required to activate VRi are not physiologically relevant (Smart &
Jerman, 2000; Szolcsanyi, 2000a; Szolcsanyi, 2000b; Zygmunt et al., 2000). It is
still not clear at what concentration anandamide might be present at peripheral nerve
terminals. To determine this would require direct measurement of anandamide
concentration at peripheral terminals requiring techniques that are not currently
available. It is possible that levels of locally produced ligand are sufficient for
activation of nearby sensory nerve terminals. Similarly, it is possible that an
unknown endogenous compound, similar to anandamide in structure with a higher
affinity for the VRi receptor, exists. Regardless ofwhether the ability of anandamide
to activate the vanilloid receptor has any physiological significance, it does have
pharmacological relevance with regard both to the pharmacological profile of
anandamide and to the development of novel vanilloid receptor ligands.
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TABLES AND FIGURES
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Table 5.1 - Effect of anandamide on evoked excitation from nociceptive
afferents by ATP, bradykinin and capsaicin.
Comparison of the ability of a close-arterial injection of anandamide (860
nmol) to inhibit evoked excitation from articular nociceptive afferents
innervating the normal and arthritic rat knee joint. Results are the mean
afferent discharge frequency ± sem (impulses s~1).
Anandamide at high doses is not able to inhibit the excitation of nociceptive
afferents by ATP, bradykinin, or capsaicin in normal and arthritic joints.
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Table 5.2 - Responses evoked by bradykinin and apmeATP before and
after capsazepine
Comparison of the excitation evoked from articular nociceptive afferents
innervating the normal and arthritic rat knee joint by bradykinin and
apmeATP following the close-arterial injection of capsazepine (1 mg kg"1).
Capsazepine does not inhibit excitation evoked from nociceptive afferents by
bradykinin or apmeATP.
After Capsazepine
Response (lmg kg"1; i.a.)
Bradykinin Discharge
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Figure 5.1 - Anandamide excites a population of sensory afferents in
the normal rat knee joint.
Multi-fibre neural discharge (left panel) recorded from a portion of the MAN
showing the response evoked from individual fibres (right panel) by close-
arterial injection of A) anandamide (860 nmol, which activated fibres 1, 3, and
4), B) capsaicin (9 nmol, activated fibres 1, 3-6), C) bradykinin (9 nmol,
activated fibres 3 and 4), and D) a(3meATP (60 nmol, activated fibres 2 and
6). Anandamide response shown in comparison to data presented earlier
(see Figure 3.3). Filters were set to allow only discharge above noise level to
be captured. Individual fibres are shown on the right panel.














Chapter 5 - Anandamide and Peripheral Nociceptors
Figure 5.2 - Proportion of C and A5 fibres activated by anandamide
Proportion of afferent fibres both A) C-fibre polymodal nociceptors and B) AS
mechanonociceptors activated by anandamide (860 nmol-2900 nmol; close
i.a.) in normal (n=41 individual fibres from 16 animals) and arthritic (n=21
individual fibres from 10 animals) rat knee joints.
Anandamide activated a population of C-fibre polymodal nociceptors in both
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Figure 5.3 - Anandamide activates sensory afferents in a dose-
dependent manner
Typical log dose response curves displaying the dose-related increase in A)
the total number of action potentials produced (impulses) and B) discharge
frequency (impulses s"1) evoked by close arterial injection of anandamide
(8.6 - 2900 nmol) in a normal knee joint.
Anandamide evoked action potential discharge in a dose-dependent manner
from nociceptive afferents of the MAN
I 1—i—i i i 1111 1—i—i i 11111 1—i—i i 11111 1—i—i i i 1111
1Q-9 10-8 10-7 10'6 10"5
Anandamide dose (mol)
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Figure 5.4 - Excitatory effects of anandamide on afferent discharge
recorded from normal and arthritic knee joints.
Neural discharge showing the response evoked from individual nociceptive
(capsaicin positive) fibres (right panel) recorded from the MAN innervating
the A) normal and B) arthritic rat knee joint by close-arterial injection of
anandamide (860 nmol; arrow). The upper panels show the arterial blood
pressure and the lower panel is a bar graph representing the pooled
discharge of the individual fibres. Individual fibres are shown in the right
panel. Discharge is displayed in 1 s bins.
Close arterial injection of anandamide induces a rapid, short duration
excitation from articular afferents innervating both normal and arthritic joints.
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Figure 5.5 - Comparison of the excitatory response recorded from
nociceptive afferents in normal and arthritic rat knee joints following
injection of anandamide
Comparison of the A) latency to onset, B) response duration, C) change in
action potential discharge frequency and D) change in total action potential
discharge following a close arterial injection of anandamide (860 nmol). Data
shown represents the mean ± sem for responses from normal (n=15
individual fibres from 5 animals) and chronically arthritic (n=11 individual
fibres from 6 animals) joints.
There is no significant difference in any facet of the response in comparisons
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Figure 5.6 - Comparison of the excitation evoked by capsaicin and
anandamide from articular nociceptive afferents innervating normal rat
knee joints.
Comparison of the A) latency to onset, B) duration of the response, C) action
potential discharge frequency and D) total number of action potentials elicited
following a close arterial injection of sub-maximal doses of either capsaicin (9
nmol) or anandamide (860 nmol). Data shown are mean ± sem for pooled
responses from n=5 rats. ** P<0.01, * P<0.05; unpaired t-test.
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Figure 5.7 - Effect of capsazepine on afferent discharge evoked by
capsaicin and anandamide from nociceptive afferents innervating a
normal rat knee joint.
Afferent discharge from a single C-fibre innervating a normal knee joint
before by A) capsaicin (9 nmol) or B) anandamide (2900 nmol) before and
after a bolus injection of capsazepine 1mg kg"1. Capsaicin was administered
at the arrows and capsazepine at the circle. The time interval between
panels is 20 minutes. Histogram shows the number of action potentials
generated and is grouped into 1s bins.
Capsazepine reversibly abolished the excitatory responses to capsaicin and
to anandamide.
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6. FCA-induced unilateral arthritis in the mouse
knee joint
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6.1 INTRODUCTION
Experimental arthritis using FCA induces a chronic inflammation in the rat
knee joint that causes sensitisation of sensory nociceptors. The unilateral nature of
the inflammation allows the behavioural examination of hyperalgesia and allodynia
associated with the inflammation. A number of inflammatory mediators have been
examined in the rat including bradykinin (Kelly et al., 1995a), 5-hydroxytriptamine
(Birrell et al., 1990a), ATP (Dowd et al., 1998b) and adenosine (Dowd et al., 1998a)
using both behavioural testing of hyperalgesia and electrophysiological examination
of nociceptor function. To fully characterise the responses requires specific agonists
and antagonists for the receptor of interest. Developments in molecular biology now
mean that receptors can be targeted by genetic manipulation without the need for
specific pharmacological tools.
The manipulation of DNA in experimental animals, particularly in the mouse,
has allowed nociception to begin to be examined at the level of the gene. Using this
technology a great number of transgenic mouse lines have been derived with
relevance to inflammatory or painful conditions in which a specific receptor or
protein has been over expressed or completely removed in the animal from the start
of development. This provides an opportunity to study these animals for alterations
in their ability to develop chronic inflammation and the sensitisation of peripheral
nociceptors by the application of appropriate models to the genetically altered
animals.
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MURINE MODELS OF ARTHRITIS
Animal models do not provide an exact mimicry of any human arthritic
disease, however they do provide insight into key aspects of the human condition and
can be used to improve therapeutic treatment. Models follow from specific ideas
involving the aetiology of the condition.
Collagen-induced arthritis (CIA) is based on the principle that arthritis
(particularly RA) is a result of a loss of tolerance against a collagen specific auto-
antigen (Holmdahl et al., 1988; Holmdahl et al., 1989; Trentham et al., 1977). The
CIA model is characterised by a polyarthritis and a pathogenesis that is in many
ways similar to that seen in RA with characteristic changes including an intense
synovitis with severe cartilage and bone erosion by a pannus-like tissue (Stuart et al.,
1985). Although the model allows for the examination of mediators involved in
autoimmune cartilage and bone destruction it is only inducible in susceptible strains.
The susceptible strains include DBA/1 and B10RIII mice, however even in these
strains only 20-40% of the animals develop arthritis with CIA ((Myers et al., 1995;
Myers et al., 1997).
Other models utilise a local T-cell mediated inflammation to produce a long
lasting inflammation. Antigen-induced arthritis (AIA) is produced by the
introduction of methylated bovine serum albumin (mBSA) into the knee joint after
immunisation (Brackertz et al., 1977b; Brackertz et al., 1977c). The mBSA is not
readily cleared from the joint space and remains in the joint inducing a chronic
inflammation by a local immune response (van den Berg et al., 1982; van den Berg
et al., 1984). Once the response to the antigen has been established it is possible to
produce flare-up by systemic administration (Lens et al., 1984). AIA is inducible in
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a number of mouse strains however the severity of the arthritis varies greatly
between strains with C57BL6 mice producing a maximal response (Brackertz et al.,
1977a; Williams et al., 1993).
Producing a local inflammation by the introduction of xenobiotic material
from either yeast or bacteria can also induce arthritis by the activation of
complement. Zymosan is a yeast component that when injected into the knee joint of
mice produces cartilage and joint destruction (Keystone et al., 1977; van den Berg et
al., 1981). Streptococcal cell wall (SCW) induced arthritis, in addition to stimulating
complement, also shows cross reactivity as activated immune cells attack
components of the articular cartilage that resemble bacterial constituents. Given
systemically in the rat SCW injection leads to a severe polyarthritis with a
pathogenesis like that seen for systemic administration of FCA (van den Broek,
1989). In the mouse, systemic injection of SCW does not lead to a chronic
inflammation however arthritis can be induced by either single or repeated local
injections (van den Broek et al., 1988).
AIA and SCW-arthritis are characterised by inflammatory cell infdtration,
hyperplastic changes in the synovial lining as well as pannus formation with
associated cartilage destruction and bone erosion (Andersson et al., 1998a;
Andersson et al., 1998b; van den Broek et al., 1988).
TRANSGENIC MOUSE STRAINS AND ARTHRITIS
Murine models of arthritis permit the examination of the role of a specific
receptor or protein in the development and maintenance of the disease state by
testing the model on transgenic animals. Genetically modified animals are
theoretically capable of conclusively showing the relevance of a particular receptor
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or mediator by eliminating it completely through disrupting the gene sequence or
over-expressing it by adding multiple copies of the gene into the DNA of the animal.
However, it should be noted that genetic manipulation does not always produce the
expected phenotype; this observation is particularly common where genes encoding
targets known to be involved in pain processing are deleted, producing no overt
disease-relevant phenotype (COX-1, COX-2, mu-opiate - see (Wilson & Mogil,
2001)). In these cases, observation of the effect of the transgene would not have
supported development of analgesics based on manipulation of these targets, yet
clearly such analgesics are clinically effective. Nonetheless, in the absence of
effective pharmacological tools, the transgenic process remains an important and
potentially useful manner of assessing the effectiveness of manipulation of a target in
models of disease. This process was used to examine the role of the purinoceptor
P2X7 in experimental arthritis by producing a strain of mice lacking the P2X7
receptor.
The P2X7 receptor is a subtype of ATP-gated cation channel receptors
(Khakh et al., 2001; Rassendren et al., 1997) that are expressed primarily on immune
cells (Chessell et al., 1997; Collo et al., 1997; DiVirgilio, 1995; DiVirgilio et al.,
1998; Ferrari et al., 1997b). As extracellular levels of ATP are elevated during
inflammation it has been proposed that the P2X7 receptor may play a role in the
development of inflammatory conditions. ATP is able to trigger the release of the
pro-inflammatory cytokine IL-1(3 from immune cells and it does this via activation of
the P2X7 receptor (Ferrari et al., 1997a; Grahames et al., 1999). Once released, IL-
ip is has been shown to be responsible for cartilage degradation and bone erosion in
a number of animal models (Joosten et al., 1999; Kuiper et al., 1998) and in human
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RA patients (van den Berg, 2000a). Direct injection of IL-1 into the knee joint has
been shown to produce arthritis in rabbits (Pettipher et al., 1988), rats (Hrubey et al.,
1991) and mice (Chandrasekhar et al., 1990; van de Loo et al., 1989) and an existing
inflammatory condition can be exacerbated by IL-1 injection (van de Loo et al.,
1992). Furthermore, studies with monoclonal antibodies have shown that blocking
IL-1 reduces arthritic changes (Joosten et al., 1999; Joosten et al., 1996). If the P2X7
mediated release of IL-1 contributes to a large proportion of the IL-1 present in
arthritic joints then the interruption of receptor function may go a long way to
preventing the pathological changes seen in arthritis.
AIMS OF THE STUDY
The aim of this study was to use a unilateral model of murine arthritis to
examine transgenic mice with alterations relevant to chronic inflammation and pain.
We examined previously described methods for the induction of unilateral arthritis in
mice. When it was shown that existing methods did not provide the model required
we developed a new model using intra-articular injections of FCA. The model was
characterised to show its relevance as an arthritis-like inflammation. The model was
then used to examine the role of the purinoceptor P2X7 in the induction or
experimental arthritis. Furthermore, to correlate with electrophysiological work done
in the rat, a technique was developed to permit recording from sensory afferents
innervating the mouse knee joint.
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6.2 METHODS
INDUCTION OF UNILATERAL ARTHRITIS
This component of the thesis details the development of a murine model of
unilateral arthritis. The protocol presented below is the final adopted method for the
induction of chronic inflammation.
Male C57 Black 6 (C57BL6; Charles River, UK) and DBA-1 (Harlan, UK)
mice (8 weeks old) were used to establish a unilateral model of chronic joint
inflammation. Animals were housed 8 per cage in a 12-hour light/dark environment
and were given free access to standard animal feed and water for the duration of the
study. Mice were injected with either Freund's Complete Adjuvant (FCA, 1 mg ml"1
Mycobacterium tuberculosis in paraffin oil, Sigma) or vehicle (heavy liquid paraffin
oil, HLP). Briefly, injections were carried out during transient anaesthesia (3%
halothane in oxygen) and a small incision was made over the left knee joint to allow
visual identification of the patella tendon. FCA or HLP (5 pi) was injected under the
patella tendon and directly into the synovial space of the knee joint using a 30-gauge
needle mounted on a 50 pi Hamilton syringe. To achieve a long lasting inflammation
the injections were repeated 4 times (once a week for four weeks).
ASSESSMENT OF ARTHRITIS
Animals were scored for inflammation and a hyperalgesic or allodynic
response to a mild noxious stimulus, and weighed; this was done before inducing
arthritis, and at least twice weekly thereafter. Joint swelling, gait and hyperalgesia
were each measured subjectively (scored 0-3, where 3 is maximal). The same
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experienced operator performed all measurements and used his experience to apply
consistent stimuli that were subjectively assessed.
Body Weight
Body weight of the animals was monitored throughout the experiment and
was used as an overall measure of animal health and potential level of discomfort
associated with the repeated injection protocol. Animals in severe chronic pain will
not gain weight as normal (Greenwald & Diamond, 1988).
Inflammation
Inflammation (when present) induced by either FCA or HLP was monitored
throughout the experiment by measuring the joint diameter of both the injected and
uninjected hind limb using micro-callipers, accurate to 0.01 mm (Mitutoyo, Japan).
Joint swelling was also assessed subjectively by evaluation using a 0 (normal) to 3
(extreme joint deformation).
Hyperalgesia/weight bearing allodynia
Subjective measures were used to correlate apparent hyperalgesia and
allodynia with inflammation of the joint induced by FCA; a 0 (normal) - 3 (extreme
discomfort) scale of the response to a noxious stimulus was employed in the absence
of any rapid, reproducible and convenient qualitative index. Testing involved
squeezing the joint between thumb and forefinger and determining the level at which
the animal withdrew the limb (normal end-point) or vocalised (rare). To estimate the
amount of pressure being applied to the joint, saline-filled elastic tubing the same
diameter as the joint and connected to a pressure transducer was squeezed in a
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similar manner to the joint to provide a force in pressure in g/mm2 (Table 6.2). In the
majority of cases, in response to gradually increasing applied pressure the animal
withdrew the limb without vocalising. Similarly the weight-bearing allodynia
(favouring of the injected limb during normal locomotion) was assessed by
examining the gait of the animal and protecting the injected limb by raising it off the
ground, again qualitatively by using a 0 (normal gait) to 3 (three legged gait) scale.
Drug treatment
Treatment of an established arthritis was carried out using two standard
drugs, namely the steroid prednisolone and the non-steroidal anti-inflammatory
indomethacin and vehicle-treated controls. Prednisolone (1 mg kg"1) was
administered daily by intra-peritoneal (i.p.) injection. Indomethacin (1 mg kg"1) was
administered daily by sub-cutaneous (s.c.) injection. Treatment began 7 days after
the final injection of FCA on experimental day 28 and was continued for a period of
7 days. Drugs were coded before the injections began and were unknown to the
person measuring the animals until the end of the experiment.
Histopathology
Animals were killed on day 28 (no drug treatment) or day 35 (with drug
treatment) by cervical dislocation and the left and right knee joints surgically
removed for histology. In some cases the ipsilateral ankle joint was removed to
check for spread of the inflammation to additional joints.
Fixation of tissue
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The knee joints were collected by cutting through both the femur and the
tibia. Joints were taken with the skin intact and placed into screw-top vials where
they were fixed in 30 ml of 10 % neutral buffered formalin (Sigma) for a minimum
of 5 days at room temperature.
Decalcification ofknee joints
Fixed tissue was transferred from the vials to cassettes and then decalcified in
Kristenson's Fluid (5.1 M formic acid, 0.6 M sodium formate) for 1 week. After 1
week the samples were trimmed to remove excess tissue. The skin was removed
from the samples and then a cut was made straight through the joint just off the
midline. Samples were placed cut side down in the cassettes and returned to the
decalcification solution for at least one week.
Histology and staining
After decalcification the samples were embedded in paraffin wax and
sectioned. Briefly, samples were stored on ice until they were sectioned to keep the
tissue and wax firm. Two sections, each of 3 pm, were cut from each joint and
floated out in a 50 °C water bath. Each section was transferred to a labelled glass
slide. For each knee joint one section was stained with haematoxylin/eosin and the
other section stained with toluidine blue.
Evaluation ofjoint damage
The stained sections were evaluated at GlaxoSmithKline (Ware, UK) by Dr.
Christopher Clarke. The evaluation was done on coded specimens without prior
knowledge of the treatment groups or transgenic status. The severity of the
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inflammation, joint damage, and characteristic markers of arthritis was arbitrarily
scored subjectively on a sliding scale (1 = slight to maximum 5 = very marked) in the
categories shown in Table 6.1.
Electrophysiological recording from the saphenous nerve
Male C57BL6 mice (8-12 weeks), either normal or 7-14 days after treatment
with FCA, were used for the electrophysiological characterisation of sensory
afferents innervating the knee joint. The preparation was set up much the same as
for the rat (see Chapter 2.2) with a few changes made due to size differences between
rats and mice - for a schematic of the preparation see Figure 6.1. The small size of
the nerve made it impossible to record from the medial articular nerve (MAN) in the
mouse. The afferents that make up the MAN join the main saphenous nerve in the
medial aspect of the leg, so recordings were made from the saphenous nerve and the
input restricted to afferents that make up the receptive field of the knee joint by
eliminating all responses other than that through the MAN.
Anaesthesia and surgicalprocedures
Animals were anaesthetised with urethane (0.7 ml per 100 g of body weight,
i.p., 20% w/v ethyl carbamate in saline). Deep anaesthesia was defined as the point
at which the toe-pinch withdrawal reflex was abolished. If the initial injection of
urethane did not produce deep anaesthesia then additional urethane (0.1 ml per
injection; i.p.) was given until the mouse was adequately anaesthetised. The animal
was placed on a thermal blanket to maintain body temperature at 37°C. The trachea
was cannulated (cannula OD: 1.0 mm) to facilitate artificial respiration if required.
The right femoral artery was cannulated with a small diameter cannula (OD < 0.5
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mm), made by pulling out a plastic 1 ml syringe. The cannula was inserted as near as
possible to the abdominal aorta to allow for the introduction of drugs to the left hind
limb by close arterial injection (i. art.) - as in the rat (see Chapter 2.2)
Recordingfrom the saphenous nerve
The left hind limb was fixed to a stable support and a small pouch made by
opening the skin above the joint and sewing it to a small brass ring. The pouch was
filled with HLP to produce an electrically isolated system. Recording from the very
fine afferents innervating the mouse knee joint involved cutting the saphenous nerve
above and below the knee, thereby recording only from afferents with receptive
fields in the knee joint. Monopolar recording of afferent neural discharge from
nerves innervating the joint was recorded using bipolar platinum-iridium electrodes
where the saphenous nerve was laid on one electrode while the other electrode was
grounded via fatty tissue surrounding the joint. Impulses were recorded and analysed
as for neural recordings in the rat (see section 2.2).
6.3 RESULTS
INDUCTION OF UNILATERAL ARTHRITIS IN MICE
Sub-cutaneous injection of FCA around the mouse ankle joint
DBA/1 mice were originally used because of their susceptibility to arthritic
conditions - both spontaneously occurring and artificially induced (see Introduction).
Initially the hypothesis tested was that unilateral arthritis could be induced in mice,
by a single sub-cutaneous injection of FCA over the ankle joint, as in rats (Birrell et
al., 1990a; Birrell et al., 1990b; Birrell et al., 1991; Birrell et al., 1990c; Grubb et al.,
136
Chapter 6: FCA-Induced Unilateral Arthritis
1991; Grubb et al., 1988; McQueen et al., 1990). Furthermore, because of the
difference in size between rats and mice, the mouse ankle provided easier access for
the purposes of measuring the joint diameter. A single subcutaneous injection of
FCA (50 pg) over the ankle joint failed to induce chronic inflammation in DBA/1
mice (Figure 6.2), although there was an initial inflammation that returned to near
basal levels after approximately 7 days. Unlike the response in the rat, there was no
secondary chronic phase, and indeed at 21 days there was no significant difference in
the diameter of the injected joints in the FCA treated group and those of either the
contralateral limb, the ipsilateral limb in uninjected control animals, or animals that
received the HLP control.
Sub-cutaneous injection of FCA around the mouse knee joint
The aim was to establish a chronic inflammation in the knee joint of the
mouse to permit pharmacological studies on nociceptive afferents, as in our existing
rat model (Dowd et al., 1998a; Dowd et al., 1998b). Therefore all further
development was done in the knee joint rather than first establishing the model in the
ankle and subsequently transferring it. An attempt was made to induce a chronic
inflammation by a single sub-cutaneous injection of FCA over the knee using a
larger dose than that used in the ankle. The results show that FCA given at either
100 or 150 pg was unable to induce chronic inflammation (Figure 6.3). There was no
significant difference between either dose of FCA and HLP controls at day 22 (P =
0.5320, Kruskal-Wallis), or between the injected and uninjected limbs in the FCA
treated groups at either dose (P = 0.53, P = 0.42 respectively; paired t-test)
Furthermore, in animals treated with 150 pg of FCA on day 0, followed by a booster
137
Chapter 6: FCA-Induced Unilateral Arthritis
injection of FCA (100 pg, s.c. over the knee) at day 22, there was still no chronic
inflammation, and the diameter of the injected joint did not differ significantly that of
HLP controls (P = 0.42, day 45, Mann-Whitney).
Antigen induced arthritis with methylated bovine serum albumin
As FCA injected around the joint failed to cause chronic inflammation, it was
decided to administer FCA by intra-articular injection into the mouse knee joint. A
number of days were spent learning the technique from Dr. Leo Joosten in the
Department of Rheumatology, University of Nijmegen, The Netherlands. The group
at the University of Nijmegen had developed a number of unilateral models of
murine arthritis, including an antigen-induced model of arthritis (AIA), as detailed in
the introduction. Upon returning to Edinburgh the AIA model in C57BL6 mice
using methylated Bovine Serum Albumin (mBSA) was investigated. Briefly the
technique involved immunising each animal on day 0 with 100 pg of mBSA in 100
pi of PBS/FCA (1:1), injected sub-cutaneously at six different points on the back of
the animal (-17 pl/injection). On day 7 the animals were given a booster of 100 pg
mBSA in 100 pi of PBS/FCA (1:1), injected at two sites on the back. Finally on day
28 the animals were challenged with 60 pg of mBSA in 6 pi saline injected i. art.
into the left knee joint under transient anaesthesia (3% halothane in oxygen).
Control animals were injected with saline only. Animals were expected to show a
maximum response 4-5 days after the challenge, and a sustained inflammation that
would still be present 28 days post-challenge (van den Berg et al., 1984). The results
obtained (Figure 6.4) showed that in C57BL6 mice an inflammatory response
occurred, which peaked at day 5; however this inflammation resolved back to basal
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levels within 14 days of the challenge. A similar result was seen in the DBA/1 mice
(Figure 6.5), which also failed to exhibit chronic inflammation.
Unilateral arthritis with repeated injections of FCA in DBA/1 mice
According to Dr. Joosten the method utilising purified streptococcal cell
walls (SCW) was robust and had worked in every strain of mice that they had tested
(personal communication). In addition it was anticipated that repeated injections of
SCW would generate a chronic inflammation. As I had previously shown that FCA
could induce inflammation of joints in the mouse, the hypothesis that a chronic
inflammation should be obtained using the bacterial components present in the FCA,
in the same way as was possible with the SCW model, was tested.
Knee joint diameter
It proved possible to induce a chronic inflammation of the knee joint with
repeated injections of FCA in DBA-1 mice. Subjective examination of the mice
throughout the experiment showed that all animals (8 of 8) treated with FCA showed
some form of inflammation, and in every mouse the inflammation was restricted to
the injected left knee joint. There was no evidence of inflammation present in the
contralateral limb (Figure 6.6). Prior to the injections of FCA (day 0) there was no
significant difference between the two groups in the diameter of the left knee joint (P
= 0.33: unpaired t-test). Furthermore in the group that was to receive the FCA there
was no significant difference between the left and the right knee joint (P = 0.61;
paired t-test). The group that was to receive HLP did show a slight difference in the
starting diameters between the left and right knee joints that was just statistically
significant (P = 0.05; paired t-test).
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After each injection of FCA (5pl, i.art.) there was an acute inflammation that
resolved, as had been the case seen with the single sub-cutaneous injections. With
each subsequent injection the acute phase of the inflammation, as measured by the
diameter of the knee joint, was significantly greater. In addition, as the acute
inflammation resolved the diameter of the knee joint never returned to its starting
size, indication residual alterations. After four injections, the joint size had increased
markedly and the accumulated changes were consistent with chronic inflammation.
The cumulative effect of multiple challenges is shown schematically in Figure 6.7.
At day 28 the diameter of the left (injected) knee joint was significantly increased in
the group treated with FCA when compared to F1LP controls (P = 0.005; unpaired t-
test; Figure 6.6A). This increase in joint diameter was restricted to the injected joint
as there was no significant difference in the contralateral knee joint between FCA
and HLP treated mice at day 28 (P = 0.07; Mann-Whitney; Figure 6.6B). As the
inflammation was restricted to the left (injected) knee joint we were able to use the
right knee as an internal control and examine the percent increase in the injected joint
(left) when compared to the uninjected (right) joint (Figure 6.6C). The percent
increase in the diameter of the injected joint was greater in FCA treated animals
(16.7 ± 2.7 %) when compared to HLP controls (2.9 ± 1.0%; P = 0.001, paired t-test).
Examination of the knee joint at day 28 in comparison to the starting diameter at day
0 (Figure 6.6D) again also showed that there was a increase in the FCA injected joint
(0.69 ±0.13 mm) that was not seen in the HLP controls (0.25 ± 0.04 mm) and that
this increase was statistically significant (P = 0.007; unpaired t-test).
Body weight
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The level of discomfort induced in these animals was sufficient in some cases
to produce limping in the days immediately following each injection. However the
animals continued to feed normally and there was no significant difference in the
their weight gain when compared to HLP-injected control animals. Throughout the
course of the experiment there was no significant difference in the average body
weight of the two groups (day 0: P = 0.38, day 14: P = 0.34, day 28: 0.20; unpaired t-
tests; Figure 6.8A). This was further confirmed when reviewing weight gain in
individual animals by looking at the change from the starting body weight at day 0
(Figure 6.8B). There was no significant difference (P = 0.48; unpaired t-test) in the
change in body weight between FCA treated (3.0 ± 0.2 g) and HLP treated (3.3 ± 0.3
g) groups at day 28.
Hyperalgesia/allodynia
After each injection of FCA there was a short period during which some of
the animals displayed discomfort in walking, as manifest by a three-legged gait
(measured as 3 on the 0-3 scale, see section 6.2). This was observed in both the FCA
and the HLP treated groups and was therefore probably a consequence of mild
trauma associated with the injection procedure.
Discomfort in walking during chronic inflammation
Seven days after the final injection, the acute inflammation associated with
the last injection resolved and the animals were left with a chronic arthritis in the
injected knee joint. Subjective examination of the animals showed that, in mice
treated with repeated injections of FCA, only 2/8 (25%) animals in the FCA group
and 0/8 (0%) animals in the HLP treated group exhibited a mild limping behaviour,
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scored as 1 on the subjective 0-3 scale (Figure 6.9). The majority of animals showed
normal gait even when extensive inflammation was present in the knee joint.
Response to noxious pressure on the knee joint
The withdrawal response to a noxious stimulus (squeezing the joint at an
increasing intensity until the animal withdrew its limb) was also measured in order to
establish the degree of hyperalgesia associated with the experimental inflammation.
Animals receiving repeated intra-articular injections of FCA showed a decrease in
the threshold pressure evoking withdrawal at day 28, seven days after the final
injection, when compared with the contra-lateral joint (P = 0.004; Mann-Whitney) or
the vehicle treated controls (P = 0.004; Mann-Whitney) - see Figure 6.10A. In FCA
treated animals at day 28 the majority of mice, 7/8 (87%), showed some sensitisation
to moderate pressure applied to the joint (median hyperalgesia score: 1.5) that was
not seen in the contralateral limb (median: 0) or in HLP controls (median: 0) in
which no animals (0/8 mice for each; 0%) displayed hyperalgesia. Furthermore the
hyperalgesia score was significantly correlated (r2 = 0.1724; P = 0.003, Spearman
Rank Correlation; Figure 6.10B) with the increase in the diameter of the joint,
indicating that the degree of swelling present in the joint was directly related to the
hyperalgesia experienced by the animal.
Histopathology
Knee joints were collected from recently killed animals from all groups on
day 28, 7 days after the last injection of FCA or HLP. The joints were processed as
stated in the methods and midline sections were stained either with haematoxylin and
eosin (H&E) or Toluidine Blue. Samples were coded and scored blind.
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Figure 6.11 shows the pathological changes resulting from repeated injections
of FCA or HLP into the mouse knee joint. The right knee joint (uninjected) showed
no notable changes. All FCA treated animals showed pathological changes in the
left knee joint (injected). There was moderate hypertrophy of the synovial
membrane and the infiltration of a large number of PMNs and macrophages into the
joint space. In all animals there was extensive inflammation of tissues outside the
joint including tendons, ligaments and surrounding muscle. Small amounts of
pannus were noted producing mild erosion of the articular cartilage and slight
changes in bone formation and/or erosion in most animals. Thickening of the
synovial membrane, PMN infiltration and peri-articular inflammation were seen in
animals receiving HLP, however far less severe than that seen in arthritic joints.
Pathological changes were graded on a 0 (normal) to 5 (severe) scale (Table
6.1) by Dr. Christopher Clarke (GlaxoSmithKline, Ware). Gradings were pooled as a
histological score for each individual knee joint (Figure 6.12). There was a
significant difference in the histological score between the left (injected) and right
(uninjected) knee joint in both FCA and HLP treated animals (P = 0.0006 and P =
0.0006, respectively; Mann-Whitney). The median histological score in FCA
injected joints was 12 (n=8) and 5 (n=8) for HLP injected joints. This difference was
found to be significant (P = 0.002; Mann-Whitney)
Unilateral arthritis with repeated injections of FCA in C57BL6 mice
In order to develop a robust model of unilateral arthritis it was necessary to
induce the inflammation in more than one strain of mouse, as there can be large
strain difference in experimental arthritis models. The transgenic animals that we
were planning to study have a C57BL6 genetic background, and consequently
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C57BL6 animals were used. Experiments were performed on 8-week-old mice with
8 mice per group.
Knee joint diameter
As with the DBA/1 mice, subjective examination over the course of the
experiment showed that it was possible to induce a chronic inflammation in the knee
joint of adult male C57BL6 mice with repeated injections of FCA (Figure 6.13). All
mice in the FCA treated group (8/8; 100%) showed moderate to severe inflammation
in the injected joint compared to only 1/8 (12%) mice showing a mild inflammation
in vehicle controls. Prior to the injection of either FCA or HLP there was no
significant difference between groups in the diameter of either the left or right knee
joints (P = 0.51 and P = 0.12 respectively; unpaired t-test). One week after the
repeated injections of FCA (on day 0, 7, 14, and 21) there was a significant increase
in the average diameter of the left (injected) joint when compared to either the
contralateral (uninjected) limb (P = 0.0001; paired t-test) or the corresponding limb
injected with HLP in the control animals (P = 0.0001; unpaired t-test; Figure 6.13A).
This increase in diameter was restricted to the injected limb - there was no significant
difference between the right (uninjected) limb and either limb in the HLP controls (P
= 0.12 and 0.25 respectively; unpaired t-test; Figure 6.13B). As there was no change
in the right limb it was possible to use it as an internal control and express the
increase in diameter of the left limb as a percentage of the right limb's diameter for
each animal (Figure 6.13C). On average, on day 28 there was an increase in
diameter of the left knee in comparison with the right knee diameter of FCA treated
animals (21.2 ± 2.0%). That did not occur in HLP treated controls (2.5 ± 1.1%). This
increase was statistically significant (P = 0.0001; unpaired t-test). The diameter of
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the knee joint at day 28 was also compared to the diameter pre-FCA (Figure 6.13D);
there was an increase in joint diameter of FCA treated mice (+0.97 ±0.11 mm) that
was not seen in the HLP controls (-0.03 ± 0.05 mm) which was statistically
significant (P = 0.0001; unpaired t-test).
Body weight
Body weight was used as an overall measure of animal health and potential
level of discomfort associated with the repeated injection protocol (Figure 6.14).
Prior to injection with either FCA or F1LP there was no significant difference in the
average weight between the two groups (P = 0.23; unpaired t-test). Both FCA and
F1LP treated groups gained weight at similar rates and at day 28,7 days after the final
injection; there was no significant difference in the average body weight between the
two groups (P = 0.65; unpaired t-test: Figure 6.14A). In addition, on average, there
was no difference (P = 0.20; unpaired t-test) in the weight gained by each animal at
day 28 when compared to the starting weight at day 0 for either FCA (3.3 ± 0.4 g) or
HLP (2.5 ± 0.4 g) - see Figure 6.14B.
Hyperalgesia/alIodyn ia
As stated above there was a period (3-4 days) following each injection of
either FCA or HLP in which some animals displayed discomfort in walking as
manifest by limping, or in extremis, a three-legged gait. As it was present in both
groups it was likely to have been associated with the mild trauma resulting from the
injection procedure.
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Discomfort in walking during chronic inflammation
Seven days following the final injection of FCA at day 28, the acute
inflammatory response had resolved, and as shown above, some animals were left
with a chronic inflammation present in the left knee joint. Subjective examination
showed that a number of animals in the FCA group (3/8; 38%) showed discomfort in
walking whereas there were no animals showing such behaviour in HLP control
group (0/8; 0%) - See Figure 6.15A. However the discomfort in walking observed
was very mild and was scored as a 1 on the 0-3 scale (see section 6.2). There was,
however, was a significant correlation (P = 0.004; r2 = 0.48; Spearman Rank
Correlation) between the discomfort in walking and the level of inflammation present
in the joint (Figure 6.15B).
Response to noxious pressure on the knee joint
The withdrawal response evoked by a mild noxious stimulus (squeezing of
the joint) was measured to determine the degree of inflammation-associated
hyperalgesia. Animals receiving repeated intra-articular injections of FCA showed
an increase in the withdrawal response at day 28 when compared to the contralateral
joint (P = 0.0002; Mann-Whitney) or the vehicle treated controls (P = 0.002; Mann-
Whitney) - see Figure 6.16A. All FCA treated animals (8/8, 100%) showed some
form of sensitisation to squeezing the injected joint (median hyperalgesia score: 2)
that was not seen in the contralateral joint (median hyperalgesia score: 0; n = 8) or
the corresponding limb in HLP controls (median hyperalgesia score: 0.5; n = 8).
Furthermore, the amount of inflammation present in the injected knee joint at day 28
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significantly correlated with the hyperalgesia score (P = 0.0001; r = 0.70; Figure
6.16B).
Histopathology
Knee joints were collected from recently killed animals from all groups on
day 28, 7 days after the last injection of FCA or HLP. The joints were processed as
stated in the methods and midline sections were stained either with haematoxylin and
eosin (H&E) or Toluidine Blue. Samples were coded and scored blind.
Figure 6.17 shows the pathological changes resulting from repeated injections
of FCA or HLP into the mouse knee joint. The right knee joint (uninjected) showed
no pathology. All animals that received repeated intra-articular injections of FCA
showed pathological changes consistent with a moderate arthritis. These changes
were restricted to the left knee joint. In all animals there was extensive peri-articular
inflammation affecting the tendons, ligaments and surrounding muscle. There was
moderate hypertrophy of the synovial membrane and the infiltration of a large
number of PMN and macrophages into the joint space. Small amounts of pannus
were noted producing mild erosion of the articular cartilage, however formation
and/or erosion of the bone surface was present only in two animals. Thickening of
the synovial membrane, PMN infiltration and peri-articular inflammation were seen
in animals receiving HLP, however far less severe than that seen in arthritic joints.
Pathological changes were graded on a 0 (normal) to 5 (severe) scale (Table
6.1) by Dr. Christopher Clarke (GlaxoSmithKline, Ware). Gradings were pooled as
a histological score for each individual knee joint (Figure 6.18). There was a
significant difference in the histological score between the left (injected) and right
(uninjected) knee joint in both FCA and HLP treated animals (P = 0.0006 and P =
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0.01, respectively; Mann-Whitney). There was a significant difference in the
histological score between FCA (median: 13; n=7) and HLP injected joints (median:
5; n=4; P = 0.006; Mann-Whitney).
COMPARISON OF UNILATERAL ARTHRITIS DEVELOPMENT IN
DIFFERENT STRAINS OF MICE
As detailed in the introduction many existing models of arthritis in mice
display large variation when transferred from one strain of mouse to another
(Brackertz et al., 1977a; Wooley et al., 1981). It was therefore necessary to examine
the differences between development of RA in the two strains being investigated,
namely DBA/1 and C57BL6. As the two strains vary in size when adult, all the
results were compared in terms of a percentage differences in adult mice.
Knee joint diameter
The percent increase in the left knee diameter in comparison to the right was
examined in both DBA/1 and C57BL6 mice. Prior to the injection of FCA there was
no significant difference between the two strains (P = 0.22; unpaired t-test). Once
chronic inflammation was induced (day 28) there was a significant increase in the
left knee diameter when compared to the right in each strain with a 16.7 ± 2.7 %
increase in DBA/1 mice and 21.2 ± 2.0 % in C57BL6 mice. Comparing the two
strains there was no significant difference in these increases (P = 0.21; unpaired t-
test; Figure 6.19).
Hyperalgesia/allodynia
Discomfort in walking in chronic inflammation
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Once chronic inflammation was induced, there was no effect on mobility in
these animals. The median walking score for both groups at day 28 was 0, and both
strains seemed to adapt equally well to the chronic inflammation (Figure 6.20).
Response to noxious pressure on the knee joint
Both C57BL6 and DBA/1 strains showed sensitisation to noxious pressure
(median scores: 1.5 and 2 respectively) of the injected knee joint, but not of the
contralateral knee (Figure 6.21). There was no significant difference between DBA/1
and C57BL6 mice in their response to applied noxious pressure (P = 0.09; Mann-
Whitney).
Histopathology
The pathological changes induced by repeated injections of FCA were
broadly similar in both DBA/1 and C57BL6 mice - see Figures 6.11 and 6.17.
Changes seen in both strains included inflammation of the peri-articular tissues,
infiltration of the joint space by PMNs and macrophages, and thickening of the
synovial membrane. In most cases there was mild pannus formation that resulted in
damage to articular cartilage and minor bone changes.
Comparing the histological scores showed that there was no significant
difference between DBA/1 and C57BL6 in terms of the overall severity of the
pathological changes induced by the intra-articular injections of FCA (P = 0.57;
Mann-Whitney; Figure 6.22).
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EFFECT OF THE STEROID PREDNISOLONE ON ESTABLISHED FCA-
INDUCED UNILATERAL ARTHRITIS DBA/1 MICE
To validate the model of FCA-induced unilateral arthritis it was necessary to
establish the effects of a number of "gold standards" in terms of inflammation and
pain relief. One of the drugs we used was the steroid, prednisolne, commonly used
in man as an effective anti-inflammatory (Kelley et al., 1997). The experiment was
carried out in two groups of 8 week-old, male DBA/1 mice (n=8 per group).
Unilateral arthritis was induced in the left knee joint as detailed above. Animals
were monitored both subjectively and quantitatively throughout the experiment to
determine the extent of the inflammation and hyperalgesia/allodynia produced.
Measurements were made twice weekly, once just prior to each injection of FCA and
once midway between each injection. After unilateral arthritis was established the
mice continued to be measured during treatment with either prednisolone (10 mg kg"1
i.p. daily) or vehicle. Drugs were coded and administered blind.
Knee joint diameter
The diameter of both the left (injected) and right (uninjected) knee joints was
monitored throughout the course of the experiment. Chronic unilateral arthritis was
induced in both groups and treatment with prednisolone or vehicle began on day 28,
seven days after the final injection of FCA (Figure 6.23). Prior to the injection of
FCA (day 0) there was no significant difference in the diameters of either left or right
knee joints (P = 0.64 and P = 0.76 respectively; unpaired t-tests).
Pre-treatment: After the repeated injections of FCA (day 28) there was no
significant difference between the two groups in the diameter of either knee joint
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(left: P = 0.71, Right: 0.16; unpaired t-test). There was a significant difference in
both groups when comparing the left and right knee diameters (P = 0.79 and P =
0.37; paired t-test). The extent of the inflammation induced was similar for both
groups. The percent increase in the left knee diameter when compared to the right
knee was 11.3 ± 1.8 % and 12.6 ± 1.9 %, which were not statistically different (P =
0.62; unpaired t-test).
Response to treatment: At day 28 treatment with daily i.p. injections of
prednisolone (10 mg kg"1) or vehicle for seven days commenced. After the seven
days of treatment, at day 35, there was a significant decrease from values on day 28
in the left to right knee diameter ratio of prednisolone treated mice (-10.3 ± 2.9 %; P
= 0.002; paired t-test) that was not seen in the vehicle controls (-0.4 ± 1.8 %; P =
0.10; paired t-test; Figure 6.23C). Furthermore examining each animal for the
change in the left knee diameter from day 0 showed that on average prednisolone
treated animals had returned to baseline levels (pre-FCA treatment) with a mean
change of +0.02 ± 0.04 mm from the starting diameter, which was significantly
different (P = 0.0001; unpaired t-test) in comparison with vehicle controls, which
remained chronically inflamed (+0.43 mm ± 0.06 mm) with respect to day 0 values
(Figure 6.23D).
Body weight
There was no significant difference between the two groups in mean body
weights, either prior to FCA treatment (P = 0.21; unpaired t-test), or once the chronic
inflammation had been established at day 28 (P = 0.39; unpaired t-test; Figure 6.24).
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Pre-treatment: In addition, on average there was no significant difference
between the two groups in the weight gained by each animal up to day 28 (3.0 ± 0.2
g and 3.4 ± 0.1 g; P = 0.10; unpaired t-test).
Response to treatment: Seven days of treatment with prednisolone induced a
weight loss in the treated group, as there was a significant difference in average body
weight at day 35 in comparison with vehicle controls (P = 0.02; unpaired t-test;
Figure 6.24A). Examining the body weight over the entire course of the experiment
the change from day 0 to day 35 was not statistically significant when comparing
prednisolone and vehicle treated groups (2.6 ± 0.3 g and 3.3 ± 0.2 g respectively; P =
0.09; unpaired t-test; Figure 6.24B).
Hyperalgesia/allodynia
Discomfort from walking during chronic inflammation
Pre-treatment: All animals displayed evidence of chronic inflammation on
day 28, but neither group showed any sign of difficulty in walking. Prior to
prednisolone or vehicle treatment each group contained individual animals
displaying mild limping behaviour (median score: 0 and 1 for 2/8 mice and 6/8 mice
respectively Figure 6.25A).
Response to treatment: After seven days of treatment with prednisolone there
was no sign of discomfort as the steroid-treated animals walked normally. In the
vehicle treated group, where 6 animals had shown mild limping at day 28, limping
was seen in only one animal (Figure 6.25B).
Response to noxious pressure on the knee joint
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Pre-treatment: Immediately prior to treatment with prednisolone or vehicle,
at day 28, both groups were sensitive to a painful stimulus as a result of chronic
inflammation. This was restricted to the left joint (median scores: 1.5 and 2 in 8/8
for both groups), as there was no sensitisation in either of the right knee joints
(median score: 0 in 8 mice in both groups). The difference between the left knee
median scores was not significant (P = 0.22; Mann-Whitney; Figure 6.26A).
Response to treatment: After seven days of treatment with either
prednisolone or vehicle, at day 35, the prednisolone treated group showed a reduced
sensitivity/increased threshold to a noxious pressure stimulus applied to the joint
(median score: 0) that was not seen in the vehicle controls (median score: 1.5) - see
Figure 6.26B. The difference was statistically significant (P = 0.007, Mann-
Whitney).
Histopathology
Knee joints were collected from recently killed animals from all groups on
day 35 following 7 days of treatment with either prednisolone (10 mg kg"1) or
vehicle. The joints were processed as stated in the methods and midline sections
were stained either with haematoxylin and eosin (H&E) or Toluidine Blue. Samples
were coded and scored blind by Dr. Christopher Clarke (GlaxoSmithKline, Ware).
Knee joints from both treatment groups showed evidence of significant
amounts of inflammation and joint destruction associated with the chronic
inflammation (Figure 6.27). In all cases the pathological changes were unilateral,
restricted to the left knee joint and present to a greater or lesser degree in each
animal. There was marked periarticular inflammation involving the tendons and
muscles present in all FCA-treated animals, and other changes observed included
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mild synovial hypertrophy, fibrosis and pannus formation. These effects were
consistent both within each group and between the two treatments. There did not
appear to be any significant differences in the prednisolone treated animals. Scores
for the histological criteria, shown in Table 6.1, were pooled for each animal and the
median score taken for each group (Figure 6.28). There was no significant difference
in the inflammation and joint destruction between the prednisolone (median score:
10) and vehicle (median score: 7) treated animals (P = 0.13; Mann-Whitney).
EFFECT OF NSAID INDOMETHACIN ON ESTABLISHED FCA-INDUCED
UNILATERAL ARTHRITIS IN C57BL6 MICE
For additional validation of the model of murine FCA-induced unilateral
arthritis a second "gold standard" for inflammation and pain relief was used. The
non-steroidal anti-inflammatory, indomethacin, was used on mice with a chronically
inflamed joint (Kelley et al., 1997). Unilateral arthritis was induced in the left knee
joint of C57BL6 mice and drug treatment carried out once the chronic inflammation
had been established, seven days after the final injection of FCA (day 28).
The experiment was carried out in two groups of 8 week-old, male C57BL6
mice (n=8 per group). Animals were monitored both subjectively and objectively
throughout the experiment to determine the extent of the inflammation and
hyperalgesia/allodynia produced. Parameters were measured twice per week, once
just prior to each injection of FCA and once midway between each injection. Once
the unilateral arthritis was established in both groups the mice continued to be
measured as above while being treated with either indomethacin (1 mg kg"1 sub¬
cutaneous daily) or vehicle. Drugs were coded and administered blind.
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Knee joint diameter
The diameter of both left (injected) and right (uninjected) knee joints was
measured throughout the course of the experiment. Chronic unilateral arthritis was
induced in both groups and treatment with indomethacin or vehicle began on day 28,
seven days after the final injection of FCA (Figure 6.29). Prior to the first FCA
injection (day 0) there were significant differences in the right knee joint diameters
(P = 0.03, unpaired t-test) but not the left knee diameters (P = 0.09; unpaired t-test)
between the two groups.
Pre-treatment: In the chronically inflamed joints, 7 days after the final FCA
injection (day 28) there was a significant increase in the left knee joint that was not
seen in the contralateral limb in both groups (19.4 ± 3.1 % and 21.2 ± 2.0 %). The
extent of the inflammation induced was similar for both groups as there was no
significant difference in the diameter of the injected joint between groups (P = 0.64;
unpaired t-test) - see Figure 6.29A-B.
Response to treatment: After seven days of treatment, at day 35, the
previously swollen left knee decreased towards the diameter of the uninjected
contralateral limb. Using the contralateral limb as an internal control, the chronic
inflammation remained elevated in vehicle controls with the mean left knee diameter
19.3 ± 2.0 % larger with respect to the right. Treatment with indomethacin decreased
the difference between limbs to 8.3 ± 2.9%, considered significant (P = 0.007;
unpaired t-test; Figure 6.29C). However, examining each animal at day 35 for the
change in the left knee diameter from day 0 showed that on average indomethacin
treated animals (+0.34 ±0.17 mm) were not statistically different (P = 0.15; unpaired
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t-test) from vehicle treated animals with a change from the starting diameter of +0.64
±0.10 mm (Figure 6.29D).
Body weight
Prior to the induction of unilateral arthritis with FCA there was no significant
difference in the starting body weights prior to the induction of unilateral arthritis
with FCA (P = 0.39; unpaired t-test).
Pre-treatment: Once the chronic inflammation had been established at day 28
there was no difference in the average body weights between the two groups (P =
0.81; unpaired t-test; Figure 6.30. Furthermore, on average there was no significant
difference between the two groups in the weight gained by each animal up to day 28
(3.3 ± 0.4 g and 3.8 ± 0.5 g; P = 0.50; unpaired t-test).
Response to treatment: Seven days of treatment with indomethacin did not
alter the mean body weights, there was no significant difference at day 35 from
vehicle controls for the average body weight (P = 0.62; unpaired t-test; Figure
6.30A). In addition, when comparing the change in body weight from day 0 for both
indomethacin and vehicle treated animals; there was no significant difference in the
weight gained (3.6 ± 0.6 g and 2.3 ± 0.7 g respectively; P = 0.50; unpaired t-test;
Figure 6.30B).
Hyperalgesia/allodynia
Discomfort from walking during chronic inflammation
Pre-treatment: Although on day 28 all animals displayed chronic
inflammation, there was no real sign of discomfort or impairment in walking for
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either group. Each group contained some animals with very mild limping (3/8 mice
for both groups; median score: 0; Figure 6.31A).
Response to treatment: After seven days of treatment with indomethacin
there was no change in the number of animals showing limping behaviour (3/8 mice;
37%; median score: 0), which was not statistically different from the vehicle treated
group (P = 0.39; Mann-Whitney; Figure 6.3IB).
Response to noxious pressure on the knee joint
Pre-treatment: During chronic inflammation, at day 28, both groups were
sensitised to a painful noxious stimulus. The sensitisation was restricted to the
arthritic left knee joint with 8/8 animals (100%) in each group showing hyperalgesia
(median scores: 1.5 and 2). There was no sensitisation in the right knee of any
animal in either group (0/8; 0%). Between groups, the difference in the median
hyperalgesia response in the left knee was not significant (P = 0.40; Mann-Whitney;
Figure 6.32A) as both groups displayed similar levels of hyperalgesia.
Response to treatment: After 7 days of treatment with indomethacin, at day
35, there was a significant decrease in the hyperalgesia score for the left limb over
that observed at day 28 (median: 0; P = 0.007, Mann-Whitney) - see Figure 6.32B.
Indeed there was no significant difference in the hyperalgesia score between the left
and right knee joints in indomethacin treated animals (P = 0.40; Mann-Whitney).
Vehicle treated animals still displayed hyperalgesia in the chronically inflamed left
knee joint when compared to the contralateral limb (P = 0.007, Mann-Whitney).
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Histopathology
Knee joints were collected from recently killed animals from all groups on
day 35 following 7 days of treatment with either indomethacin (1 mg kg"1) or vehicle.
The joints were processed as stated in the methods and midline sections were stained
either with haematoxylin and eosin (H&E) or Toluidine Blue. Samples were coded
and scored blind by Dr. Christopher Clarke (GlaxoSmithKline, Ware).
Examination of knee joints from both treatment groups showed the presence
of significant amounts of inflammation, both within the joint and in the surrounding
soft tissues (Figure 6.33). In all cases the pathological changes were unilateral,
restricted to the left knee joint and present to a greater or lesser degree in each
animal. There was marked periarticular inflammation involving the tendons and
muscles present in all FCA-treated animals, and other changes observed included
mild synovial hypertrophy, fibrosis and pannus formation. These effects were
consistent both within each group and between the two treatments. There did not
appear to be any significant differences in the indomethacin treated animals.
Histological scores were pooled for each animal and the median score taken
for each group (Figure 6.34). There was no significant difference in the
inflammation and joint destruction between the indomethacin (median score: 12) and
vehicle (median score: 13) treated animals (P = 0.28; Mann-Whitney).
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INDUCTION OF FCA UNILATERAL ARTHRITIS IN P2X7 KNOCK OUT
MICE
Background
Experiments were performed on 12 transgenic animals, which contained a
mutation that disrupted the gene encoding the purinoceptor P2X7, a receptor
expressed primarily on immune cells and considered to play a role in chronic
inflammation (North & Surprenant, 2000). Mice carrying a targeted null mutation of
the P2X7 gene were produced according to the published protocol (Conquet, 1995).
Briefly, the P2X7 gene was isolated from a genomic library obtained from 129/Sv
mice, and sequencing of 5' exons permitted ligation of 2 fragments into the
neomycin resistant "knockout vector", pGN (Le Mouellic et ai, 1990).
Heterologous recombination of the resulting plasmid DNA into embryonic stem cells
resulted in a disrupted P2X7 gene. Disruption of the gene was confirmed by PCR
and Western blot analysis in the resulting C57B16/129 hybrid mice. Six rounds of
backcrossing onto a C57BL6 strain were performed resulting in 98.4% C57BL6
genetic background. These animals were supplied from GlaxoSmithKline
(Stevenage, UK) to the University of Edinburgh under the appropriate Home Office
licence. In addition to the transgenic animals (KO), this study included 12 wild type
littermates (WT) to act as normal controls. All animals were transported to the
University of Edinburgh from GlaxoSmthKline, (Stevenage, UK) when 8-10 weeks
old and were housed for 1 week after transfer before any procedures were performed.
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Knee joint diameter
Throughout the course of the experiment the animals were examined for
evidence of swelling in the FCA injected knee joint, the contralateral uninjected knee
joint, and the ipsilateral ankle joint - the latter to monitor for spreading of the
inflammation to nearby joints. In addition to the regular subjective examination of
the joints, both knees were quantitatively measured once per week prior to each
injection of either FCA or HLP (Figure 6.35). Prior to any treatment (day 0) there
was no significant difference between any of the groups in the diameter of either the
left or right knee joints (P = 0.74 and P = 0.84 respectively; one-way ANOVA). To
eliminate the contribution of the acute inflammation caused by each intra-articular
injection of FCA or HLP, the analysis of the effect of the unilateral arthritis was
examined at day 28 - seven days after the final injection of FCA, to restrict the study
to measurement of chronic inflammation. Subjective examination of the mice that
received repeated intra-articular injections of FCA into the left knee joint showed
that there was substantial swelling in both KO and WT animals. Swelling was not
seen in the joints of HLP-treated animals, in either in KO or WT groups.
Quantitatively there was a significant increase in knee diameter of the FCA-injected
joints in comparison with those that received HLP, both in the KO and WT animals
(P = 0.004 and P = 0.004 respectively; Mann-Whitney). However, when comparing
the KO and WT groups there was no significant difference between the two groups 7
days after the final injection of FCA (P = 0.82; unpaired t-test) (Figure 6.35A). This
increase in joint diameter was not seen in the contralateral (right) knee joint (Figure
6.35B). Using the within animal control of the injected (left) and uninjected (right)
knee joint it was possible to normalise the increase in the diameter of the injected
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joint in comparison to the uninjected joint (Figure 6.35C). Comparing left and right
joints showed that there was a significant increase in the diameter of the injected
joint (left) of both KO and WT receiving FCA (P = 0.0001 for both; paired t-test)
with an average increase of 24.1 ± 1.6% and 27.1 ± 3.3% respectively. These
increases in joint diameter were not significantly different when comparing between
the KO and WT groups (P = 0.42; unpaired t-test). The diameter of the injected joint
at day 28 was compared with the diameter at day 0 in each mouse (Figure 6.35D) and
the results showed that the injected knee joint of both KO and WT animals treated
with FCA were larger than the starting diameter (+1.12 ± 0.09 mm and +1.29 ±
0.17mm respectively) when compared to HLP injected controls (KO: +0.04 ± 0.05
mm, WT: +0.03 ± 0.11 mm). In both KO and WT the increase in joint diameter was
significantly greater than that in the corresponding HLP controls (P = 0.004 and P =
0.01 respectively; Mann-Whitney). There was however no significant difference
between KO and WT groups in the FCA treated group (P = 0.41; unpaired t-test).
Body weight
Throughout the course of the experiment body weight was measured as an
indicator of normal eating, weight gain and overall health (Figure 6.36). All animals
used were male, adults (8-12 weeks), but because animals came from different litters,
the different breeding times meant that there was a wider range of starting weights
than normally seen in stock animals. Although overall there was no significant
difference in the mean weights at the start of the study prior to any treatment (P =
0.07; Kruskal-Wallis), the WT mice that were to be treated with FCA weighed
significantly less when compared with KO mice that were to receive FCA (P = 0.02,
Mann-Whitney), but not to the other two groups that were to be given HLP (P = 0.09
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and P = 0.21 for KO and WT respectively; Mann-Whitney; Figure 6.36A). As the
mean weight of the four groups, the measurement of weight gain in these animals
was expressed as the increase in weight (weight at day 28 - day 0) for each
individual mouse (Figure 6.36B). At day 28 groups treated with FCA gained less
weight (KO: -0.25 ± 0.60 g, WT: 0.14 ± 0.35 g) when compared to HLP treated
controls (KO: 2.83 ± 0.60 g, WT: 2.40 ± 0.93 g). The lack of weight gain in FCA
treated animals was statistically significant in both KO and WT animals (P = 0.004
and P = 0.02 respectively; Mann-Whitney). However, there was no significant
difference in weight gain in FCA treated groups when comparing KO and WT
animals (P = 0.59; unpaired t-test).
Hyperalgesia/allodynia
Each intra-articular injection caused an acute hyperalgesia/allodynia response
lasting for a couple of days and was present in both FCA and HLP injected mice.
Discomfort in walking was manifest in a limping behaviour in associated with the
injected limb that in some animals reached its maximum with a three-legged gait.
Discomfort in walking during chronic inflammation
Seven days after the final injection, when the acute effect of the injection had
subsided there was a increase in the apparent discomfort associated with walking
(Figure 6.37) in the majority of animals (7/8 (87%) for both KO and WT) that
received repeated injections of FCA (KO median score: 2; WT median score: 2).
This was not seen in any animals (0/8 (0%) both KO and WT) that were injected
with HLP (KO median score: 0; WT median score: 0). This increase in apparent
discomfort associated with walking was significant when comparing FCA injected
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groups with HLP controls for both KO and WT animals (P = 0.03 and P = 0.03
respectively; Mann-Whitney) but there was no significant difference between KO
and WT animals in FCA treated animals (P = 0.59; unpaired t-test).
Response to noxious pressure on the knee joint
Seven days after the final injection of FCA there was a significant
sensitisation to a noxious pressure on the knee joint in animals that received FCA
when compared to HLP controls in both KO and WT groups (P = 0.004 and P = 0.01
respectively: Mann-Whitney; Figure 6.38). The level of sensitisation was not
significantly different in KO and WT FCA-treated animals (P>0.99: unpaired t-test).
The apparent hyperalgesia was almost exclusively observed in FCA- treated animals
(8/8 (100%) animals for both groups; KO and WT median score: 2.5) with only one
animal showing mild hyperalgesia in the HLP-treated animals (1/8; 12%). The
hyperalgesia was restricted to the FCA-injected joint and was not seen in the
contralateral limb.
Histopathology
Knee joints were collected from recently killed mice from all groups at day
28, seven days after the final injection of either FCA or HLP. The joints were
processed as described in the methods (see section 6.2) and midline sections were
stained either with H/E or toluidine blue. Mice treated with FCA showed a
significant amount of inflammation and joint destruction characteristic of an arthritic
condition. In KO or WT animals treated with FCA the most striking feature was the
large amount of periarticular inflammation. This inflammation was present in the
majority of tissue surrounding the joint including the ligaments, tendons and muscle.
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As seen above in previous experiments with FCA-induced unilateral arthritis there
was a moderate amount of inflammatory cell infiltration into the joint space and
areas previously containing adipose tissue. Furthermore the large amount of cell
debris in the joint space indicated a persistent and chronic inflammation of the joint.
In both KO and WT animals there was also a moderate amount of pannus formation
overgrowing the cartilage and causing cartilage destruction. Other changes included
a noticeable amount of vascularisation in the tissue surrounding the joint. These
changes were only present in the injected joint of FCA treated animals. HLP treated
animals showed little or no joint destruction. The contralateral knee joints of both
mice treated with either FCA or HLP showed no histological changes and presented
as normal (untreated) healthy knee joints.
The histological score was pooled for each animal and the median score taken
for each group (Figure 6.39). There was an increase in the histological score in FCA
treated mice (KO median: 20.5; WT median 20.5) when compared to their HLP
controls (KO median: 2.5; WT median: 3.5) that was significant for both KO and
WT animals (P = 0.004 and P = 0.008 respectively; Mann-Whitney). There was no
significant difference in the median histological score between KO and WT mice (P
= 0.59; Mann-Whitney).
RECORDING FROM THE SAPHENOUS NERVE IN NORMAL AND
ARTHRITIC KNEE JOINTS OF C57BL6 MICE
Neural recordings were carried out according to the final adopted methods
detailed above in Section 6.2. A total of 10 normal and 6 arthritic C57BL6 mice
(average weight: 28.0 ± 0.9 g; range: 24.5-31.9 g) were used for electrophysiological
studies. Neural experiments were conducted on arthritic animals 7-14 days after the
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final intra-articular injection of FCA and the mice showed an average knee diameter
increase in the injected joint of 24.6 ± 3.3 %. Animals were anaesthetised with
urethane (1.4 g kg"1) and the trachea and right femoral artery were cannulated.
Neural activity was recorded using a bipolar electrode on the saphenous nerve of the
left limb that had been cut both proximally and distally to isolated the receptive field
to the knee joint. Data recorded was analysed off-line using Spike2 software.
This was a pilot study and the successes rate for viable neural recordings was
only 56% with 9 neural recordings made from 16 C57BL6 mice. Successful
recordings were made from 17 afferents from 4 normal knee joints and 10 afferents
innervating 3 arthritic knee joints. Classification of the afferents by conduction
velocities was not possible due to limitations of size preventing the placement of the
stimulating electrode on to the joint. However, probing the knee joint capsule with a
hand-held plastic probe could mechanically activate all fibres tested and all
responded to capsaicin (33-980 pmol) and as such were assumed to be C-fibres
polymodal nociceptors (Figure 6.40). To prevent desensitisation of the preparation
and effort was made to minimise mechanical probing of the joint and a minimum of
20 minutes was left between close-arterial injections of drugs.
Basal discharge of nociceptors innervating normal and arthritic knee joints
The small number of experiments conducted in both normal and arthritic knee
joints did not permit an extensive examination of basal firing however 3/4 (75%)
normal animals compared to only 1/3 (33%) arthritic animals showed spontaneous
afferent activity. The rate of discharge in normal knee joints was 0.45 ± 0.42
impulses s"1 when compared to the value of 0.1 impulses s"1 for the single arthritic
knee joint that showed spontaneous discharge.
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Dose-related increase in the action potential discharge evoked by capsaicin and
bradykinin
Both capsaicin and bradykinin evoked a dose dependent response from
afferents innervating normal knee joints. Individual dose response curves were
generated for each experiment for both capsaicin (n=3) and bradykinin (n=l; Figure
6.41 and Figure 6.42 respectively).
Features of the capsaicin and bradykinin evoked responses
Afferent discharge was evoked by capsaicin (33-980 pmol) in all fibres
innervating both normal (17/17; 100%) and arthritic (10/10; 100%) knee joints.
Similarly, bradykinin (94-2830 pmol) evoked an increase in afferent discharge from
10/14 (71%) fibres in normal joints but only 1/7 (14%) fibres in arthritic joints.
Typical responses to capsaicin and bradykinin are shown in Figure 6.43. For both
capsaicin and bradykinin the elements of the response, including delay to onset,
duration, and the magnitude of the response were examined in more detail (Figure
6.44)
Capsaicin (330 pmol; n = 4) evoked a response with both a short delay to
onset (3.6 ± 0.4 s) and duration (6.3 ±3.2 s). The mean change in the discharge
frequency generated capsaicin was 100.9 ± 38.5 impulses s"1 and the mean total
afferent discharge for the response was 431 ± 132 impulses.
Bradykinin (940 pmol; n = 3) evoked a response that had a longer delay than
capsaicin (6.3 ± 2.9 s) but had a similar average duration (6.9 ± 3.1 s). The mean
change in the discharge frequency evoked by bradykinin was 28.7 ± 8.6 impulses s"1
and the mean total discharge was 244 ± 164 impulses.
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6.4 DISCUSSION
The main finding in this component of the study is the result that it is possible
to induce a chronic unilateral arthritis in both DBA/1 and C57BL6 mice using
repeated intra-articular injections of FCA into the knee joint. The development of
this murine model progressed from the rat FCA model of unilateral arthritis
previously developed in this laboratory.
One of the aims of this project was to examine the induction of unilateral
arthritis in particular transgenic mice, so the genetic background of the transgenic
lines of interest influenced the choice of mouse strain. Furthermore we needed to
establish a model that would produce a robust and consistent response across the
strains tested. The P2X7 knock out strain used in this study, and a strain with an
alteration to a somatostatin receptor (not used in this study), were on DBA/1 and
C57BL6 genetic backgrounds, respectively. These strains were also of interest
because they have previously been used in the study of experimentally induced
arthritis. DBA/1 mice spontaneously developing an RA like condition (Holmdahl et
al., 1992; Nordling et al., 1992a; Nordling et al., 1992b), as well as being the only
strain that responds to collagen induced arthritis (Joosten et al., 1999; Joosten et al.,
1996; Joosten et al., 2000; Lubberts et al., 2000; Wooley et al., 1981); and C57BL6
mice have been primarily used in the development of antigen- induced arthritis
(Brackertz et al., 1977b; Brackertz et al., 1977c; van de Putte et al., 1983; van Lent
et al., 2000; van Meurs et al., 1999).
The starting point of investigation was to study single sub-cutaneous
injections of FCA around an ankle or knee joint in mice, as previously studied in the
rat unilateral model (Birrell et al., 1990a; Birrell et al., 1990b; Birrell et al., 1990c;
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Donaldson et al., 1993; Dowd et al., 1997; Dowd et al., 1998b). The mouse
experiments produced an acute inflammatory response that resolved back to a base
line value within a matter of days. The arthritis was obtained in both the ankle and
knee joints, but despite using increased concentrations of FCA, the inflammation
following the single dose of FCA failed to become chronic.
Since it was not possible to directly transfer the single-dose FCA unilateral
model from rat to mouse it was necessary to explore alternative methods for the
induction of establishing unilateral arthritis in mice. These other methods we looked
at included antigen induced arthritis (AIA) using mBSA (Klasen et al., 1986; van den
Berg et al., 1982; van den Berg et al., 1984), and repeated injections of FCA. Both
models involved learning the technique of intra-articular injections into the mouse
knee joint, which was undertaken, under the direction of Dr. Leo Joosten in the
Department of Rheumatology, University ofNijmegen, The Netherlands.
Attempts to induce unilateral arthritis with AIA using mBSA injected into the
left knee joint, following immunisation were undertaken in C57BL6 and DBA/1
mice. As was the case with a single injection of FCA, it was not possible to produce
a chronic inflammation of the knee with AIA. Mild inflammation, in the order of a 5-
10% increase in the diameter of the injected joint, could be induced acutely in both
strains, but the inflammation resolved back to baseline levels within a week for both
strains.
Another model used by Dr. Joosten involved an intra-articular injection of
purified bacterial cell walls from group-A Streptococci (SCW) (van den Broek et al.,
1988). A single intra-articular injection of SCW evoked an acute inflammation that
peaked approximately 4 days after injection and persisted for up to a week (van den
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Broek et al., 1988). Furthermore, it was possible to induce a more chronic
inflammation by repeated injections of the SCW (Dr. Joosten - personal
communication). Our group has experience using FCA and is familiar with its use in
vivo, so we speculated that it might prove possible to substitute the bacterial
components of the Mycobacterium tuberculosis present in the FCA for the SCW, and
use FCA to induce a chronic unilateral inflammation by repeated intra-articular
injections ofFCA into a knee joint.
As the results show, four injections of 5 pi of FCA given at weekly intervals
proved able to evoke chronic unilateral arthritis in both DBA/1 and in C57BL6 mice
with similar progression of the condition in both strains. In the initial phase acute
inflammation occurred after each injection; this flared and then resolved within seven
days, as seen with the single sub-cutaneous injections. However, with each
subsequent injection the acute phase response was greater and the inflammation
resolved less and less such that one week after the final injection inflammation
persisted in the injected joint and chronic inflammation was thus established. The
inflammation was restricted to the injected joint and with the doses of FCA used
there was no swelling in the contralateral leg, such as can be induced with a
sufficiently high dose of FCA in the rat (Donaldson et al., 1993). Further studies
will be done to determine where it is possible to produce the crossover of
inflammation in mice by increasing the dose of FCA.
The knee diameter was the primary measure used to assess the extent of the
inflammation in the mice, however other measures, both quantitative and qualitative,
were also used. For example, the course of inflammation was tracked by measuring
the increase in temperature associated with increased blood flow in arthritic joints
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(Abbot et al., 1996; Bray et al., 1996; Haywood & Walsh, 2001) using an infrared
thermometer (Braun, ThermoScan). This was tried for a number of experiments
(data not shown in this study) but it proved impossible to obtain consistent difference
between normal and inflamed joints and there was a high variability between
animals. The measurements were greatly affected by ambient temperature with large
fluctuations from day to day that correlated with changes in room temperature.
Normalising responses to a ratio of injected to uninjected joint still showed a large
variability both between animals and within animals tested on consecutive days.
Further work examining inflammation in terms of changes in local blood flow in the
knee joint could be developed using laser Doppler perfusion imaging (Ferrell et al.,
1996) or "Technicium uptake (Kruijsen et al., 1981).
In addition to the subjective measures of apparent motility allodynia and
hyperalgesia, as measured by a reduced threshold for application of increasing
moderate to intense pressure to a joint by squeeze, we briefly examined a number of
alternative measures including the ability of the animals to grasp a bar and the ability
to maintain position on a series of gradients and surfaces (Williams et al., 1993).
These did not provide useable information and were not pursued following pilot
studies.
As stated above we examined the weight bearing allodynia subjectively by
monitoring the gait of the animal and its willingness to apply weight to the injected
limb. Following each intra-articular injection there was a period of days where the
animals displayed a limping behaviour where, in extremis, an animal guarded one leg
and only walked on three legs. The allodynia typically lasted less than a week, and
animals walked normally by the next injection in the series. Limping following each
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injection was present in both DBA/1 and C57BL6 irrespective of FCA or HLP
treatment, and was likely an artefact of the injection procedure.
Both strains could bear weight on the injected limb in the chronically
inflamed joint while walking, The examination of changes in gait might not provide
as much information on the apparent analgesia as the mice can distribute their body
weight across all four limbs. Measurements made in static animals could force the
mice to distribute their weight between a normal and a chronically inflamed limb. As
mentioned above, in the rat model of unilateral FCA arthritis weight bearing in a
static animal can be assessed using a sensitive double balance (Clayton et al., 1997).
This method is capable of detecting slight changes in weight distribution
(allodynia/hyperalgesia) that are not significant enough to evoke limping or
guarding of the injected joint. In mice, it was not possible to examine weight bearing
objectively, as in the rat, due to limitations of the equipment. The double balance
was not sufficiently sensitive to allow the measurement of the weight bearing, and
mice are very mobile and difficult to restrain, so we were not able to ascertain weight
bearing in the static animal. One project for future research would be the
development of a sensitive weight bearing apparatus for mice, addressing the
problems of restraining the mice while maintaining access to the hind limbs for
measurement.
Inflammation causes hyperalgesia and this was assessed in terms of the
sensitisation of the knee joint to a noxious stimulus, in this case squeezing the joint
between thumb and forefinger. Again due to the very small size of mouse joints it
was not feasible in the time available to develop a quantitative measuring device for
hyperalgesia as has been previously used in our laboratory in rats. Measurements
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therefore were based on subjective scoring and conducted blind. As stated in the
Methods, attempts to quantify the procedure were made by reproducing the squeeze
pressure applied to the joint on a pressure transducer. The average result on the
transducer divided by the average surface area of the knee joint provided an average
force applied (in g/mm2) for each score. The results show that in both DBA/1 and
C57BL6 mice there is a sensitisation that is restricted to the injected limb, permitting
an internal control for hyperalgesia. Future work is planned to provide a quantitative
measure of the hyperalgesia in the joint using some form of pressure transducer
linked to an inflatable cuff or sensitive strain gauge bonded onto callipers that can be
automatically closed to apply gradually-increasing force to the joint.
The behavioural changes in the response to pain as well as the gross changes
in the inflamed joint were correlated with the pathology associated with FCA treated
joints. Overall, the extent of the inflammatory changes in both DBA/1 and C57BL6
mice was consistent with a mild to moderate arthritis that was restricted to the
injected limb. Lack of any pathology in the contralateral limb or the ipsilateral ankle
(data not shown here) meant that the inflammation was indeed isolated to the injected
knee joint. The results show that the primary feature of the histology is the presence
of a large amount of peri-articular inflammation - inflammation of the tissue
surrounding the joint capsule and including the muscle, tendons and ligaments. The
smaller amount of fibrosis present in peri-articular inflammation, in comparison with
the inflammation within the joint, shows that the inflammation began within the joint
and later moved to extra-articular tissues. The large amount of extra-articular
inflammation and the fact that it was less well established than that seen within the
joint was probably the result of later injections. Large amounts of swelling in the
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joint, particularly prior to the third and fourth FCA injections, meant that it was not
always possible to identify the patella tendon to ensure that the injection was made
directly into the joint capsule, and it is possible that the later injections were made
into the surrounding tissue where they would produce a large amount of extra¬
articular inflammation.
The arthritis present appeared to be more characteristic of an OA as opposed
to RA (Rosenberg, 1999). Characteristics of a rheumatoid type arthritis include the
presence of pannus and although in some cases there was a small amount present it
was not a prominent feature as is seen in some other mouse models including
collagen induced poly-arthritis (Stuart et ai, 1984; Trentham et ai, 1977)
In both DBA/1 and C57BL6 strains there was a significant correlation
between the inflammation induced and the pressure required to get the animal to
withdraw the limb. This correlation indicates that drugs that decrease the amount of
inflammation will also have an effect on the hyperalgesia present in the joint.
Proving the model with two "gold standards" further supported this. The "gold
standards" used in our study were a steroid, prednisolone, and a non-steroidal anti¬
inflammatory (NSAID) indomethacin, both capable of reducing inflammation and
pain in a number of animal models and in clinical situations (Kelley et al., 1997).
Ideally for the drugs to be considered true standards they should have been
administered orally but a limitation in my Home Office Personal Licence prevented
me from being able to administer the drugs in this way. Problems were experienced
with determining the most effective route of administration particularly with the
NSAID, indomethacin. Initially, it was thought that both prednisolone and
indomethacin could be administered i.p. However the initial dose of indomethacin
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(10 mg/kg) was highly toxic by this route as was a ten-fold reduction (1 mg/kg). It
was decided that it should be given by the sub-cutaneous route, which proved to be
effective. Both prednisolone and indomethacin at the doses given significantly
reduced the inflammation in the injected limb and in the case of prednisolone the
knee diameter was restored to pre-FCA injection values. Furthermore, both drugs
were able to significantly reduce the hyperalgesia in the inflamed joint to the level of
the contralateral limb or to HLP injected controls. Although, the drugs were able to
reduce inflammation and pain the histology did not show any significant difference
between drug treatment and the corresponding controls. This is consistent with the
fact that the treatment was short-duration and started in an established arthritis where
there is very little in terms of reversal of the pathology (Dr. Clarke - personal
communication). Further work will be required to determine whether with longer-
term steroid/NSAID administration it is possible to resolve the pathological changes.
It would also be interesting to study whether the induction of arthritis can be
prevented by administering these same drugs prior to, or in conjunction with, the
FCA injections. The reduction of inflammation and hyperalgesia by the two drugs in
the established arthritis means that the FCA-induced unilateral arthritis model could
be useful for to predicting effective drugs for treating arthritis and the development
of drugs with less severe side effect profdes than that associated with chronic use of
both steroids and NSAIDs.
Recent reports have shown that the pro-inflammatory cytokine IL-1 plays a
definitive role in inflammatory hyperalgesia (Cunha et al., 2000), and in conjunction
with TNFa is responsible for the inflammation and joint destruction associated with
RA (reviewed in Carteron, 2000; van den Berg, 2000a; van den Berg, 2001c).
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Furthermore clinical trials have begun using anti-TNFa and anti-IL-1 as treatment
for the condition (Feldmann & Maini, 2001; Maini & Taylor, 2000; van den Berg,
2001a) showing the importance of these cytokines in the human condition. For this
reason future experiments should look at the role of TNFa and IL-1 in this model of
arthritis to determine its relevance to human RA.
As stated above the purinoceptor P2X7 receptor was hypothesised to have a
role in the development of arthritis through the release of IL-1 from activated
immune cells. The results in the unilateral FCA mouse model showed there was no
significant difference between KO and WT mice in terms of the ability to induce a
chronic arthritis or the pain associated with that arthritic condition. Furthermore,
there was no difference in the histological score, meaning that the extent of the
inflammation and joint destruction was similar in both. Therefore in this particular
model there is no apparent link between the P2X7 receptor and the ability to induce a
chronic inflammation using FCA. Although ATP has been shown to be a potent
trigger for the release of IL-1 from inflammatory cells (Ferrari et al., 1997a;
Grahames et al., 1999) it is unknown what proportion of the total IL-1 released
during inflammation is mediated by P2X7 stimulation and it may be that a significant
amount of IL-1 is still produced in the arthritic joint. In order to determine the level
of IL-1 released as a result ofP2X7 activation it would be interesting to examine IL-1
levels in the synovium of both KO and WT animals in response to FCA arthritis.
Also, as with most knockout mice it is possible that as the receptor was knocked out
during development there was compensation from other systems allowing the
inflammation to perpetuate - potentially through the release of IL-1, so although the
evidence doesn't support the hypothesis, it is not definitive.
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Recent reports have shown that the P2X7 receptor is expressed more widely
than previously reported by Collo et al. (1997) and is present in the normal adult in
both the brain and spinal cord and appears to have functionality not restricted to the
release of inflammatory or cytolytic mediators from macrophages (Deuchars et al.,
2001). The P2X7 receptor has been located on the presynaptic terminals of
excitatory neurons in the CNS and in motor nerve terminals in the PNS (Deuchars et
al., 2001). This new role of P2X7 in the facilitation of excitatory synaptic
transmission particularly in the spinal cord means that it can now be investigated
both in the periphery for the initiation of an inflammatory response and centrally as
to its role in the modulation of synaptic transmission under inflammatory conditions.
One of the other objectives of this project was to be able to develop a way to
complement information from behavioural studies by obtaining direct evidence
through recording from sensory afferents in the knee joint, much as is done in the rat
model (Dowd et al., 1998a; Dowd et al., 1998b; Gauldie et al., 2001). Much of the
time spent on this particular component of the thesis involved developing a protocol
that was able to maintain a mouse under adequate anaesthesia for a full day, devising
methods for recording from joint afferents, and the ability to administer the drugs to
a joint by close arterial injection. The Spike 2 software enabled the multi-fibre
recording to be analysed by and separating out the individual spikes that make up the
response - as was used in the recordings from joint afferents in the rat.
The results show that it is possible to record from both normal and arthritic
knee joints in the mouse. Further characterisation is required to definitively identify
the fibre types being recorded, however as stated previously, the ability to activate
these fibres both mechanically and with algogens such as capsaicin and bradykinin as
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well as the long spike duration leads one to assume that they are C-fibre polymodal
nociceptors (Gee et al., 1999; Iggo, 1978; Wall & Melzack, 1999).
It has previously been shown, in Section 3.3, that in the rat basal discharge is
present in a higher proportion of arthritic joints when compared to normal joints.
This is consistent with the accepted theory that spontaneous firing is present in a
higher proportion of arthritic joints when compared to normal joints. Furthermore, in
joints where there is spontaneous firing present the discharge frequency is higher in
the arthritic joints. When looking at the basal discharged recorded from both normal
joints in the mouse there appears to be a higher proportion of spontaneous afferents
in normal joints when compared to arthritic joints. The small number of experiments
in both normal and arthritic animals is likely the reason for the discrepancy and
further experiments will be required to verify this finding.
For both capsaicin and bradykinin a true maximum was not established for
the dose response curves because high doses of both compounds, particularly
capsaicin, are capable of desensitising both the response (Szallasi & Blumberg,
1999).and in some cases the entire preparation (personal observation). For this
reason, and the difficulty in setting up the preparation, it was decided to use doses
that would evoke a response but not produce desensitisation. Therefore, ED5o values
were not calculated as they did not provide a meaningful evaluation of the response.
Elements of the response to both capsaicin and bradykinin appear to be roughly
similar to those see in the rat. The short delay to onset and short duration are typical
of a capsaicin response in the rat, as is the slightly longer delay to onset of the
evoked response to bradykinin.
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The results presented in this study are preliminary and many more
experiments are required both to refine the technique and to develop a coherent
picture both of the types of afferents involved and their pharmacological
characteristics. However, what has been demonstrated is the ability to activate and
record from the sensory afferents that innervate the mouse knee joint - in normal and
arthritic animals. The fact that these fibres could be activated by capsaicin implies
that they contain C-fibres with VR-1 receptor gated ion-channels and, because
bradykinin was effective on the same afferents, GPCRs are also intimately associated
with these polymodal nociceptors. Much more investigation is required to determine
the pharmacological profile of these afferents, but the basis for doing so has been
established.
Many of the problems encountered during studies on murine joint nociceptors
are directly related to the size difference between rat and mouse. It was impossible
during the course of experiments to measure conductance velocities in the fibres
recorded from because there was insufficient room around the joint to be able to put
the stimulating electrode on the receptive field. Furthermore, it was not feasible to
monitor blood pressure during the experiments because of problems in obtaining
adequate BP signals from the fine catheters (high resistance) that were used for
cannulating arteries. There are a number of refinements that need to be made in
order for the technique to yield valuable results, but the pilot work has been very
encouraging..
In conclusion these studies show it is possible to induce a chronic, unilateral
joint inflammation in both DBA/1 and C57BL6 mice by repeated intra-articular
injections of FCA. The pathology present in these joints is consistent with a mild to
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moderate arthritis and it responds well to both prednisolone and indomethacin.
Furthermore, I have developed a technique for recording from branches of the
saphenous nerve innervating the mouse knee joint and can elicit responses that have
been recorded from sensory nociceptors that, using known algogens such as
capsaicin, are similar to those obtained in rat. Neural recordings, in conjunction with
the unilateral model of arthritis, will allow examination of the effects of drugs and
genetic manipulations on behavioural measures of pain as well as their effects on
nociceptive transmission in both normal and chronically inflamed joints. This should
provide some insight into the relationship between inflammation and nociception in
chronic inflammatory conditions such as arthritis.
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TABLES AND FIGURES
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Table 6.1 - Criteria for histopathology scoring
Criteria on which histological sections were examined blind to evaluate the
extent of inflammation and joint destruction. Each variable was scored
arbitrarily on an analog scale 0 (mild) to 5 (severe).
Synovium • Synovial hypertrophy
• Oedema
• Vascularity
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Table 6.2 - Explanation of hyperalgesia scores resulting from a joint
squeeze
Applying the squeeze between thumb and forefinger to a pressure transducer
and taking the average measurement for each hyperalgesia score it was
possible to estimate the pressure applied to the joint. The average pressure
applied was divided by the average knee joint area to get an approximate






0 Severe squeeze >60
1 Moderate squeeze 48.0 ±0.8
2 Mild squeeze 35.5 ± 1.2
3 Touching or light squeeze 24.5 ± 1.2
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Figure 6.1 - Schematic of the experimental set up for recording from
saphenous nerve in mice
Schematic of the experimental set up for recording neural activity from
sensory afferents in the saphenous nerve that innervate the mouse knee
joint. Cannulas were inserted in the trachea and the right femoral artery for
the close-arterial injection of drugs. The left limb was fixed to a solid support
and the skin was tied to a small brass ring to form a cavity, which is filled with
heavy liquid paraffin, producing an electrically isolated system. The
saphenous nerve was cut above and below the entry point of the MAN and
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Figure 6.2 - Effect on joint diameter of a single sub-cutaneous injection
of FCA over the ankle of DBA1 mice.
Diameter of the A) ipsilateral (left; injected) and B) contralateral (right;
uninjected) ankle joints of animals receiving (at arrows) no injections (control,
A), or single sub-cutaneous injection of either FCA (•; 50 pi of a 1 mg ml"1
suspension) or FILP (O; 50 pi). C) Increase in the left knee diameter
expressed as a percentage of the right knee diameter, pooled data from
comparisons of individual animals. Each data point represents the mean ±
SEM.
A single injection of FCA produced an acute inflammation but was unable to
evoke a chronic arthritis.
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Figure 6.3 - Effect on joint diameter of a single sub-cutaneous injection
of FCA (or a single plus a booster injection) over the knee of DBA/1
mice.
Diameter of the A) ipsilateral (left; injected) and B) contralateral (right;
uninjected) knee joints of DBA/1 mice receiving (at filled arrows) a single sub¬
cutaneous injection over the knee of HLP (O; 50 pi), FCA at a dose of either
100 pg (•; 50 pi of 2 mg ml"1 suspension) or 150 pg (A; 50 pi of 3 mg ml"1
suspension) or FCA (■; 50 pi of 3 mg ml"1 suspension) plus a booster
injection of FCA at day 21 (empty arrows; 50 pi of 2 mg ml"1 suspension). C)
Increase in the left knee diameter as a percentage increase over the right
knee diameter, pooled data from comparisons of individual animals. Each
data point represents the mean ± SEM.
A single FCA injection was incapable of inducing a chronic inflammation even
at a dose of 150 pg. Furthermore a booster injection of FCA at day 21 does
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Figure 6.4 - Effect on knee diameter of mBSA-induced inflammation in
the knee of C57BL6 mice.
Diameter of the A) ipsilateral (left; injected) and B) contralateral (right;
uninjected) knee joints of mice receiving an intra-articular challenge injection
of mBSA (•; 6 pi of a 10 mg ml"1 solution) or saline control (O; 6 pi) 21 days
following immunisation with mBSA. C) Increase in the left knee diameter as
a percentage increase over the right knee diameter, pooled data from
comparisons of individual animals. Each data point represents the mean ±
SEM. C
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Figure 6.5 - Effect on joint diameter of mBSA-induced inflammation in
the knee of DBA/1 mice.
Diameter of the A) ipsilateral (left; injected) and B) contralateral (right;
uninjected) knee joints of mice receiving an intra-articular challenge injection
of mBSA (•; 6 pi of a 10 mg ml"1 solution) or saline control (O; 6 pi) 21 days
following immunisation with mBSA. C) Increase in the left knee diameter as
a percentage increase over the right knee diameter, pooled data from
comparisons of individual animals. Each data point represents the mean ±
SEM.
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Figure 6.6 - Effect on joint diameter of repeated i.art. injections of FCA
into the knee of DBA/1 mice.
Diameter of A) ipsilateral (left; injected) and B) contralateral (right; uninjected)
knee joints of mice receiving repeated intra-articular injections (at arrows; 1
per week for 4 weeks) of FCA (•; 5 pi of 1 mg ml"1 suspension) or HLP (O; 5
pi). C) Increase in the left knee diameter as a percentage increase over the
right knee diameter, pooled data from comparisons of individual animals. D)
Change in the left knee diameter of each animal as compared to the starting
value (day 0). Each data point represents the mean ± SEM.





































































Chapter 6: FCA-Induced Unilateral Arthritis
Figure 6.7 - Schematic of inflammatory response to repeated intra¬
articular injections of FCA
There are two components to the inflammatory response induced by FCA.
The first component is an acute phase that immediately follows each injection
(at arrows) and results in a large increase in swelling in the knee joint. The
second phase is a more chronic phase that exists once the acute phase has
resolved. With each injection the swelling produced in the acute phase is
significantly greater. Furthermore, after the second a subsequent injections
the acute inflammation resolves but never to the starting diameter indicating
additional changes. After 4 injections the joint size has increased
dramatically and remains swollen as the accumulated changes have induced
a chronic inflammation.
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Figure 6.8 - Effect of repeated injections of FCA on body weight in
DBA/1 mice
A) Body weight and B) change in body weight from day 0, in DBA/1 mice
receiving repeated intra-articular injections (at arrows; 1 per week for 4
weeks) of FCA (•; 5 pi of 1 mg ml"1 suspension) or HLP (O; 5 pi). Each data
point represents the mean ± SEM.
Treatment with FCA did not significantly alter the ability of DBA/1 mice to
gain weight.
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Figure 6.9 - Effect of repeated injections of FCA on mobility in DBA/1
mice
Score of individual DBA/1 mice and the median (thick line) of the discomfort
associated with walking 7 days after receiving repeated intra-articular
injections (1 per week for 4 weeks) of FCA (5 pi of a 1 mg ml"1) or HLP (5 pi).
The mice were subjectively scored on a 0-3 scale (3 maximum) for signs that
they were in pain when bearing weight on the injected limb.
There was no significant difference between FCA and HLP treated groups in
the ability to walk normally (P = 0.62; Mann-Whitney).
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Figure 6.10 - Effect of FCA on hyperalgesia evoked by noxious
pressure applied to the knee joint in DBA/1 mice
A) Individual hyperalgesia scores and median (thick line) in response to
pressure applied to the ipsilateral (left; injected) or contralateral (right;
uninjected) knee joint in DBA/1 mice 7 days after repeated injections (1 per
week for 4 weeks) of FCA (5 pi of a 1 mg ml"1) or HLP (5 pi). Joints were
subjectively scored on a 0-3 scale (3 maximum) for withdrawal from the
noxious stimulus. B) Correlation of the hyperalgesia score and the left knee
diameter as a percentage increase over the right knee diameter, pooled data
from comparisons of individual animals.
There was a significant increase in the median hyperalgesia score for
animals that were treated with FCA (** P = 0.004, Mann-Whitney).
Furthermore there was a significant correlation between the knee joint
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Figure 6.11 - Histopathology of DBA/1 mice receiving repeated intra¬
articular injections of FCA
Histopathology of a normal (A,B) and arthritic (C-F) knee joints of DBA/1
mice. The normal joint shows an acellular joint space, thin synovial
membrane and smooth, healthy cartilage (B; dark blue staining). C) PMNs
and macrophages infiltrating the synovium and joint space. D) Thickening of
the synovial membrane. E) Peri-articular inflammation of surrounding muscle
and ligament. F) Pannus formation causing cartilage destruction and bone
erosion. Midline sections stained with H&E (A,C,D,E) or toluidine blue (B,F).
Abbreviations: S, synovial membrane; JS, joint space; C, cartilage; F, femur;
T, tibia; P, patella. Original magnification: A,C -40X; B,D,E,F - 100x.
Repeated intra-articular injections of FCA produce marked joint and peri
articular inflammation resulting in synovial thickening, cartilage destruction,
and bone erosion.
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Figure 6.12 - Histopathology of DBA/1 mice receiving repeated intra¬
articular injections of FCA
Individual histology scores and median (thick line) from left (injected) or right
(uninjected) knee joints from DBA/1 mice 7 days after repeated injections (1
per week for 4 weeks) of FCA (5 pi of a 1 mg ml"1) or HLP (5 pi). ** P<0.01;
*** P <0.001.
Repeated intra-articular injections of FCA induce a chronic inflammation with
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Figure 6.13 - Effect on joint diameter of repeated injections of FCA in
the knee of C57BL6 mice
Diameter of A) ipsilateral (left; injected) and B) contralateral (right; uninjected)
knee joints of mice receiving repeated intra-articular injections (at arrows; 1
per week for 4 weeks) of FCA (•; 5 pi of 1 mg ml"1 suspension) or HLP (O; 5
pi). C) Increase in the left knee diameter as a percentage increase over the
right knee diameter, pooled data from comparisons of individual animals. D)
Change in the left knee diameter of each animal as compared to the starting
value (day 0). Each data point represents the mean ± SEM.
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Figure 6.14 - Effect of repeated injections of FCA on body weight in
C57BL6 mice
A) Body weight and B) change in body weight from day 0, in C57BL6 mice
receiving repeated intra-articular injections (at arrows; 1 per week for 4
weeks) of FCA (•; 5 pi of 1 mg ml"1 suspension) or HLP (O; 5 pi). Each data
point represents the mean ± SEM.
Treatment with FCA did not significantly alter the ability of C57BL6 mice to
gain weight.
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Figure 6.15 - Effect of repeated injections of FCA on mobility in C57BL6
mice
A) Individual scores and median (thick line) of the discomfort associated with
walking and B) the correlation of the walking score with the increase in joint
diameter in C57BL6 mice 7 days (Day 28) after receiving repeated intra¬
articular injections (1 per week for 4 weeks) of FCA (5 pi of 1 mg ml"1
suspension) or HLP (5 pi).
There was no significant effect on the gait of either group as such no
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Figure 6.16 - Effect of FCA on hyperalgesia evoked by noxious
pressure applied to the knee joint in C57BL6 mice
A) Individual hyperalgesia scores and median (thick line) for pressure applied
to the ipsilateral (left; injected) or contralateral (right; uninjected) knee joint in
C57BL6 mice 7 days after repeated injections (1 per week for 4 weeks) of
FCA (5 pi of a 1 mg ml"1) or HLP (5 pi). Joints were subjectively scored on a
0-3 scale (3 maximum) for withdrawal from the noxious stimulus. B)
Correlation of the hyperalgesia score and the left knee diameter as a
percentage increase over the right knee diameter, pooled data from
comparisons of individual animals.
There is a significant increase in the hyperalgesia score for animals that were
treated with FCA (** P = 0.002, *** P = 0.0001; Mann-Whitney). Furthermore
there is a significant correlation between the knee joint inflammation and the
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Figure 6.17 - Histopathology of DBA/1 mice receiving repeated intra¬
articular injections of FCA
Histopathology of a normal (A,B) and arthritic (C-F) knee joints of C57BL6
mice. The normal joint shows an acellular joint space, thin synovial
membrane and smooth, healthy cartilage (B; dark blue staining). C) PMNs
and macrophages infiltrating the synovium and joint space. D) Pannus
formation overgrowing articular cartilage and the joint space contains many
inflammatory cells and cell debris. E) Thickening of the synovial membrane
and the formation of sparsely packed bone. F) Pannus formation causing
cartilage destruction and bone erosion. Midline sections stained with H&E
(C,D,E) or toluidine blue (A,B,F). Abbreviations: S, synovial membrane; JS,
joint space; C, cartilage; F, femur. Original magnification: A,C - 40X;
B,D,E,F - 100x.
Repeated intra-articular injections of FCA produce marked joint and peri
articular inflammation resulting in synovial thickening, cartilage destruction,
and bone erosion/formation.
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Figure 6.18 - Histopathology of C57BL6 mice receiving repeated intra¬
articular injections of FCA
Individual histology scores and median (thick line) from left (injected) or right
(uninjected) knee joints from C57BL6 mice 7 days after repeated injections (1
per week for 4 weeks) of FCA (5 pi of a 1 mg ml"1) or HLP (5 pi). * P<0.05; **
p<0 01; *** p <0.001.
Repeated intra-articular injections of FCA induce a chronic inflammation with
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Figure 6.19 - Comparison of knee diameter during FCA-induced
unilateral arthritis in DBA/1 and C57BL6 mice
Increase in the left knee diameter as a percentage increase over the right
knee diameter in DBA/1 (■) and C57BL6 (•) mice receiving repeated intra¬
articular injections of FCA (at arrows; 1 per week for 4 weeks; 5 pi of 1 mg
ml"1 suspension). Each data point represents the mean ± SEM.
There was no significant difference between DBA/1 and C57BL6 mice in the
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Figure 6.20 - Comparison of mobility during FCA-induced unilateral
arthritis in DBA/1 and C57BL6 mice
Individual mobility scores and median (thick line) in DBA/1 and C57BL6 mice
7 days after receiving repeated intra-articular injections of FCA (1 per week
for 4 weeks; 5 pi of 1 mg ml"1 suspension).
Neither strain showed any alteration in gait during chronic unilateral
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Figure 6.21 - Comparison of hyperalgesia evoked by noxious pressure
applied to the knee joint in DBA/1 and C57BL6 mice
Hyperalgesia score and median (thick line) of the left (chronically inflamed)
and right (control) knee joints in DBA/1 and C57BL6 mice 7 days after
receiving repeated intra-articular injections (1 per week for 4 weeks) of FCA
(5 pi of 1 mg ml"1 suspension). * P<0.05, *** P<0.0001 (Mann-Whitney).
Both strains showed a significant sensitisation to noxious pressure on the
inflamed joint when compared to the contralateral control. There was no
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Figure 6.22 - Comparison of histological scores in DBA/1 and C57BL6
mice receiving repeated intra-articular injections of FCA
Individual histology scores and median (thick line) from left (injected) or right
(uninjected) knee joints from DBA/1 and C57BL6 mice 7 days after repeated
injections (1 per week for 4 weeks) of FCA (5 pi of a 1 mg ml"1) or HLP (5 pi).
*** P <0.001.
There is no significant difference in the histological score of pathological
changes resulting from FCA-induced chronic inflammation between DBA/1
and C57BL6 mice.
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Figure 6.23 - Effect of prednisolone on knee diameter during
established FCA induced unilateral arthritis in DBA/1 mice
Diameter of A) left (chronically inflamed) and B) right (control) knee joints of
mice receiving repeated intra-articular injections (at arrows; 1 per week for 4
weeks) of FCA (5 pi of 1 mg ml"1 suspension) and a 7 day treatment (thick
bar; daily i.p. injection) with prednisolone (#; 10 mg kg"1) or injection of
vehicle (O) starting from Day 28. C) Increase in the left knee diameter as a
percentage increase over the right knee diameter, pooled data from
comparisons of individual animals. D) Change in the left knee diameter of
each animal as compared to the starting value (day 0). Each data point
represents the mean ± SEM.
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Figure 6.24 - Effect of prednisolone on body weight during established
FCA-induced unilateral arthritis in DBA/1 mice
A) Body weight and B) change in body weight from Day 0, of mice receiving
repeated intra-articular injections of FCA (at arrows; 1 per week for 4 weeks;
5 pi of 1 mg ml"1 suspension) and a 7 day treatment (thick bar; daily i.p.
injection) with prednisolone (•; 10 mg kg"1) or injection vehicle (O) starting
from Day 28. Each data point represents the mean ± SEM.
Treatment with prednisolone did not affect weight gain.
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Figure 6.25 - Effect of prednisolone on the mobility during established
FCA-induced unilateral arthritis in DBA/1 mice
Individual mobility scores and median (thick line) of the discomfort associated
with walking A) during chronic inflammation at Day 28 (pre-treatment) or B)
After 7 days treatment with prednisolone (10 mg kg ~1) or vehicle (daily i.p.
injections) in DBA/1 mice.
There was no significant difference between the groups before or after 7
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Figure 6.26 - Effect of prednisolone on hyperalgesia evoked by noxious
pressure during established FCA-induced unilateral arthritis in DBA/1
mice
Individual hyperalgesia scores and median (thick line) for pressure applied to
the left (chronically inflamed) or right (control) A) during chronic inflammation
at Day 28 (pre-treatment) or B) after 7 days treatment with prednisolone (10
mg kg ~1) or vehicle (daily i.p. injections) in DBA/1 mice. *** P <0.001.
Treatment with prednisolone significantly decreased the sensitisation to a
noxious stimulus in the chronically inflamed joint.
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Figure 6.27 - Effect of prednisolone on inflammation and joint
destruction during established FCA-induced unilateral arthritis in
DBA/1 mice.
Histopathology of arthritic knee joints following 7 days treatment with
prednisolone (10 mg kg ~1, daily i.p. injections) in DBA/1 mice. The normal
joint shows an acellular joint space, thin synovial membrane and smooth,
healthy cartilage (B; dark blue staining). A) Infiltration of a large number of
PMNs and macrophages into the synovial membrane, peri-articular tissues,
and joint space. B) Pannus formation and the destruction of articular
cartilage. Midline sections stained with A) H&E or B) toluidine blue.
Abbreviations'. JS, joint space; C, cartilage; F, femur. Original magnification:
A-40X; B- 100x.
Treatment with prednisolone did not significantly reverse arthritic changes in
established FCA-induced chronic inflammation.
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Figure 6.28 - Effect of prednisolone on the histological score during
established FCA-induced unilateral arthritis in DBA/1 mice
Individual histological score and median (thick line) for the left (chronically
inflamed) and right (control) knee joint 7 days after treatment with
prednisolone (10 mg kg "1) or vehicle (daily i.p. injections) in DBA/1 mice. ***
P <0.001.
Treatment with prednisolone did not alter the joint destruction in a chronically
inflamed joint.
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Figure 6.29 - Effect of indomethacin on knee diameter during
established FCA-induced unilateral arthritis in C57BL6 mice
Diameter of A) left (chronically inflamed) and B) right (control) knee joints of
mice receiving repeated intra-articular injections of FCA (at arrows; 1 per
week for 4 weeks; 5 pi of 1 mg ml"1 suspension) and a 7 day treatment (thick
bar; daily s.c. injection) with indomethacin (•; 1 mg kg"1) or injection vehicle
(O) starting from Day 28. C) Increase in the left knee diameter as a
percentage increase over the right knee diameter, pooled data from
comparisons of individual animals. D) Change in the left knee diameter of
each animal as compared to the starting value (day 0). Each data point
represents the mean ± SEM.
Treatment with indomethacin reduced the swelling present in chronically
inflamed joints.
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Figure 6.30 - Effect of indomethacin on body weight during established
FCA-induced unilateral arthritis in C57BL6 mice
A) Body weight and B) change in body weight from Day 0, of mice receiving
repeated intra-articular injections of FCA (at arrows; 1 per week for 4 weeks;
5 pi of 1 mg ml"1 suspension) and a 7 day treatment (thick bar; daily s.c.
injection) with indomethacin (•; 1 mg kg"1) or injection vehicle (O) starting
from Day 28. Each data point represents the mean ± SEM.
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Figure 6.31 - Effect of indomethacin on mobility during established
FCA-induced unilateral arthritis in C57BL6 mice
Individual mobility scores and median (thick line) of the discomfort associated
with walking A) during chronic inflammation at Day 28 (pre-treatment) or B)
After 7 days treatment with indomethacin (1 mg kg ~1) or vehicle (daily s.c.
injections) in C57BL6 mice.
There was no significant difference between the groups before or after 7
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Figure 6.32 - Effect of indomethacin on hyperalgesia evoked by
noxious pressure during established FCA-induced unilateral arthritis in
C57BL6 mice
Individual hyperalgesia scores and median (thick line) for pressure applied to
the left (chronically inflamed) or right (control) A) during chronic inflammation
at Day 28 (pre-treatment) or B) after 7 days treatment with indomethacin (1
mg kg "1) or vehicle (daily s.c.. injections) in C57BL6 mice.
0.001.
P < 0.05, P <
Treatment with indomethacin significantly decreased the sensitisation to a
noxious stimulus in chronically inflamed joints.
A
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Figure 6.33 - Effect of indomethacin on inflammation and joint
destruction in established FCA-induced unilateral arthritis in C57BL6
mice.
Histopathology of arthritic knee joints following 7 days treatment with
indomethacin (1 mg kg ~1, daily i.p. injections) in C57BL6 mice. The normal
joint shows an acellular joint space, thin synovial membrane and smooth,
healthy cartilage (B; dark blue staining). A) Extensive peri-articular
inflammation and infiltration of PMN cells into the joint space. B) Destruction
of articular cartilage and inflammation of the patella tendon. Midline sections
stained with A) H&E or B) toluidine blue. Abbreviations: JS, joint space; C,
cartilage; F, femur; PT, patella tendon. Original magnification: A - 40X; B -
100x.
Treatment with indomethacin did not significantly reverse arthritic changes in
established FCA-induced chronic inflammation.
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Figure 6.34 - Effect of indomethacin on the histological score in
established FCA-induced unilateral arthritis in C57BL6 mice
Histological score and median (thick line) for the left (chronically inflamed) or
right (control) knee joint 7 days after treatment with indomethacin (1 mg kg ~1)
or vehicle (daily s.c. injections) in C57BL6 mice. *** P <0.001 (Mann-
Whitney).
Treatment with indomethacin did not alter the pathological changes and joint
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Figure 6.35 - Effect of FCA-induced unilateral arthritis on knee diameter
in P2X7 knock out mice.
Diameter of A) ipsilateral (left) and B) contralateral (right) knee joints of P2X7
knock out transgenic mice (TG; circles) or wild type littermates (WT; squares)
on a C57BL6 background receiving repeated intra-articular injections (at
arrows; 1 per week for 4 weeks) of FCA (filled symbols; 5 pi of 1 mg ml"1
suspension) or HLP (empty symbols; 5 pi). C) Increase in the left knee
diameter as a percentage increase over the right knee diameter, pooled data
from comparisons of individual animals. D) Change in the left knee diameter
of each animal as compared to the starting value (day 0). Each data point
represents the mean ± SEM.
There was no significant difference in the ability to induced arthritis between
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Figure 6.36 - Effect of FCA on body weight in P2X7 KO and WT mice.
A) Body weight and B) Change in body weight from day 0, of P2X7 knock out
transgenic mice (KO; circles) or wild type littermates (WT; squares) on a
C57BL6 background receiving repeated intra-articular injections (at arrows; 1
per week for 4 weeks) of FCA (filled symbols; 5 pi of 1 mg ml"1 suspension)
or HLP (empty symbols; 5 pi). Each data point represents the mean ± SEM.
There was a significant difference between FCA and HLP treated animals
(P=0.02 and P=0.004 for WT and KO respectively) but not between KO and
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Figure 6.37 - Effect of repeated injections of FCA on mobility in P2X7
KO and WT mice
Individual mobility score and median (thick line) of the discomfort associated
with walking in P2X7 knock out transgenic mice (KO) or wild type littermates
(WT) on a C57BL6 background 7 days (Day 28) after receiving repeated
intra-articular injections (1 per week for 4 weeks) of FCA (5 pi of 1 mg ml"1
suspension) or HLP (5 pi).
Animals treated with FCA showed discomfort as manifest in limping. This
was not seen in HLP treated animals. There was no significant difference in
the scoring between KO and WT groups (P = 0.59; unpaired t-test).
KO FCA WT FCA KO HLP WT HLP
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Figure 6.38 - Effect of repeated injections of FCA on hyperalgesia
evoked by noxious pressure in P2X7 KO and WT mice
Individual hyperalgesia scores and median (thick line) of the hyperalgesia
produced by squeezing the knee joint in P2X7 knock out transgenic mice
(KO) or wild type littermates (WT) on a C57BL6 background 7 days (Day 28)
after receiving repeated intra-articular injections (1 per week for 4 weeks) of
FCA (5 pi of 1 mg ml"1 suspension) or HLP (5 pi) in the left knee joint.
Joints from both KO and WT mice that were injected with FCA showed a
sensitisation to a painful stimulus when compared to the contralateral limb (P
= 0.0002 and P = 0.0002 respectively; paired t-test) or to vehicle controls (P
= 0.004 and P = 0.01 respectively; Mann-Whitney). There was no significant
difference in the scoring between the injected knee joint (left) of KO and WT
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Figure 6.39 - Effect of FCA on the histological score in P2X7 KO and WT
mice
Individual histological scores and median (thick line) of joint damage in knee
joint sections of P2X7 knock out transgenic mice (KO) or wild type littermates
(WT) on a C57BL6 background 7 days (Day 28) after receiving repeated
intra-articular injections (1 per week for 4 weeks) of FCA (5 pi of 1 mg ml"1
suspension) or HLP (5 pi) in the left knee joint.
Joints from both KO and WT mice that were injected with FCA showed
significant joint damage when compared to the contralateral limb (P = 0.0001
and P = 0.0002 respectively; paired t-test) or to vehicle controls (P = 0.004
and P = 0.008 respectively; Mann-Whitney). There was no significant
difference in the scoring between the injected knee joint (left) of KO and WT
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Figure 6.40 - Activation of C-fibre polymodal nociceptors in the C57BL6
mouse knee joint
Multi-fibre neural discharge (left panel) recorded from the saphenous nerve
showing the response evoked from individual fibres (right panel) by A)
mechanical probing of the joint (at arrow) using a small diameter plastic
probe (activated fibres 1,2, and 3) and B) the close-arterial injection (at
arrow) of capsaicin (330 pmol, which activated fibres 1, 2, and 3). Filters
Filters were set to allow only discharge above noise level to be captured.
Some of the individual fibres that comprise the response are shown on the
right panel.
The fibres were thought to be C-fibre polymodal nociceptors since they
responded to noxious mechanical pressure on the joint and were also
activated by capsaicin.
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Figure 6.41 - Capsaicin activates sensory afferents innervating the
C57BL6 mouse knee joint in a dose- dependent manner
Typical log dose response curves displaying the dose-related increase in
discharge frequency (impulses s~1) and the total number of action potentials
(impulses) evoked by close arterial injection of capsaicin (33 - 980 pmol) in a
normal mouse knee joint. A,B, and C represent three different animals.
Capsaicin evoked action potential discharge from nociceptive afferents
contained in the saphenous nerve and innervating the normal mouse knee
joint in a dose-dependent manner.
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Figure 6.42 - Bradykinin activates sensory afferents innervating the
C57BL6 mouse knee joint in a dose- dependent manner
Typical log dose response curves displaying the dose-related increase in A)
discharge frequency (impulses s"1) and B) the total number of action
potentials (impulses) evoked by close arterial injection of bradykinin (94 -
2830 pmol) in a normal mouse knee joint.
Bradykinin evoked action potential discharge from nociceptive afferents
contained in the saphenous nerve and innervating the normal mouse knee
joint in a dose-dependent manner.
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Figure 6.43 - Typical responses to capsaicin and bradykinin in afferents
of the MAN in the C57BL6 mouse knee joint
Multi-fibre neural discharge (left panel) recorded from the saphenous nerve
showing the response evoked by close-arterial injection (at arrow) of A)
capsaicin (330 pmol, which activated fibres 1, 2, and 3) and B) bradykinin
(940 nmol, activated fibres 1 and 2). Data in the left panel is the raw signal
shown without the removal of the noise band. Individual fibres that comprise
the response are shown on the right panel.
It is possible to record excitation in afferents that innervate the mouse knee
joint by the close arterial injection of capsaicin and bradykinin.
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Figure 6.44 - Comparison of the excitation of mouse knee joint
afferents evoked by capsaicin and bradykinin
A) Latency to onset, B) duration of the response, C) action potential
discharge frequency and D) total number of action potentials elicited
following a close arterial injection of capsaicin (330 pmol) or bradykinin (940
pmol). Data shown are mean ± sem for pooled responses.
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7. General Discussion and Future Directions
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7.1 PROPERITES OF NOCICEPTORS INNERVATING NORMAL
AND ARTHIRTIC RAT KNEE JOINT
One of the primary aims of this thesis was to examine peripheral nociceptors
that innervate knee joints in the rat to determine whether or not there are differences
in their response characteristics in normal and arthritic (chronic inflammation) states.
In the rat a higher proportion of afferents exhibited spontaneous activity in arthritic
joints when compared to normal joints. Guilbaud et al (1985) showed that, in
addition to an increase in the proportion of afferents showing spontaneous activity,
the afferents that innervate the arthritic rat knee joint also discharged at a higher
frequency. This was confirmed in this lab in the rat ankle joint (Asghar, 1995).
However, results presented in this thesis did not provide evidence for this, as there
was no significant difference in the frequency of the spontaneous excitation of
afferents innervating normal and arthritic knee joints.
In addition to investigating spontaneous activity the excitation evoked by a
number of chemical mediators was examined in afferents innervating normal and
arthritic knee joints. Afferents excited by capsaicin (VRi receptor agonist) and
aPmeATP (P2Xj, P2X3 and P2X2/3 receptor agonist) showed no sensitisation to
activation in the arthritic joint. It has been reported that both the VRi and P2X3
receptors become sensitised during peripheral acute inflammation (Carlton &
Coggeshall, 2001; Xu & Huang, 2002). Sensitisation of peripheral nociceptors
mediated by these receptors appears to be the result of an increase in the receptor
population within 48 hours of the induced inflammation. The acute nature of the
inflammation means that these results may not be relevant to a chronic inflammatory
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condition. During chronic inflammation induced by the repeated intra-articular
injection of FCA there was conflicting evidence as to the sensitivity of VRi
receptors. Results using capsaicin as a ligand at VRi show there is desensitisation of
the afferent excitation in the chronically inflamed joint, whereas with anandamide,
also known to be a ligand for VR) receptors (Olah et ah, 2001; Smart et al., 2000;
Zygmunt et al., 1999), there was no desensitisation. In the FCA-induced arthritis
model excitatory responses to both capsaicin and aPmeATP are decreased as the
receptors are rapidly desensitised by repeated stimulation. During chronic
inflammation when the levels of endogenous ligand are elevated the receptors may
become desensitised over time. If the sensitivity of the VR) receptor decreased
during chronic inflammation, then one would predict that a corresponding increase in
the threshold to thermal nociception would occur. There are many reports in the
literature referring to the induction of thermal hyperalgesia in cutaneous and joint
afferents following acute inflammation, but there are no reports in which the thermal
properties of nociceptors have been investigated in chronically inflamed tissue. In
one human study that examined thermal sensitivity in the thumb joint of patients with
OA there was hyperalgesia to an applied thermal stimulus (Farrell et al., 2000).
However, as the stimulus was applied over the joint and the relative contribution of
skin and joint nociceptors in the overall pain response are currently not known it is
difficult to draw conclusions about the thermal sensitivity of joint nociceptors
specifically.
A further finding of this thesis is that the endogenous cannabinoid,
anandamide, was able to excite peripheral nociceptors in vivo through activation of
the VRi receptor. Since the capsaicin-evoked response was inhibited in the
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chronically inflamed joint, the anandamide-mediated excitation was examined in
nociceptive afferents innervating the normal and the arthritic knee joint. It transpired
that excitation by anandamide of afferents innervating arthritic joints did not differ
significantly from that observed in normal joints. Although the response to
anandamide could be blocked with the VRi receptor specific antagonist, capsazepine,
there appeared to be no desensitisation of the VRi receptor during chronic
inflammation. Additionally, repeated injections of anandamide, even at a maximal
dose (2900 nmol), did not desensitise the activation of afferents in either normal or
arthritic joints.
Although anandamide is a full agonist at the human VRi receptor (Smart et
al., 2000), it is much less potent than capsaicin and other vanilloid analogs (Ralevic
et al., 2001). Experiments with anandamide were limited to a maximal concentration
(2900 nmol) due to the limited solubility of the molecule and potentially the level of
excitation at the VRi receptor in our model was sufficient to produce activation but
not desensitisation. It is possible that anandamide binds to a different site on the VRi
receptor or activates the channel through a different mechanism. Activation of the
receptor complex through a different mechanism could account for the fact that, in
contrast to capsaicin, anandamide is non-pungent. However, the actions of
anandamide and capsaicin are both blocked by the competitive antagonist
capsazepine so it is unlikely that there is a secondary binding site. The fact that
anandamide is non-pungent is not linked to its lower potency at VRi receptors
because the capsaicin analog, olvanil, has been shown to be tenfold more potent at
the human VRi receptor - while still remaining non-pungent (Ralevic et al., 2001). It
has been suggested that olvanil is non-pungent because the activation kinetics of the
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ligand-receptor interaction are slower than the rate at which it inhibits the generation
of action potentials through desensitisation (Liu et al., 1997).
The two ligand-gated ion channels detailed above did not show any evidence
of sensitisation during chronic inflammation. In contrast, bradykinin, which acts
through a G-protein coupled receptor (GPCR), evoked increased afferent discharge
from afferents innervating arthritic joints. As discussed in Chapter 3 expression of
the B1 receptor is upregulated during inflammation, and the increased afferent
discharge could be the result of combined excitation of B1 and B2 receptors on
peripheral terminals.
FUTURE DIRECTIONS
The sensitisation of peripheral nociceptors during chronic inflammation is an
area of research that requires much more investigation. The role of the large number
of mediators released during chronic inflammation in the excitation and/or inhibition
of peripheral nociceptors is for the most part unknown. The information that is
available concerning the chemical excitation of joint afferents is extrapolated from
experiments on cutaneous nociceptors. Detailed characterisation of joint nociceptors
is necessary to determine whether they have a unique pharmacological profde, or
whether the pharmacological characteristics of nociceptors are uniform and
independent of the tissue they innervate.
Mediators that need to be investigated are the various prostaglandins and
thromboxanes and an ever-increasing list of cytokines, all of which play a critical
role in cell-cell interactions during inflammation and as such may also influence
sensory neurons.
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A number of questions arise from the work in this thesis, including the
mechanism for desensitisation of the VRi receptor during chronic inflammation, that
cannot be answered using whole animal electrophysiology and instead would be
better addressed by in vitro methods. Flowever further studies using this model
should enable the role of putative mediators and their pharmacological receptors in
the activation of nociceptors to be examined. To continue previous work in this
laboratory exploring the activation of nociceptors by bradykinin (Kelly, 1998; Kelly
et al., 1995a; Kelly et al., 1995b) it should be possible to use selective antagonists to
determine the role of the B1 receptor in the increased nociceptive discharge evoked
from afferents innervating the arthritic knee joint. Furthermore, recent reports have
shown that the population of P2X receptors present on sensory nerves and peripheral
terminals is more heterogeneous than previously thought, as it includes P2X], P2X2
and various combinations of P2X2 and P2X3 subunits to produce homomer and
heteromer channels (Liu et al., 2001; Pankratov Yu et al., 2001; Petruska et al.,
2000). To determine which P2X receptor is being activated on peripheral
nociceptors will require the development of subtype specific agonists or antagonist,
or the generation of subtype specific P2X receptor knockout animals. Until these
pharmacological tools become available the P2X subtype involved in nociceptor
transmission and how it behaves during chronic inflammation cannot be determined.
7.2 MODULATION OF NOCICEPTORS BY INFLAMMATORY
MEDIATORS
Another of the aims was to examine whether or not the neuropeptide
somatostatin could modulate spontaneous and/or chemically evoked stimulation of
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sensory nociceptors. Although there is an extensive literature on the use of
somatostatin as an anti-inflammatory and analgesic (see Chapter 4), in the FCA-
induced model of mild chronic inflammation there was no effect on nociceptors
innervating the knee joint. Somatostatin did not inhibit spontaneous discharge in
normal or arthritic joints, nor did it alter the excitation evoked by chemical stimuli -
capsaicin, bradykinin, or aPmeATP. It is difficult to know why there was no effect;
somatostatin is released from sensory terminals innervating the skin of the rat hind
paw in response to noxious stimulation and it has been shown that both locally
released and exogenously applied somatostatin can inhibit noxious mechanical
stimulation of these afferent C-fibres (Carlton et ai, 2001a; Carlton et al., 2001b).
The endogenous cannabinoid anandamide is also released from sensory
neurons during inflammation. Anandamide can act via CBi receptors, and as shown
in Chapter 5, can also act on the VRi receptor. Both of these receptors play a role in
nociceptive processing. However, anandamide did not inhibit chemically evoked
excitation of sensory afferents innervating either normal or arthritic rat knee joints
caused by capsaicin, bradykinin or aPmeATP.
Questions that arise from these studies concern the fact that both somatostatin
and anandamide compounds have been shown to be analgesic, and yet they were
unable to inhibit activation of peripheral nociceptor terminals by chemical stimuli.
From this one could conclude that they act centrally or on the cell bodies in the DRG
rather than the peripheral nociceptive terminals. Alternatively, it could be an
inherent fault of the way in which the drug is administered. Somatostatin acts as an
anti-inflammatory through its inhibition of the action of substance P and it may be
that levels of somatostatin have to be increased for a longer period to cause
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analgesia. Thus the effects of a single bolus injection of the drug may be too
transient to inhibit transmission.
FUTURE DIRECTIONS
To address the concern that somatostatin or anandamide are not given
sufficient time to act, further experiments could be done where the drugs are
administered over a longer period either using an infusion pump or by repeated
injections. This would allow a high systemic level of the drug to be maintained.
Furthermore, animals with FCA-induced unilateral arthritis receiving either
anandamide or somatostatin have not been tested in the weight-bearing paradigm to
determine their effectiveness in inhibiting the pain associated with chronic
inflammation. Once it has been established that these compounds can effectively
modulate nociception on a behavioural level, then the mechanisms by which this is
occurring should be investigated electrophysiologically.
Recent interest in the analgesic and anti-inflammatory properties of
endogenous and exogenous cannabinoids has opened up a whole new range of
compounds to investigate in FCA-induced model of chronic inflammation. Further
experiments could be performed to determine the efficacy of the other endogenous
cannabinoid receptor ligand, 2-arachidonyl glycerol, in modulating chemical
activation of peripheral terminals. Additionally, there are a number of CBi and CB2
receptor agonists and antagonists available, which could be used to characterise these
receptors and to establish their role in the activation and sensitisation of peripheral
nociceptors during chronic inflammation.
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7.3 MURINE UNILATERAL ARTHRITIS AND
ELECTROPHYSIOLOGICAL RECORDING FROM AFFERENTS
INNERVATING THE MOUSE KNEE JOINT
Part of this thesis was dedicated to the development of a novel model of
murine arthritis and establishing whether it is feasible to record activity from sensory
afferents innervating the mouse knee joint.
FCA-INDUCED UNILATERAL ARTHRITIS IN THE MOUSE KNEE JOINT
In the development of a new animal model of arthritis it is important to
consider two questions: does the model mimic the pathology of the clinical condition
and can it predict effective therapeutic treatments in man. Results show that repeated
intra-articular injections of FCA induced chronic joint inflammation. Histology
demonstrated that the inflammation has a number of the characteristics of arthritis,
including pannus formation, bone and cartilage destruction, and infiltration of a large
number of inflammatory cells, oedema, and fibrous deposits through out the tissue.
Additionally, contrary to other models of arthritis in the mouse (see Chapter 6), this
model appears to be consistent across two mouse strains. This allows comparisons to
be drawn on differences between strains - particularly important when studying
transgenic mice, which vary widely in terms of their genetic background.
Although no experimental model perfectly mimics the human disease, animal
models of arthritis (both RA and OA) have been very effective in the prediction of
therapeutic effectiveness of drugs in man. Drugs that inhibit the progression of
experimental arthritis, such as steroids, NSAIDS, COX-2 inhibitors, and pro¬
inflammatory cytokine blockers, are routinely used in the treatment of human
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arthritic conditions (Bendele et al, 1999; van den Berg, 2001a; van den Berg, 2001b;
van den Berg, 2000b). FCA-induced unilateral arthritis in the mouse has shown
similar properties, in that inflammation of the joint is inhibited by treatment with
steroid (e.g. prednisolone) and NSAID (e.g. indomethacin) drugs.
An additional consideration in designing models for disease is the welfare of
experimental animals. Systemic models of chronic inflammation produce a very
severe polyarthritis that is stressful and causes severe suffering in the animal. The
unilateral and mild nature of the FCA-induced arthritis means that the inflammation
is isolated to a single joint, thereby minimising the discomfort and distress to the
mouse. Furthermore, a unilateral inflammation provides an intra-animal control
allowing comparisons to be made between an injected and uninjected joint. Finally,
in the rat, the level of inflammation induced by the injection of FCA is dose
dependent. Therefore, an appropriate dose can be given to induce a mild-moderate
joint inflammation, sufficient for the examination of the condition without causing
severe discomfort in the animal. It remains to be investigated whether FCA-induced
inflammation in the mouse is similarly dose-dependent, but this can easily be
established by further experiments.
Future directions
There are a number of issues that still need to be resolved in order to validate
the model as a good predictor of treatments for arthritis. Experiments need to be
done that examine the role of IL-1 (3 and TNFa in the initiation and maintenance of
chronic joint inflammation. In addition, in order to be used as true measures of
effective treatment, steroids and NSAIDS should be administered orally - these
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experiments would not take much time but would further confirm the effectiveness
of the model.
The development of apparatus for the measurement of weight bearing on the
hind limbs is required to facilitate the objective measurement of the hyperalgesia
associated with inflammation of joints in mice. Similarly, a force transducer linked
to a pair of forceps could provide an objective measurement of the withdrawal
latency of a limb to (quantified) applied pressure.
Once the model is fully characterised it can be used as an effective tool for
the examination of transgenic mouse lines in which genes that are considered to be of
particular relevance to chronic inflammation or peripheral nociception have been
modified. To gain the most information from this system it would be best to
examine transgenics where the mutation can be temporally regulated using
chemically inducible promoters. Additionally, using site-specific promoters it may
be possible to restrict the mutation to a particular tissue (such as peripheral nerves).
ELECTROPHYSIOLOGICAL RECORDING FROM MOUSE KNEE JOINT
AFFERENTS IN VIVO
Results in this thesis detail the development of a method for recording from
peripheral afferents innervating the knee joint in a live, anaesthetised mouse. There
is no mention in the literature of other groups having achieved this. This method can
be used to record mechanical and chemical stimulation of peripheral nociceptors.
Future directions
As much of the work presented in this thesis is preliminary, based on time-
consuming and technically demanding developmental experiments, there is scope for
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a considerable amount of work to be performed in this area. Very little is known
about the innervation of the mouse knee joint, and it is only recently that the types of
fibres present in the mouse MAN were examined using electron microscopy (Ebinger
et al., 2001). As so little is known about the types of fibres that innervate the mouse
knee, there is virtually no information on the pharmacological profile of these
afferents. Future experiments in this area could examine a whole range of targets
and would provide insight into the types of receptors that are present on mouse
peripheral afferents and how this compares with the situation in other species.
Probably the most interesting use of neural recordings from afferents in the
mouse knee joint would be combining it with existing technology for the production
of transgenic mice. A large number of transgenic mouse lines with genetic
alterations relevant to nociception already exist. Using transgenic animals that over
express a particular gene or have it completely removed, one could quickly
determine whether the activation and/or sensitisation of peripheral nociceptors were
due to a particular receptor or receptor subtype. If this was combined with a
measurement of weight bearing or hyperalgesia to pressure applied to the knee joint,
it should be possible to correlate genetic alterations directly with changes in
nociceptor activation and ultimately the perception of pain.
7.4 GENERAL CONCLUSIONS
The results presented in this thesis contribute to our overall knowledge
concerning the pharmacological profile of nociceptive afferents innervating the knee
joint in rats and mice. They showed that the reported anti-nociceptive effect of
somatostatin is not mediated by action on peripheral nociceptors or the inhibition of
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tested algogens. Furthermore anandamide is able to directly activate sensory
afferents via VRi receptors.
In addition, a new model of chronic unilateral arthritis - based on repeated
intra-articular injections of FCA - has been established. Using this model, and P2X7
knockout mice, it was demonstrated that P2X7 purinoceptors do not play a role in the
induction of inflammation and hyperalgesia in unilateral arthritis. Finally, a new
technique was developed for direct measurement of mechanically and chemically
evoked discharge from the peripheral terminals of afferent nociceptors innervating
the mouse knee joint.
Results of studies on the peripheral terminals of sensory afferents provide
information relevant to the design and testing of therapeutic targets for the
modulation of nociception. Selective peripheral analgesics targeting nociceptive
terminals would minimise unwanted actions of compounds within the central
nervous system. Determining how the properties of nociceptors (and their associated
drug receptors) change during chronic inflammation will provide valuable insight
into molecular and cellular changes that are responsible for the sensitisation and
activation of peripheral nociceptor during chronic inflammatory conditions. This







Abbot, N.C., Ferrell, W.R., Lockhart, J.C. & Lowe, J.G. (1996). Laser Doppler
perfusion imaging of skin blood flow using red and near-infrared sources. J
Invest Dermatol, 107, 882-6.
Ahluwalia, J., Urban, L., Capogna, M., Bevan, S. & Nagy, I. (2000). Cannabinoid 1
receptors are expressed in nociceptive primary sensory neurons.
Neuroscience, 100, 685-8.
Andersson, S.E., Johansson, A., Lexmuller, K. & Ekstrom, G.M. (1998a).
Physiological characterization of mBSA antigen induced arthritis in the rat.
II. Joint blood flow, glucose metabolism, and cell proliferation. Journal of
Rheumatology, 25, 1778-84.
Andersson, S.E., Lexmuller, K. & Ekstrom, G.M. (1998b). Physiological
characterization of mBSA antigen induced arthritis in the rat. I. Vascular
leakiness and pannus growth. Journal ofRheumatology, 25, 1772-7.
Arthritis-Research-Foundation (2002). http://www.arc.org.uk/.
Asghar, A.U. (1995). Pharmacological studies on bradykinin and other inflammaory
mediators in rat neural preparations. In Department of Pharmacology.
Edinburgh: University ofEdinburgh.
Asghar, A.U.R., McQueen, D.S., Kelly, D.C. & Tazaki, M. (1997). Characterisation
of bradykinin receptors that affect C-fibre afferent activity from the rat ankle
joint. British Journal ofPharmacology, 122, 333-P333.
Bean, B.P. (1990). ATP-activated channels in rat and bullfrog sensory neurons:
concentration dependence and kinetics. Journal ofNeuroscience, 10, 1-10.
Belmonte, C. & Cervero, F. (1996). Neurobiology of Nociceptors. New York:
Oxford University Press.
Belmonte, C., Gallar, J., Pozo, M.A. & Rebollo, I. (1991). Excitation by irritant
chemical substances of sensory afferent units in the cat's cornea. J Physiol,
437, 709-25.
Belmonte, C. & Giraldez, F. (1981). Responses of cat corneal sensory receptors to
mechanical and thermal stimulation. JPhysiol, 321, 355-68.
Bendele, A., McComb, J., Gould, T., McAbee, T., Sennello, G., Chlipala, E. & Guy,
M. (1999). Animal models of arthritis: relevance to human disease.
Toxicologic Pathology, 27, 134-42.
Bessou, P. & Perl, E.R. (1969). Response of cutaneous sensory units with
unmyelinated fibers to noxious stimuli. Journal Of Neurophysiology, 32,
1025-43.
Bevan, S., Hothi, S., Hughes, G., James, I.F., Rang, H.P., Shah, K., Walpole, C.S. &
Yeats, J.C. (1992). Capsazepine: a competitive antagonist of the sensory
neurone excitant capsaicin. Br JPharmacol, 107, 544-52.
Biedert, R.M., Stauffer, E. & Friederich, N.F. (1992). Occurrence of free nerve
endings in the soft tissue of the knee joint. A histologic investigation. Am J
Sports Med, 20, 430-3.
Billingham, M.E. (1983). Models of arthritis and the search for anti-arthritic drugs.
Pharmacol Ther, 21, 389-428.
Birrell, G.J., Grubb, B.D., Iggo, A. & McQueen, D.S. (1990a). Sensitization of Joint
Capsule C-Delta and a-Delta High-Threshold Mechanoreceptors By 5-
241
References
Hydroxytryptamine (5-Ht) in Anesthetized Normal and Arthritic Rats.
Journal ofPhysiology-London, 420, 34-P 34.
Birrell, G.J., McQueen, D.S. & Iggo, A. (1990b). Effects of Cicaprost and Pge2 On
the Responses of Rat Ankle Joint Sensory Receptors to Bradykinin Invitro.
Journal ofPhysiology-London, 429, 29-P 29.
Birrell, G.J., McQueen, D.S., Iggo, A., Coleman, R.A. & Grubb, B.D. (1991). Pgi2-
Induced Activation and Sensitization of Articular Mechanonociceptors.
Neuroscience Letters, 124, 5-8.
Birred, G.J., McQueen, D.S., Iggo, A. & Grubb, B.D. (1990c). The effects of 5-HT
on articular sensory receptors in normal and arthritic rats. British Journal of
Pharmacology, 101, 715-21.
Birrell, G.J., McQueen, D.S., Iggo, A. & Grubb, B.D. (1993). Prostanoid-Induced
Potentiation of the Excitatory and Sensitizing Effects of Bradykinin On
Articular Mechanonociceptors in the Rat Ankle Joint. Neuroscience, 54, 537-
544.
Bjorling, D.E., Saban, M.R. & Saban, R. (1997). Effect of octreotide, a somatostatin
analogue, on release of inflammatory mediators from isolated guinea pig
bladder. Journal OfUrology, 158, 258-64.
Bleehen, T., Hobbiger, F. & Keele, C.A. (1976). Identification of algogenic
substances in human erythrocytes. JPhysiol (Lond), 262, 131-49.
Bleehen, T. & Keele, C.A. (1977). Observations on the algogenic actions of
adenosine compounds on the human blister base preparation. Pain, 3, 367-77.
Blix, M. (1884). Experimentallar Beirtag zur Losung der Frage uber die specifische
Energie der Hautnerven. Zeitschr. fur Biol., 20, 141-156.
Blum, A.M., Elliott, D.E., Metwali, A., Li, J., Qadir, K. & Weinstock, J.V. (1998).
Substance P regulates somatostatin expression in inflammation. Journal Of
Immunology, 161, 6316-22.
Brackertz, D., Mitchell, G.F. & Mackay, I.R. (1977a). Antigen-induced arthritis in
mice. I. Induction of arthritis in various strains of mice. Arthritis And
Rheumatism, 20, 841-50.
Brackertz, D., Mitchell, G.F., Vadas, M.A. & Mackay, I.R. (1977b). Studies on
antigen-induced arthritis in mice. III. Cell and serum transfer experiments.
Journal OfImmunology, 118, 1645-8.
Brackertz, D., Mitchell, G.F., Vadas, M.A., Mackay, I.R. & Miller, J.F. (1977c).
Studies on antigen-induced arthritis in mice. II. Immunologic correlates of
arthritis susceptibility in mice. Journal OfImmunology, 118, 1639-44.
Brand, M., Klusch, A., Kurzai, O., Valdeolmillos, M., Schmidt, R.F. & Petersen, M.
(2001). No evidence for bradykinin B1 receptors in rat dorsal root ganglion
neurons. Neuroreport, 12, 3165-8.
Bray, R., Forrester, K., McDougall, J.J., Damji, A. & Ferrell, W.R. (1996).
Evaluation of laser Doppler imaging to measure blood flow in knee ligaments
of adult rabbits. Med Biol Eng Comput, 34, 227-31.
Brown, N.J. (1990). Octreotide: a long-acting somatostatin analog. Am J Med Sci,
300,267-73.
Bulling, D.G., Kelly, D., Bond, S., McQueen, D.S. & Seckl, J.R. (2001). Adjuvant-
induced joint inflammation causes very rapid transcription of beta-
preprotachykinin and alpha-CGRP genes in innervating sensory ganglia.
Journal ofNeurochemistry, 77, 372-82.
242
References
Burgess, P.R. & Perl, E.R. (1967). Myelinated afferent fibres responding specifically
to noxious stimulation of the skin. Journal OfPhysiology, 190, 541-62.
Burnstock, G., Campbell, G., Satchell, D. & Smythe, A. (1970). Evidence that
adenosine triphosphate or a related nucleotide is the transmitter substance
released by non-adrenergic inhibitory nerves in the gut. Br J Pharmacol, 40,
668-88.
Burnstock, G., Cocks, T., Kasakov, L. & Wong, H.K. (1978). Direct evidence for
ATP release from non-adrenergic, non-cholinergic ("purinergic") nerves in
the guinea-pig taenia coli and bladder. Eur JPharmacol, 49, 145-9.
Butler, S.H., Godefroy, F., Besson, J.M. & Weil-Fugazza, J. (1992). A limited
arthritic model for chronic pain studies in the rat. Pain, 48, 73-81.
Calignano, A., La Rana, G., Giuffrida, A. & Piomelli, D. (1998). Control of pain
initiation by endogenous cannabinoids. Nature, 394, 277-81.
Calixto, J.B., Cabrini, D.A., Ferreira, J. & Campos, M.M. (2000). Kinins in pain and
inflammation. Pain, 87, 1-5.
Campbell, R.M. & Scanes, C.G. (1995). Endocrine peptides 'moonlighting' as
immune modulators: roles for somatostatin and GH-releasing factor. Journal
OfEndocrinology, 147, 383-96.
Carlton, S.M. & Coggeshall, R.E. (2001). Peripheral capsaicin receptors increase in
the inflamed rat hindpaw: a possible mechanism for peripheral sensitization.
Neurosci Lett, 310, 53-6.
Carlton, S.M., Du, J., Davidson, E., Zhou, S. & Coggeshall, R.E. (2001a).
Somatostatin receptors on peripheral primary afferent terminals: inhibition of
sensitized nociceptors. Pain, 90, 233-44.
Carlton, S.M., Du, J., Zhou, S. & Coggeshall, R.E. (2001b). Tonic control of
peripheral cutaneous nociceptors by somatostatin receptors. J Neurosci, 21,
4042-9.
Carteron, N.L. (2000). Cytokines in rheumatoid arthritis: trials and tribulations. Mol
Med Today, 6, 315-23.
Caterina, M.J., Rosen, T.A., Tominaga, M., Brake, A.J. & Julius, D.N.-U.C.F.C.
(1999). A capsaicin-receptor homologue with a high threshold for noxious
heat. Nature, 398, 436-441.
Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D. &
Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the
pain pathway [see comments]. Nature, 389, 816-24.
Cervero, F. (1994). Sensory innervation of the viscera: peripheral basis of visceral
pain. Physiol Rev, 74, 95-138.
Chandrasekhar, S., Elarvey, A.K., Hrubey, P.S. & Bendele, A.M. (1990). Arthritis
induced by interleukin-1 is dependent on the site and frequency of
intraarticular injection. Clin ImmunolImmunopathol, 55, 382-400.
Chapman, V. (1999). The cannabinoid CB1 receptor antagonist, SR141716A,
selectively facilitates nociceptive responses of dorsal horn neurones in the rat.
Br JPharmacol, 127, 1765-7.
Chen, C.C., Akopian, A.N., Sivilotti, L., Colquhoun, D., Burnstock, G. & Wood, J.N.




Chessell, I.P., Michel, A.D. & Humphrey, P.P.A. (1997). Properties of the pore-
forming P2X(7) purinoceptor in mouse NTW8 microglial cells. British
Journal ofPharmacology, 121, 1429-1437.
Chuang, H.H., Prescott, E.D., Kong, H., Shields, S., Jordt, S.E., Basbaum, A.I.,
Chao, M.V. & Julius, D. (2001). Bradykinin and nerve growth factor release
the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature, 411,
957-62.
Ciocci, A., Coari, G., Di Franco, M., Di Novi, M.R. & Mauceri, M.T. (1994). [Intra¬
articular treatment with somatostatin 14 in rheumatoid arthritis]. Clinica
Terapeutica, 145, 463-7.
Clarke, D., Hughes, J. & Gasser, H.S. (1935). Afferent function in the group of nerve
fibres of slowest conduction velocity. American Journal ofPhysiology, 114,
69-76.
Clayton, N.M., Oakley, I., Thompson, S., Wheeldon, A., Sargent, B. & Bountra, C.
(1997). Validation of the dual channel weight averager as an instrument of
the measurement of clinically relevant pain. British Journal of
Pharmacology, 120, 219P.
Coari, G., Di Franco, M., Iagnocco, A., Di Novi, M.R., Mauceri, M.T. & Ciocci, A.
(1995). Intra-articular somatostatin 14 reduces synovial thickness in
rheumatoid arthritis: an ultrasonographic study. International Journal of
Clinical Pharmacology Research, 15, 27-32.
Coggeshall, R.E., Hong, K.A., Langford, L.A., Schaible, H.G. & Schmidt, R.F.
(1983). Discharge characteristics of fine medial articular afferents at rest and
during passive movements of inflamed knee joints. Brain Res, 272, 185-8.
Collo, G., Neidhart, S., Kawashima, E., Kosco-Vilbois, M., North, R.A. & Buell, G.
(1997). Tissue distribution of the P2X7 receptor. Neuropharmacology, 36,
1277-83.
Conquet, F. (1995). Inactivation in vivo of metabotropic glutamate receptor 1 by
specific chromosomal insertion of reporter gene lacZ. Neuropharmacology,
34, 865-70.
Corsi, M.M., Ticozzi, C., Netti, C., Fulgenzi, A., Tiengo, M., Gaja, G., Guidobono,
F. & Ferrero, M.E. (1997). The effect of somatostatin on experimental
inflammation in rats. Anesthesia And Analgesia, 85, 1112-5.
Couture, R., Harrisson, M., Vianna, R.M. & Cloutier, F. (2001). Kinin receptors in
pain and inflammation. Eur JPharmacol, 429, 161-76.
Craig, A.D., Heppelmann, B. & Schaible, H.G. (1988). The projection of the medial
and posterior articular nerves of the cat's knee to the spinal cord. J Comp
Neurol, 276, 279-88.
Cunha, J.M., Cunha, F.Q., Poole, S. & Ferreira, S.H. (2000). Cytokine-mediated
inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J
Pharmacol, 130, 1418-24.
Darian-Smith, I. & Johnson, K.O. (1977a). Temperature sense in the primate. BrMed
Bull, 33, 143-8.
Darian-Smith, I. & Johnson, K.O. (1977b). Thermal sensibility and thermoreceptors.
J Invest Dermatol, 69, 146-53.
Darian-Smith, I., Johnson, K.O. & Dykes, R. (1973). "Cold" fiber population
innervating palmar and digital skin of the monkey: responses to cooling
pulses. JNeurophysiol, 36, 325-46.
244
References
Davis, A. & Perkins, M.N. (1993). The effect of capsaicin and conventional
analgesics in two models of monoarthritis in the rat. Agents Actions, 38 Spec
No, C10-2.
Davis, A.J. & Perkins, M.N. (1994). The involvement of bradykinin B1 and B2
receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat.
Br JPharmacol, 113, 63-8.
Davis, A.J. & Perkins, M.N. (1996). Substance P and capsaicin-induced mechanical
hyperalgesia in the rat knee joint; the involvement of bradykinin B1 and B2
receptors. Br JPharmacol, 118, 2206-12.
Deuchars, S.A., Atkinson, L., Brooke, R.E., Musa, H., Milligan, C.J., Batten, T.F.,
Buckley, N.J., Parson, S.H. & Deuchars, J. (2001). Neuronal P2X7 receptors
are targeted to presynaptic terminals in the central and peripheral nervous
systems. JNeurosci, 21, 7143-52.
Devane, W.A., Dysarz, F.A., 3rd, Johnson, M.R., Melvin, F.S. & Howlett, A.C.
(1988). Determination and characterization of a cannabinoid receptor in rat
brain. Mol Pharmacol, 34, 605-13.
Devane, W.A., Flanus, F., Breuer, A., Pertwee, R.G., Stevenson, F.A., Griffin, G.,
Gibson, D., Mandelbaum, A., Etinger, A. & Mechoulam, R. (1992). Isolation
and structure of a brain constituent that binds to the cannabinoid receptor.
Science, 258, 1946-9.
Di Marzo, V. (1999). Biosynthesis and inactivation of endocannabinoids: relevance
to their proposed role as neuromodulators. Life Sci, 65, 645-55.
Di Marzo, V., Bisogno, T., Melck, D., Ross, R., Brockie, H., Stevenson, F., Pertwee,
R. & De Petrocellis, F. (1998a). Interactions between synthetic vanilloids and
the endogenous cannabinoid system. FEBS Lett, 436, 449-54.
Di Marzo, V., Melck, D., Bisogno, T. & De Petrocellis, F. (1998b).
Endocannabinoids: endogenous cannabinoid receptor ligands with
neuromodulatory action. Trends Neurosci, 21, 521-8.
DiVirgilio, F. (1995). The P2z Purinoceptor - an Intriguing Role in Immunity,
Inflammation and Cell-Death. Immunology Today, 16, 524-528.
DiVirgilio, F., Falzoni, S., Mutini, C., Sanz, J.M. & Chiozzi, P. (1998). Purinergic
P2X(7) receptor: A pivotal role in inflammation and immunomodulation.
Drug Development Research, 45, 207-213.
Donaldson, F.F., McQueen, D.S. & Seckl, J.R. (1995). Neuropeptide Gene-
Expression and Capsaicin-Sensitive Primary Afferents - Maintenance and
Spread of Adjuvant Arthritis in the Rat. Journal ofPhysiology-London, 486,
473-482.
Donaldson, F.F., Seckl, J.R. & McQueen, D.S. (1993). A Discrete Adjuvant-Induced
Monoarthritis in the Rat - Effects of Adjuvant Dose. Journal ofNeuroscience
Methods, 49, 5-10.
Dowd, E. (1999). The Role of ATP and Adenosine in Nociception and Inflammatory
Pain. In Neuroscience. pp. 240. Edinburgh: University of Edinburgh.
Dowd, E., McQueen, D., Chessell, I.P. & Humphrey, P.P.A. (1997). Activation by
P2X purinoceptor agonists of sensory nerves innervating the rat knee joint.
British Journal ofPharmacology, 122, 286-P286.
Dowd, E., McQueen, D.S., Chessell, I.P. & Humphrey, P.P. (1998a). Adenosine A1
receptor-mediated excitation of nociceptive afferents innervating the normal
and arthritic rat knee joint. British Journal OfPharmacology, 125, 1267-71.
245
References
Dowd, E., McQueen, D.S., Chessell, I.P. & Humphrey, P.P. (1998b). P2X receptor-
mediated excitation of nociceptive afferents in the normal and arthritic rat
knee joint. British Journal OfPharmacology, 125, 341-6.
Dray, A. & Perkins, M. (1993). Bradykinin and inflammatory pain. Trends Neurosci,
16,99-104.
Dray, A. & Urban, L. (1996). New Pharmacological Strategies For Pain Relief.
Annual Review ofPharmacology and Toxicology, 36, 253-280.
Ebinger, M., Schmidt, R.F. & Heppelmann, B. (2001). Composition of the medial
and posterior articular nerves of the mouse knee joint. Somatosens Mot Res,
18, 62-5.
Edery, H. & Lewis, G.P. (1962). Inhibition of plasma kininase activity at slightly
acidic pH. British Journal ofPharmacology, 19, 299-305.
Elliott, D.E., Blum, A.M., Li, J., Metwali, A. & Weinstock, J.V. (1998).
Preprosomatostatin messenger RNA is expressed by inflammatory cells and
induced by inflammatory mediators and cytokines. Journal Of Immunology,
160,3997-4003.
Elliott, D.E., Li, J., Blum, A.M., Metwali, A., Patel, Y.C. & Weinstock, J.V. (1999).
SSTR2A is the dominant somatostatin receptor subtype expressed by
inflammatory cells, is widely expressed and directly regulates T cell IFN-
gamma release. European Journal OfImmunology, 29, 2454-63.
Erlanger, J. & Gasser, H.S. (1937). Electrical signs ofnervous activity. Philadelphia:
University of Philadelphia Press.
Farrell, M., Gibson, S., McMeeken, J. & Helme, R. (2000). Pain and hyperalgesia in
osteoarthritis of the hands. JRheumatol, 27, 441-7.
Felder, C.C., Briley, E.M., Axelrod, J., Simpson, J.T., Mackie, K. & Devane, W.A.
(1993). Anandamide, an endogenous cannabimimetic eicosanoid, binds to the
cloned human cannabinoid receptor and stimulates receptor-mediated signal
transduction. Proc Natl Acad Sci USA, 90, 7656-60.
Felder, C.C., Veluz, J.S., Williams, H.L., Briley, E.M. & Matsuda, L.A. (1992).
Cannabinoid agonists stimulate both receptor- and non-receptor-mediated
signal transduction pathways in cells transfected with and expressing
cannabinoid receptor clones. Mol Pharmacol, 42, 838-45.
Feldmann, M. & Maini, R.N. (2001). Anti-TNF alpha therapy of rheumatoid
arthritis: what have we learned? Annu Rev Immunol, 19, 163-96.
Ferrari, D., Chiozzi, P., Falzoni, S., Hanau, S. & Di Virgilio, F. (1997a). Purinergic
modulation of interleukin-1 beta release from microglial cells stimulated with
bacterial endotoxin. Journal ofExperimental Medicine, 185, 579-82.
Ferrari, D., Chiozzi, P., Falzoni, S., Hanau, S. & Di Virgilio, F. (1997b).
Purinoceptor-operated cationic channels in human B lymphocytes. Journal of
Physiology, 498, 143-51.
Ferrell, W.R. & Russell, N.J. (1985). Plasma extravasation in the cat knee-joint
induced by antidromic articular nerve stimulation. Pflugers Arch, 404, 91-3.
Ferrell, W.R., Sturrock, R.D., Mallik, A.K., Abbot, N.C., Lockhart, J.C. &
Edmondson, W.D. (1996). Laser Doppler perfusion imaging of proximal




Figueroa, C.D., Maclver, A.G., Dieppe, P., Mackenzie, J.C. & Bhoola, K.D. (1989).
Presence of immunoreactive tissue kallikrein in human polymorphonuclear
(PMN) leucocytes. Adv Exp Med Biol, 247B, 207-10.
Fioravanti, A., Franci, A., Gelli, R., Minari, C., Montemerani, M., Moscato, P. &
Marcolongo, R. (1993). [Evaluation of the efficacy of intra-articular
administration of somatostatin in rheumatoid arthritis], Clinica Terapeutica,
142, 453-7.
Fioravanti, A., Govoni, M., La Montagna, G., Perpignano, G., Tirri, G., Trotta, F.,
Bogliolo, A., Ciocci, A., Mauceri, M.T. & Marcolongo, R. (1995).
Somatostatin 14 and joint inflammation: evidence for intraarticular efficacy
of prolonged administration in rheumatoid arthritis. Drugs Under
ExperimentalAnd Clinical Research, 21, 97-103.
Fox, A.J., Barnes, P.J., Urban, L. & Dray, A. (1993). An in vitro study of the
properties of single vagal afferents innervating guinea-pig airways. JPhysiol,
469,21-35.
Freeman, M.A. & Wyke, B. (1967). The innervation of the knee joint. An anatomical
and histological study in the cat. JAnat, 101, 505-32.
Fuentes, J.A., Ruiz-Gayo, M., Manzanares, J., Vela, G., Reche, I. & Corchero, J.
(1999). Cannabinoids as potential new analgesics. Life Sci, 65, 675-85.
Gardner, E. (1944). The distribution and termination of nerves in the knee joint of the
cat. J. Comp. Neurol., 80, 11-32.
Gasser, H.S. & Erlanger, J. (1927). The role played by the sizes of the consituent
fibres of a nerve trunk in determining the form of its action potential wave.
American Journal ofPhysiology, 80, 522-547.
Gauldie, S.D., McQueen, D.S., Pertwee, R. & Chessell, I.P. (2001). Anandamide
activates peripheral nociceptors in normal and arthritic rat knee joints. British
Journal ofPharmacology, 132, 617-21.
Gee, M.D., Lynn, B., Basile, S., Pierau, F.K. & Cotsell, B. (1999). The relationship
between axonal spike shape and functional modality in cutaneous C-fibres in
the pig and rat. Neuroscience, 90, 509-518.
Giraldez, F., Geijo, E. & Belmonte, C. (1979). Response characteristics of corneal
sensory fibers to mechanical and thermal stimulation. Brain Res, 177, 571-6.
Grahames, C.B., Michel, A.D., Chessell, I.P. & Humphrey, P.P. (1999).
Pharmacological characterization of ATP- and LPS-induced IL-lbeta release
in human monocytes. Br JPharmacol, 127, 1915-21.
Greenwald, R.A. & Diamond, H.S. (1988). CRC Handbook ofAnimals Models for
the Rheumatic Diseases. Boca Raton: CRC Press.
Greenwood, F., Horiuchi, H. & Matthews, B. (1972). Electrophysiological evidence
on the types of nerve fibres excited by electrical stimulation of teeth with a
pulp tester. Arch Oral Biol, 17, 701-9.
Grimaldi, M., Florio, T. & Schettini, G. (1997). Somatostatin inhibits interleukin 6
release from rat cortical type I astrocytes via the inhibition of adenylyl
cyclase. Biochem Biophys Res Commun, 235, 242-8.
Grubb, B.D., Birrell, G.J., McQueen, D.S. & Iggo, A. (1991). The Role of Pge2 in
the Sensitization of Mechanoreceptors in Normal and Inflamed Ankle Joints
of the Rat. Experimental Brain Research, 84, 383-392.
247
References
Grubb, B.D., McQueen, D.S., Iggo, A., Birrell, G.J. & Dutia, M.B. (1988). A study
of 5-HT-receptors associated with afferent nerves located in normal and
inflamed rat ankle joints. Agents andActions, 25, 216-8.
Guilbaud, G., Iggo, A. & Tegner, R. (1985a). Sensory Changes in Joint-Capsule
Receptors of Arthritic Rats - Effect of Aspirin. Advances in Pain Research
and Therapy, 9, 81-89.
Guilbaud, G., Iggo, A. & Tegner, R. (1985b). Sensory Receptors in Ankle Joint
Capsules ofNormal and Arthritic Rats. Experimental Brain Research, 58, 29-
40.
Guilbaud, G., Iggo, A. & Tegner, R. (1984). Sensory Receptors in the Joints of Rats
With Adjuvant-Induced Arthritis. Journal of Physiology-London, 346, 58-P
58.
Guo, A., Vulchanova, L., Wang, J., Li, X. & Elde, R. (1999). Immunocytochemical
localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides,
the P2X(3) purinoceptor and IB4 binding sites. European Journal of
Neuroscience, 11, 946-958.
Halata, Z., Rettig, T. & Schulze, W. (1985). The ultrastructure of sensory nerve
endings in the human knee joint capsule. Anat Embryol (Berl), 172, 265-75.
Hall, J.M. (1997). Bradykinin receptors. General Pharmacology, 28, 1-6.
Hanesch, U., Heppelmann, B. & Schmidt, R.F. (1991). Substance P- and calcitonin
gene-related peptide immunoreactivity in primary afferent neurons of the
cat's knee joint. Neuroscience, 45, 185-93.
Hardy, J.D., Wolff, H.G. & Goodell, H. (1952). Pain Sensation and Reactions.
Baltimore: Williams and Wilkins.
Hargreaves, K.M., Troullos, E.S., Dionne, R.A., Schmidt, E.A., Schafer, S.C. &
Joris, J.L. (1988). Bradykinin is increased during acute and chronic
inflammation: therapeutic implications. Clin Pharmacol Ther, 44, 613-21.
Haywood, L. & Walsh, D.A. (2001). Vasculature of the normal and arthritic synovial
joint. Histology and Histopathology, 16, 277-84.
Heinbecker, P., Bishop, G.H. & O'Leary, J. (1932). Fibres in mixed nerves and their
dorsal roots responsible for pain. Proceedings of the Society For
Experimental Biology and Medicine, 29, 928-930.
Heppelmann, B. (1997). Anatomy and histology ofjoint innervation. JPeripher Nerv
Syst, 2, 5-16.
Heppelmann, B., Heuss, C. & Schmidt, R.F. (1988). Fiber size distribution of
myelinated and unmyelinated axons in the medial and posterior articular
nerves of the cat's knee joint. Somatosens Res, 5, 273-81.
Heppelmann, B., Messlinger, K., Neiss, W.F. & Schmidt, R.F. (1990). Ultrastructural
three-dimensional reconstruction of group III and group IV sensory nerve
endings ("free nerve endings") in the knee joint capsule of the cat: evidence
for multiple receptive sites. J Comp Neurol, 292, 103-16.
Heppelmann, B. & Pawlak, M. (1997a). Inhibitory effect of somatostatin on the
mechanosensitivity of articular afferents in normal and inflamed knee joints
of the rat. Pain, 73, 377-82.
Heppelmann, B. & Pawlak, M. (1999). Peripheral application of cyclo-somatostatin,
a somatostatin antagonist, increases the mechanosensitivity of rat knee joint
afferents. Neuroscience Letters, 259, 62-4.
248
References
Heppelmann, B. & Pawlak, M. (1997b). Sensitisation of articular afferents in normal
and inflamed knee joints by substance P in the rat. Neurosci Lett, 223, 97-
100.
Heppelmann, B., Pfeffer, A., Schaible, H.G. & Schmidt, R.F. (1986). Effects of
acetylsalicylic acid and indomethacin on single groups III and IV sensory
units from acutely inflamed joints. Pain, 26, 337-51.
Heppelmann, B., Shahbazian, Z. & Hanesch, U. (1997). Quantitative examination of
calcitonin gene-related peptide immunoreactive nerve fibres in the cat knee
joint capsule. Anat Embryol (Berl), 195, 525-30.
Hildebrand, C., Oqvist, G., Brax, L. & Tuisku, F. (1991). Anatomy of the rat knee
joint and fibre composition of a major articular nerve. Anat Rec, 229, 545-55.
Hohmann, A.G. & Herkenham, M. (1999). Cannabinoid receptors undergo axonal
flow in sensory nerves. Neuroscience, 92, 1171-1175.
Hokfelt, T., Broberger, C., Xu, Z.Q., Sergeyev, V., Ubink, R. & Diez, M. (2000).
Neuropeptides—an overview. Neuropharmacology, 39, 1337-56.
Holmdahl, R., Andersson, M., Enander, I., Goldschmidt, T., Jansson, L., Larsson, P.,
Mo, J., Nordling, C. & Klareskog, L. (1988). Nature of the type II collagen
autoimmunity in mice susceptible to collagen-induced arthritis. International
Reviews ofImmunology, 4, 49-64.
Holmdahl, R., Jansson, L., Andersson, M. & Jonsson, R. (1992). Genetic, hormonal
and behavioural influence on spontaneously developing arthritis in normal
mice. Clinical and Experimental Immunology, 88, 467-72.
Holmdahl, R., Mo, J., Nordling, C., Larsson, P., Jansson, L., Goldschmidt, T.,
Andersson, M. & Klareskog, L. (1989). Collagen induced arthritis: an
experimental model for rheumatoid arthritis with involvement of both DTH
and immune complex mediated mechanisms. Clinical and Experimental
Rheumatology, 7 Suppl 3, S51-5.
Holton, P. (1959). The Liberation of Adenosine Triphosphate on Antidromic
Stimulation of Sensory Nerves. Journal ofPhysiology-London, 145.
Howlett, A.C. & Mukhopadhyay, S. (2000). Cellular signal transduction by
anandamide and 2-arachidonoylglycerol. Chem Phys Lipids, 108, 53-70.
Hrubey, P.S., Harvey, A.K., Bendele, A.M. & Chandrasekhar, S. (1991). Effects of
anti-arthritic drugs on IL-1 induced inflammation in rats. Agents Actions, 34,
56-9.
Hudson, L.J., Bevan, S., Wotherspoon, G., Gentry, C., Fox, A. & Winter, J. (2001).
VR1 protein expression increases in undamaged DRG neurons after partial
nerve injury. Eur J Neurosci, 13, 2105-14.
Hunt, S.P. & Rossi, J. (1985). Peptide- and non-peptide-containing unmyelinated
primary afferents: the parallel processing of nociceptive information. Philos
Trans R Soc Lond B Biol Sci, 308, 283-9.
Hunter, D.D., Myers, A.C. & Undem, B.J. (2000). Nerve growth factor-induced
phenotypic switch in guinea pig airway sensory neurons. Am J Respir Crit
Care Med, 161, 1985-90.
Iggo, A. (1978). The physiological interpretation of electrical stimulation of the
nervous system. Electroencephalogr Clin Neurophysiol Suppl, 335-41.
Imai, S., Tokunaga, Y., Konttinen, Y.T., Maeda, T., Hukuda, S. & Santavirta, S.
(1997). Ultrastructure of the synovial sensory peptidergic fibers is
distinctively altered in different phases of adjuvant induced arthritis in rats:
249
References
ultramorphological characterization combined with morphometric and
immunohistochemical study for substance P, calcitonin gene related peptide,
and protein gene product 9.5. JRheumatol, 24, 2177-87.
Jahr, C.E. & Jessell, T.M. (1983). ATP excites a subpopulation of rat dorsal horn
neurones. Nature, 304, 730-3.
Johanek, L.M., Heitmiller, D.R., Turner, M., Nader, N., Hodges, J. & Simone, D.A.
(2001). Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal
and peripheral mechanisms. Pain, 93, 303-15.
Johansson, H., Sjolander, P. & Sojka, P. (1991). Receptors in the knee joint
ligaments and their role in the biomechanics of the joint. Crit Rev Biomed
Eng, 18, 341-68.
Joosten, L.A., Helsen, M.M., Saxne, T., van De Loo, F.A., Heinegard, D. &
van Den Berg, W.B. (1999). IL-1 alpha beta blockade prevents cartilage and
bone destruction in murine type II collagen-induced arthritis, whereas TNF-
alpha blockade only ameliorates joint inflammation. Journal ofImmunology,
163, 5049-55.
Joosten, L.A., Helsen, M.M., van de Loo, F.A. & van_den_Berg, W.B. (1996).
Anticytokine treatment of established type II collagen-induced arthritis in
DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1
alpha/beta, and IL-lRa. Arthritis and Rheumatism, 39, 797-809.
Joosten, L.A., van De Loo, F.A., Lubberts, E., Helsen, M.M., Netea, M.G.,
van_Der_Meer, J.W., Dinarello, C.A. & vanJDenBerg, W.B. (2000). An
IFN-gamma-independent proinflammatory role of IL-18 in murine
streptococcal cell wall arthritis. Journal ofImmunology, 165, 6553-8.
Ju, G., Hokfelt, T., Brodin, E., Fahrenkrug, J., Fischer, J.A., Frey, P., Elde, R.P. &
Brown, J.C. (1987). Primary sensory neurons of the rat showing calcitonin
gene-related peptide immunoreactivity and their relation to substance P-,
somatostatin-, galanin-, vasoactive intestinal polypeptide- and
cholecystokinin-immunoreactive ganglion cells. Cell Tissue Res, 247, 417-31.
Kanaka, R., Schaible, H.G. & Schmidt, R.F. (1985). Activation of fine articular
afferent units by bradykinin. Brain Res, 327, 81-90.
Karalis, K., Mastorakos, G., Chrousos, G.P. & Tolis, G. (1994). Somatostatin
analogues suppress the inflammatory reaction in vivo. Journal Of Clinical
Investigation, 93, 2000-6.
Keele, C.A. & Armstrong, D. (1964). Substances producing pain and itch. London:
Edward Arnold.
Kelley, W.N., Harris, E.D., Ruddy, S. & Sledge, C.B. (1997). Textbook of
Rheumatology. Philadelphia: W.B. Saunders Company.
Kelly, D.C. (1998). The role of kinins in inflammatory pain and their modulation by
other inflammatory mediators. In Pharmacology, pp. 136. Edinburgh:
University of Edinburgh.
Kelly, D.C., Asghar, A.U.R., Marr, C.G., McQueen, D.S. & Perkins, M.N. (1995a).
Effects of Bradykinin On the Activity of C-Fiber Afferents Innervating the
Rat Knee-Joint - Studies in-Vivo and in-Vitro. British Journal of
Pharmacology, 114, 223-P 223.
Kelly, D.C., Asghar, A.U.R., Marr, C.G., McQueen, D.S. & Perkins, M.N. (1995b).
Excitation of Knee-Joint Mechanociceptors By a Bradykinin B-l Receptor
250
References
Agonist in Interleukin-1-Beta-Treated Rat Knee Joints - Studies in-Vitro.
British Journal ofPharmacology, 116, 447-P 447.
Kelly, D.C., McQueen, D.S. & Perkins, M.N. (1997). Indomethacin prevents the IL-
1 beta-induced increase in neural discharge and enhancement of kinin-
mediated activation of C-fibre mechanociceptors innervating the rat knee
joint. British Journal ofPharmacology, 122, 357-P357.
Keystone, E.C., Schorlemmer, H.U., Pope, C. & Allison, A.C. (1977). Zymosan-
induced arthritis: a model of chronic proliferative arthritis following
activation of the alternative pathway of complement. Arthritis Rheum, 20,
1396-1401.
Khakh, B.S., Burnstock, G., Kennedy, C., King, B.F., North, R.A., Seguela, P.,
Voigt, M. & Humphrey, P.P. (2001). International union of pharmacology.
XXIV. Current status of the nomenclature and properties of P2X receptors
and their subunits. Pharmacol Rev, 53, 107-18.
Khanolkar, A.D. & Makriyannis, A. (1999). Structure-activity relationships of
anandamide, an endogenous cannabinoid ligand. Life Sci, 65, 607-16.
Klasen, I.S., Donselaar, I.G., Ladestein, R.M., van den Berg, W.B. & Benner, R.
(1986). Joint inflammations and flare-up reactions in mice induced by a
helper T cell clone. Agents andActions, 19, 331-4.
Kolasinski, S.L., Haines, K.A., Siegel, E.L., Cronstein, B.N. & Abramson, S.B.
(1992). Neuropeptides and inflammation. A somatostatin analog as a
selective antagonist of neutrophil activation by substance P. Arthritis And
Rheumatism, 35, 369-75.
Kress, M. & Reeh, P.W. (1996). Chemical excitation and sensitization in
nociceptors. In Neurobiology ofNociceptors, eds Belmonte, C. & Cervero, F.
pp. 258-297. Oxford: Oxford University Press.
Kress, M., Reeh, P.W. & Vyklicky, L. (1997). An interaction of inflammatory
mediators and protons in small diameter dorsal root ganglion neurons of the
rat. Neurosci Lett, 224, 37-40.
Krishtal, O.A., Marchenko, S.M. & Obukhov, A.G. (1988a). Cationic channels
activated by extracellular ATP in rat sensory neurons. Neuroscience, 27, 995-
1000.
Krishtal, O.A., Marchenko, S.M., Obukhov, A.G. & Volkova, T.M. (1988b).
Receptors for ATP in rat sensory neurones: the structure-function relationship
for ligands. British Journal ofPharmacology, 95, 1057-62.
Krishtal, O.A., Marchenko, S.M. & Pidoplichko, V.I. (1983). Receptor for ATP in
the membrane of mammalian sensory neurones. Neuroscience Letters, 35, 41-
5.
Kruijsen, M.W., van den Berg, W.B., van de Putte, L.B. & van den Broek, W.J.
(1981). Detection and quantification of experimental joint inflammation in
mice by measurement of 99mTc-pertechnetate uptake. Agents Actions, 11,
640-2.
Krulich, L., Dhariwal, A.P. & McCann, S.M. (1968). Stimulatory and inhibitory
effects of purified hypothalamic extracts on growth hormone release from rat
pituitary in vitro. Endocrinology, 83, 783-90.
Kuiper, S., Joosten, L.A., Bendele, A.M., Edwards, C.K., Arntz, O.J., Helsen, M.M.,
Van de Loo, F.A. & Van den Berg, W.B. (1998). Different roles of tumour
251
References
necrosis factor alpha and interleukin 1 in murine streptococcal cell wall
arthritis. Cytokine, 10, 690-702.
Langford, L.A. & Schmidt, R.F. (1983). Afferent and efferent axons in the medial
and posterior articular nerves of the cat. Anat Rec, 206, 71-8.
Lawson, S.N. (1996). Neurochemistry of cutaneous nociceptors. In Neurobiology of
Nociceptors, eds Belmonte, C. & Cervero, F. pp. 72-91. Oxford: Oxford
University Press.
Le Mouellic, FL, Lallemand, Y. & Brulet, P. (1990). Targeted replacement of the
homeobox gene Hox-3.1 by the Escherichia coli lacZ in mouse chimeric
embryos. Proc Natl Acad Sci USA, 87, 4712-6.
Lens, J.W., van den Berg, W.B. & van_de_Putte, L.B. (1984). Flare-up of antigen-
induced arthritis in mice after challenge with intravenous antigen: studies on
the characteristics of and mechanisms involved in the reaction. Clinical and
Experimental Immunology, 55, 287-94.
Levy, D. & Zochodne, D.W. (2000). Increased mRNA expression of the B1 and B2
bradykinin receptors and antinociceptive effects of their antagonists in an
animal model of neuropathic pain. Pain, 86, 265-71.
Liu, L., Lo, Y., Chen, I. & Simon, S.A. (1997). The responses of rat trigeminal
ganglion neurons to capsaicin and two nonpungent vanilloid receptor
agonists, olvanil and glyceryl nonamide. JNeurosci, 17, 4101-11.
Liu, M., King, B.F., Dunn, P.M., Rong, W., Townsend-Nicholson, A. & Bumstock,
G. (2001). Coexpression of P2X(3) and P2X(2) receptor subunits in varying
amounts generates heterogeneous populations of P2X receptors that evoke a
spectrum of agonist responses comparable to that seen in sensory neurons. J
Pharmacol Exp Ther, 296, 1043-50.
Lubberts, E., Joosten, L.A., Van Den Bersselaar, L., Helsen, M.M., Bakker, A.C.,
Xing, Z., Richards, C.D. & Van Den Berg, W.B. (2000). Intra-articular IL-
10 gene transfer regulates the expression of collagen-induced arthritis (CIA)
in the knee and ipsilateral paw. Clinical and Experimental Immunology, 120,
375-83.
Lundberg, J.M. (1996). Pharmacology of cotransmission in the autonomic nervous
system: integrative aspects on amines, neuropeptides, adenosine triphosphate,
amino acids and nitric oxide. Pharmacol Rev, 48, 113-78.
Ma, Q.P. (2001). The expression of bradykinin B(l) receptors on primary sensory
neurones that give rise to small caliber sciatic nerve fibres in rats.
Neuroscience, 107, 665-73.
Ma, Q.P., Hill, R. & Sirinathsinghji, D. (2000). Basal expression of bradykinin B1
receptor in peripheral sensory ganglia in the rat. Neuroreport, 11, 4003-5.
Maini, R.N. & Taylor, P.C. (2000). Anti-cytokine therapy for rheumatoid arthritis.
Annu Rev Med, 51, 207-29.
Mapp, P.I. (1995). Innervation of the synovium. Annals of the Rheumatic Diseases,
54, 398-403.
Mapp, P.I., Kerslake, S., Brain, S.D., Blake, D.R. & Cambridge, H. (1996). The
effect of intra-articular capsaicin on nerve fibres within the synovium of the
rat knee joint. Journal ofChemical Neuroanatomy, 10, 11-8.
Marceau, F. (1995). Kinin B1 receptors: a review. Immunopharmacology, 30, 1-26.
252
References
Marceau, F., Lussier, A., Regoli, D. & Giroud, J.P. (1983). Pharmacology of kinins:
their relevance to tissue injury and inflammation. Gen Pharmacol, 14, 209-
29.
Martin, B.R., Mechoulam, R. & Razdan, R.K. (1999). Discovery and
characterization of endogenous cannabinoids. Life Sci, 65, 573-95.
Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C. & Bonner, T.I. (1990).
Structure of a cannabinoid receptor and functional expression of the cloned
cDNA. Nature, 346, 561-4.
Matucci-Cerinic, M., Borrelli, F., Generini, S., Cantelmo, A., Marcucci, I., Martelli,
F., Romagnoli, P., Bacci, S., Conz, A., Marinelli, P. & et al. (1995).
Somatostatin-induced modulation of inflammation in experimental arthritis.
Arthritis & Rheumatism, 38, 1687-93.
McDougall, J.J., Karimian, S.M. & Ferrell, W.R. (1994). Alteration of substance P-
mediated vasodilatation and sympathetic vasoconstriction in the rat knee joint
by adjuvant-induced inflammation. Neurosci Lett, 174, 127-9.
McDougall, J.J., Karimian, S.M. & Ferrell, W.R. (1995). Prolonged alteration of
vasoconstrictor and vasodilator responses in rat knee joints by adjuvant
monoarthritis. Exp Physiol, 80, 349-57.
McQueen, D.S., Iggo, A., Birrell, G.J. & Grubb, B.D. (1990). Effects of Aspirin and
Paracetamol On High-Threshold Tarsal Joint Mechanoreceptors in
Anesthetized Rats With Adjuvant-Induced Arthritis. Journal of Physiology-
London, 425, 35-P 35.
McQueen, D.S., Iggo, A., Birrell, G.J. & Grubb, B.D. (1991). Effects of Paracetamol
and Aspirin On Neural Activity of Joint Mechanonociceptors in Adjuvant
Arthritis. British Journal ofPharmacology, 104, 178-182.
Mechoulam, R., Fride, E. & Di Marzo, V. (1998). Endocannabinoids. Eur J
Pharmacol, 359, 1-18.
Mechoulam, R. & Hanus, L. (2000). A historical overview of chemical research on
cannabinoids. Chem Phys Lipids, 108, 1-13.
Mense, S. & Meyer, H. (1985). Different types of slowly conducting afferent units in
cat skeletal muscle and tendon. JPhysiol, 363, 403-17.
Meyer, R.A., Raja, S.N. & Campbell, J.N. (1996). Neural mechanisms of primary
hyperalgesia. In Neurobiology ofNociceptors, eds Belmonte, C. & Cervero,
F. pp. 370-389. Oxford: Oxford University Press.
Michael, G.J. & Priestley, J.V. (1999). Differential expression of the mRNA for the
vanilloid receptor subtype 1 in cells of the adult rat dorsal root and nodose
ganglia and its downregulation by axotomy. Journal Of Neuroscience, 19,
1844-54.
Millan, M.J. (1999). The induction of pain: an integrative review. Prog Neurobiol,
57, 1-164.
Munro, S., Thomas, K.L. & Abu-Shaar, M. (1993). Molecular characterization of a
peripheral receptor for cannabinoids. Nature, 365, 61-5.
Myers, L.K., Miyahara, H., Terato, K., Seyer, J.M., Stuart, J.M. & Kang, A.H.
(1995). Collagen-induced arthritis in B10.RIII mice (H-2r): identification of
an arthritogenic T-cell determinant. Immunology, 84, 509-13.
Myers, L.K., Rosloniec, E.F., Cremer, M.A. & Kang, A.H. (1997). Collagen-induced
arthritis, an animal model of autoimmunity. Life Sciences, 61, 1861-78.
253
References
Nordling, C., Karlsson_Parra, A., Jansson, L., Holmdahl, R. & Klareskog, L.
(1992a). Characterization of a spontaneously occurring arthritis in male
DBA/1 mice. Arthritis and Rheumatism, 35, 717-22.
Nordling, C., Kleinau, S. & Klareskog, L. (1992b). Down-regulation of a
spontaneous arthritis in male DBA/1 mice after administration ofmonoclonal
anti-idiotypic antibodies to a cross-reactive idiotope on anti-collagen
antibodies. Immunology, 77, 144-6.
North, R.A. & Surprenant, A. (2000). Pharmacology of cloned P2X receptors. Annu
Rev Pharmacol Toxicol, 40, 563-80.
Novakovic, S.D., Kassotakis, L.C., Oglesby, I.B., Smith, J.A.M., Eglen, R.M., Ford,
A. & Hunter, J.C. (1999). Immunocytochemical localization of P-2X3
purinoceptors in sensory neurons in naive rats and following neuropathic
injury. Pain, 80, 273-282.
Nustad, K., Vaaje, K. & Pierce, J.V. (1975). Synthesis of kallikreins by rat kidney
slices. Br JPharmacol, 53, 229-34.
Ohtori, S., Takahashi, K., Chiba, T., Yamagata, M., Sameda, H. & Moriya, H.
(2001). Phenotypic inflammation switch in rats shown by calcitonin gene-
related peptide immunoreactive dorsal root ganglion neurons innervating the
lumbar facet joints. Spine, 26, 1009-13.
Olah, Z., Karai, L. & Iadarola, M.J. (2001). Anandamide activates vanilloid receptor
1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically
expressing VR1. Journal ofBiological Chemistry, 276, 31163-70.
Pankratov Yu, V., Lalo, U.V., Dashkin, A.N. & Krishtal, A. (2001). Heterogeneity of
the functional expression of P2X3 and P2X2/3 receptors in the primary
nociceptive neurons of rat. Neurochem Res, 26, 993-1000.
Park, W., Masuda, I., Cardenal-Escarcena, A., Palmer, D.L. & McCarty, D.J. (1996).
Inorganic pyrophosphate generation from adenosine triphosphate by cell-free
human synovial fluid. Journal ofRheumatology, 23, 665-71.
Partsch, G. & Matucci-Cerinic, M. (1992). Effect of substance P and somatostatin on
migration of polymorphonuclear (PMN) cells in vitro. Inflammation, 16, 539-
47.
Patel, Y.C. (1997). Molecular pharmacology of somatostatin receptor subtypes. J
Endocrinol Invest, 20, 348-67.
Patel, Y.C. (1999). Somatostatin and its receptor family. Front Neuroendocrinal, 20,
157-98.
Paukert, M., Osteroth, R., Geisler, H.S., Brandle, U., Glowatzki, E., Ruppersberg,
J.P. & Grunder, S. (2001). Inflammatory mediators potentiate ATP-gated
channels through the P2X(3) subunit. JBiol Chem, 276, 21077-82.
Peluso, G., Petillo, O., Melone, M.A., Mazzarella, G., Ranieri, M. & Tajana, G.F.
(1996). Modulation of cytokine production in activated human monocytes by
somatostatin. Neuropeptides, 30, 443-51.
Perkins, M.N., Campbell, E. & Dray, A. (1993). Antinociceptive activity of the
bradykinin B1 and B2 receptor antagonists, des-Arg9, [Leu8]-BK and HOE
140, in two models of persistent hyperalgesia in the rat. Pain, 53, 191-7.
Perkins, M.N., Kelly, D. & Davis, A.J. (1995). Bradykinin B1 and B2 receptor




Pertwee, R.G. (2001). Cannabinoid receptors and pain. Progress in Neurobiology,
63,569-611.
Pesquero, J.B., Araujo, R.C., Heppenstall, P.A., Stucky, C.L., Silva, J.A., Jr.,
Walther, T., Oliveira, S.M., Pesquero, J.L., Paiva, A.C., Calixto, J.B., Lewin,
G.R. & Bader, M. (2000). Hypoalgesia and altered inflammatory responses in
mice lacking kinin B1 receptors. Proc Natl Acad Sci USA, 97, 8140-5.
Petruska, J.C., Cooper, B.Y., Gu, J.G., Rau, K.K. & Johnson, R.D. (2000).
Distribution of P2X1, P2X2, and P2X3 receptor subunits in rat primary
afferents: relation to population markers and specific cell types. J Chem
Neuroanat, 20, 141-62.
Pettipher, E.R., Higgs, G.A. & Henderson, B. (1988). Studies on interleukin-1-
induced arthritis. Dev Biol Stand, 69, 111-4.
Polacek, P. (1966). Receptors of the joints: their structure, variability and
classification. Acta. Facultat. Med. Universitat Brunensis, 23, 1-107.
Rae, M.G., Rowan, E.G. & Kennedy, C. (1998). Pharmacological properties of
P2X(3)-receptors present in neurones of the rat dorsal root ganglia. British
Journal ofPharmacology, 124, 176-180.
Rainsford, K.D. (1982). Adjuvant polyarthritis in rats: is this a satisfactory model for
screening anti-arthritic drugs? Agents & Actions, 12, 452-8.
Ralevic, V. & Burnstock, G. (1998). Receptors for purines and pyrimidines.
Pharmacol Rev, 50, 413-92.
Ralevic, V., Kendall, D.A., Jerman, J.C., Middlemiss, D.N. & Smart, D. (2001).
Cannabinoid activation of recombinant and endogenous vanilloid receptors.
Eur JPharmacol, 424, 211-9.
Randall, M.D. & Kendall, D.A. (1998a). Anandamide and endothelium-derived
hyperpolarizing factor act via a common vasorelaxant mechanism in rat
mesentery. Eur JPharmacol, 346, 51-3.
Randall, M.D. & Kendall, D.A. (1998b). Endocannabinoids: a new class of
vasoactive substances. Trends in Pharmacological Sciences, 19, 55-8.
Randic, M. & Miletic, V. (1978). Depressant actions of methionine-enkephalin and
somatostatin in cat dorsal horn neurones activated by noxious stimuli. Brain
Res, 152, 196-202.
Rassendren, F., Buell, G.N., Virginio, C., Collo, G., North, R.A. & Surprenant, A.
(1997). The permeabilizing ATP receptor, P2X7. Cloning and expression of a
human cDNA. Journal OfBiological Chemistry, 272, 5482-6.
Reichlin, S. (1983). Somatostatin. NEngl JMed, 309, 1495-501.
Reichlin, S. (1995). Somatostatin and its receptor. Introduction. Ciba Found Symp,
190,1-6.
Richardson, J.D., Aanonsen, L. & Hargreaves, K.M. (1998a). Antihyperalgesic
effects of spinal cannabinoids. European Journal ofPharmacology, 345, 145-
153.
Richardson, J.D., Kilo, S. & Hargreaves, K.M. (1998b). Cannabinoids reduce
hyperalgesia and inflammation via interaction with peripheral CB1 receptors.
Pain, 75, 111-9.
Rosenberg, A. (1999). Bones, Joints, and Soft Tissue Tumors. In Bobbins Pathologic




Rupniak, N.M., Boyce, S., Webb, J.K., Williams, A.R., Carlson, E.J., Hill, R.G.,
Borkowski, J.A. & Hess, J.F. (1997). Effects of the bradykinin B1 receptor
antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2
receptor on nociception in rats and mice. Pain, 71, 89-97.
Russo, S., Mangrella, M., Vitagliano, S., Russo, P. & Berrino, L. (1997). [Local
administration of somatostatin in joint diseases in athletes]. Minerva Medica,
88, 265-70.
Ryan, L.M., Rachow, J.W., McCarty, B.A. & McCarty, D.J. (1996). Adenosine
triphosphate levels in human plasma. Journal ofRheumatology, 23, 214-9.
Sakane, T. & Suzuki, N. (1998). The role of somatostatin in the pathophysiology of
rheumatoid arthritis. Clinical And Experimental Rheumatology, 16, 745-9.
Sanchez, J.F., Krause, J.E. & Cortright, D.N. (2001). The distribution and regulation
of vanilloid receptor VR1 and VR1 5' splice variant RNA expression in rat.
Neuroscience, 107, 373-81.
Schaible, H.G. & Grubb, B.D. (1993). Afferent and spinal mechanisms of joint pain.
Pain, 55, 5-54.
Schaible, H.G. & Schmidt, R.F. (1983a). Activation of groups III and IV sensory
units in medial articular nerve by local mechanical stimulation of knee joint. J
Neurophysiol, 49, 35-44.
Schaible, H.G. & Schmidt, R.F. (1986). Discharge characteristics of receptors with
fine afferents from normal and inflamed joints: influence of analgesics and
prostaglandins. Agents Actions Suppl, 19, 99-117.
Schaible, H.G. & Schmidt, R.F. (1985). Effects of an experimental arthritis on the
sensory properties of fine articular afferent units. J Neurophysiol, 54, 1109-
22.
Schaible, H.G. & Schmidt, R.F. (1988). Excitation and sensitization of fine articular
afferents from cat's knee joint by prostaglandin E2. JPhysiol, 403, 91-104.
Schaible, H.G. & Schmidt, R.F. (1996). Neurobiology of articular nociceptors. In
Neurobiology ofNociceptors, eds Belmonte, C. & Cervero, F. pp. 202-119.
Oxford: Oxford University Press.
Schaible, H.G. & Schmidt, R.F. (1983b). Responses of fine medial articular nerve
afferents to passive movements of knee joints. JNeurophysiol, 49, 1118-26.
Schepelmann, K., Messlinger, K., Schaible, H.G. & Schmidt, R.F. (1992).
Inflammatory mediators and nociception in the joint: excitation and
sensitization of slowly conducting afferent fibers of cat's knee by
prostaglandin 12. Neuroscience, 50, 237-47.
Schindler, M., Humphrey, P.P. & Emson, P.C. (1996). Somatostatin receptors in the
central nervous system. Prog Neurobiol, 50, 9-47.
Schulz, S., Schreff, M., Schmidt, H., Handel, M., Przewlocki, R. & Hollt, V. (1998).
Immunocytochemical localization of somatostatin receptor sst2A in the rat
spinal cord and dorsal root ganglia. Eur JNeurosci, 10, 3700-8.
Selmer, I., Schindler, M., Allen, J.P., Humphrey, P.P. & Emson, P.C. (2000).
Advances in understanding neuronal somatostatin receptors. Regul Pept, 90,
1-18.
Senaris, R.M., Schindler, M., Humphrey, P.P. & Emson, P.C. (1995). Expression of
somatostatin receptor 3 mRNA in the motorneurones of the rat spinal cord,




Sherrington, C.S. (1906). The Integrative Action of the Nervous System. New York:
Charles Scribner's Sons.
Silveri, F., Morosini, P., Brecciaroli, D. & Cervini, C. (1994). Intra-articular
injection of somatostatin in knee osteoarthritis: clinical results and IGF-1
serum levels. International Journal OfClinical Pharmacology Research, 14,
79-85.
Skoglund, S. (1956). Anatomical and physiological studies of knee joint innervation
in the cat. Acta. Physiol. Scand., 36, 1-101.
Smart, D., Gunthorpe, M.J., Jerman, J.C., Nasir, S., Gray, J., Muir, A.I., Chambers,
J.K., Randall, A.D. & Davis, J.B. (2000). The endogenous lipid anandamide
is a full agonist at the human vanilloid receptor (hVRl). British Journal of
Pharmacology, 129, 227-230.
Smart, D. & Jerman, J.C. (2000). Anandamide: an endogenous activator of the
vanilloid receptor [letter]. Trends in Pharmacological Sciences, 21, 134.
Smith, G.D., Seckl, J.R. & Harmar, A.J. (1993). Distribution of neuropeptides in
dorsal root ganglia of the rat; substance P, somatostatin and calcitonin gene-
related peptide. Neuroscience Letters, 153, 5-8.
Snider, W.D. & McMahon, S.B. (1998). Tackling pain at the source: new ideas about
nociceptors. Neuron, 20, 629-32.
Steranka, L.R., Burch, R.M., Vavrek, R.J., Stewart, J.M. & Enna, S.J. (1988).
Multiple bradykinin receptors: results of studies using a novel class of
receptor antagonists. Adv Exp Med Biol, 236, 111-27.
Stuart, J.M., Townes, A.S. & Kang, A.H. (1984). Collagen autoimmune arthritis.
Annual Review ofImmunology, 2, 199-218.
Stuart, J.M., Townes, A.S. & Kang, A.H. (1985). Type II collagen-induced arthritis.
Annals of the New York Academy ofSciences, 460, 355-62.
Sukharev, S.I., Blount, P., Martinac, B. & Kung, C. (1997). Mechanosensitive
channels of Escherichia coli: the MscL gene, protein, and activities. Annu Rev
Physiol, 59, 633-57.
Szallasi, A. & Blumberg, P.M. (1999). Vanilloid (Capsaicin) receptors and
mechanisms. Pharmacological Reviews, 51, 159-212.
Szolcsanyi, J. (2000a). Anandamide and the question of its functional role for
activation of capsaicin receptors [letter]. Trends in Pharmacological
Sciences, 21, 203-4.
Szolcsanyi, J. (2000b). Are cannabinoids endogenous ligands for the VR1 capsaicin
receptor? Trends in Pharmacological Sciences, 21, 41-2.
Szolcsanyi, J. (1987). Capsaicin and nociception. Acta Physiol Hung, 69, 323-32.
Szolcsanyi, J., Anton, F., Reeh, P.W. & Handwerker, H.O. (1988). Selective
excitation by capsaicin of mechano-heat sensitive nociceptors in rat skin.
Brain Res, 446, 262-8.
Szolcsanyi, J., Helyes, Z., Oroszi, G., Nemeth, J. & Pinter, E. (1998a). Release of
somatostatin and its role in the mediation of the anti-inflammatory effect
induced by antidromic stimulation of sensory fibres of rat sciatic nerve.
British Journal OfPharmacology, 123, 936-42.
Szolcsanyi, J., Pinter, E., Helyes, Z., Oroszi, G. & Nemeth, J. (1998b). Systemic anti¬
inflammatory effect induced by counter-irritation through a local release of




Tavernarakis, N. & Driscoll, M. (1997). Molecular modeling of
mechanotransduction in the nematode Caenorhabditis elegans. Annu Rev
Physiol, 59, 659-89.
ten Bokum, A.M., Melief, M.J., Schonbrunn, A., van der Ham, F., Lindeman, J.,
Hofland, L.J., Lamberts, S.W. & van Hagen, P.M. (1999).
Immunohistochemical localization of somatostatin receptor sst2A in human
rheumatoid synovium. JRheumatol, 26, 532-5.
Than, M., Nemeth, J., Szilvassy, Z., Pinter, E., Helyes, Z. & Szolcsanyi, J. (2000).
Systemic anti-inflammatory effect of somatostatin released from capsaicin-
sensitive vagal and sciatic sensory fibres of the rat and guinea-pig. Eur J
Pharmacol, 399, 251-8.
Torebjork, H.E. & Hallin, R.G. (1974). Identification of afferent C units in intact
human skin nerves. Brain Research, 67, 387-403.
Trentham, D.E., Townes, A.S. & Kang, A.H. (1977). Autoimmunity to type II
collagen an experimental model of arthritis. JExp Med, 146, 857-68.
van de Loo, A.A., Arntz, O.J. & van den Berg, W.B. (1992). Flare-up of
experimental arthritis in mice with murine recombinant IL-1. Clinical and
Experimental Immunology, 87, 196-202.
van de Loo, A.A., van Beuningen, H.M., van Lent, P.L. & van den Berg, W.B.
(1989). Direct effect of murine rIL-1 on cartilage metabolism in vivo. Agents
Actions, 26, 153-5.
van de Putte, L.B., Lens, J.W., van den Berg, W.B. & Kruijsen, M.W. (1983).
Exacerbation of antigen-induced arthritis after challenge with intravenous
antigen. Immunology, 49, 161-7.
van den Berg, W.B. (2001a). Anti-cytokine therapy in chronic destructive arthritis.
Arthritis Res, 3, 18-26.
van den Berg, W.B. (2000a). Arguments for interleukin 1 as a target in chronic
arthritis. Ann Rheum Dis, 59 SuppI 1, i81-4.
van den Berg, W.B. (2001b). Lessons from animal models of osteoarthritis. Curr
Opin Rheumatol, 13, 452-6.
van den Berg, W.B. (2001c). Uncoupling of inflammatory and destructive
mechanisms in arthritis. Semin Arthritis Rheum, 30, 7-16.
van den Berg, W.B. (2000b). What we learn from arthritis models to benefit arthritis
patients. Baillieres Best Pract Res Clin Rheumatol, 14, 599-616.
van den Berg, W.B., Kruijsen, M.W., van de Putte, L.B., van Beusekom, H.J., Sluis,
v.d., van der Pol, M. & Zwarts, W.A. (1981). Antigen-induced and zymosan-
induced arthritis in mice: studies on in vivo cartilage proteoglycan synthesis
and chondrocyte death. British Journal ofExperimental Pathology, 62, 308-
16.
van den Berg, W.B., van Beusekom, H.J., van de Putte, L.B., Zwarts, W.A. & van
der Sluis, M. (1982). Antigen handling in antigen-induced arthritis in mice:
an autoradiographic and immunofluorescence study using whole joint
sections. American Journal ofPathology, 108, 9-16.
van den Berg, W.B., van de Putte, L.B., Zwarts, W.A. & Joosten, L.A. (1984).
Electrical charge of the antigen determines intraarticular antigen handling and
chronicity of arthritis in mice. Journal ofClinical Investigation, 74, 1850-9.
258
References
van den Broek, M.F. (1989). Streptococcal cell wall-induced polyarthritis in the rat.
Mechanisms for chronicity and regulation of susceptibility. Apmis, 97, 861-
78.
van den Broek, M.F., van den Berg, W.B., van de Putte, L.B. & Severijnen, A.J.
(1988). Streptococcal cell wall-induced arthritis and flare-up reaction in mice
induced by homologous or heterologous cell walls. American Journal of
Pathology, 133, 139-49.
van Hagen, P.M., Hofland, L.J., ten Bokum, A.M., Lichtenauer-Kaligis, E.G.,
Kwekkeboom, D.J., Ferone, D. & Lamberts, S.W. (1999). Neuropeptides and
their receptors in the immune system. Ann Med, 31 Suppl 2, 15-22.
van Lent, P.L., van Vuuren, A.J., Blom, A.B., Holthuysen, A.E., van de Putte, L.B.,
van de Winkel, J.G. & van den Berg, W.B. (2000). Role of Fc receptor
gamma chain in inflammation and cartilage damage during experimental
antigen-induced arthritis. Arthritis and Rheumatism, 43, 740-52.
van Meurs, J.B., van Lent, P.L., Flolthuysen, A.E., Singer, I.I., Bayne, E.K. & van
den Berg, W.B. (1999). Kinetics of aggrecanase- and metalloproteinase-
induced neoepitopes in various stages of cartilage destruction in murine
arthritis. Arthritis and Rheumatism, 42, 1128-39.
von Frey, M. (1894). Beitrag zur physiologie des schemerzsinns. Koenigl. Saechs.
Ges. Wiss., Math.-Phys., 46, 185-196.
von Frey, M. (1922). Versuche uber schmerzerregende reize. Z. Biol., 76, 1-24.
Vulchanova, L., Riedl, M.S., Shuster, S.J., Buell, G., Surprenant, A., North, R.A. &
Elde, R. (1997). Immunohistochemical study of the P2X2 and P2X3 receptor
subunits in rat and monkey sensory neurons and their central terminals.
Neuropharmacology, 36, 1229-42.
Walker, J.M., Huang, S.M., Strangman, N.M., Tsou, K. & Sanudo_Pena, M.C.
(1999). Pain modulation by release of the endogenous cannabinoid
anandamide. Proceedings of the National Academy ofSciences of the United
States ofAmerica, 96, 12198-203.
Wall, P.D. & Melzack, R. (1999). Textbook of Pain. London: Churchill Livingston.
Weinstock, J.V. & Elliott, D. (1998). The substance P and somatostatin interferon-
gamma immunoregulatory circuit. Annals Of The New York Academy Of
Sciences, 840, 532-9.
Whalley, E.T., Clegg, S., Stewart, J.M. & Vavrek, R.J. (1987). The effect of kinin
agonists and antagonists on the pain response of the human blister base.
Naunyn Schmiedebergs Arch Pharmacol, 336, 652-5.
Wiesenfeld-Hallin, Z. (1985). Intrathecal somatostatin modulates spinal sensory and
reflex mechanisms: behavioral and electrophysiological studies in the rat.
Neurosci Lett, 62, 69-74.
Williams, J.M., Zurawski, J., Mikecz, K. & Giant, T.T. (1993). Functional
assessment of joint use in experimental inflammatory murine arthritis.
Journal OfOrthopaedic Research, 11, 172-80.
Wilson, S.G. & Mogil, J.S. (2001). Measuring pain in the (knockout) mouse: big
challenges in a small mammal. Behav Brain Res, 125, 65-73.
Wojtys, E.M., Beaman, D.N., Glover, R.A. & Janda, D. (1990). Innervation of the
human knee joint by substance-P fibers. Arthroscopy, 6, 254-63.
259
References
Wood, J.N., Winter, J., James, I.F., Rang, H.P., Yeats, J. & Bevan, S. (1988).
Capsaicin-induced ion fluxes in dorsal root ganglion cells in culture. J
Neurosci, 8, 3208-20.
Wooley, P.H., Luthra, H.S., Stuart, J.M. & David, C.S. (1981). Type II collagen-
induced arthritis in mice. I. Major histocompatibility complex (I region)
linkage and antibody correlates. Journal ofExperimental Medicine, 154, 688-
700.
Wotherspoon, G. & Winter, J. (2000). Bradykinin B1 receptor is constitutively
expressed in the rat sensory nervous system. Neurosci Lett, 294, 175-8.
Xu, G.Y. & Huang, L.Y. (2002). Peripheral inflammation sensitizes P2X receptor-
mediated responses in rat dorsal root ganglion neurons. J Neurosci, 22, 93-
102.
Zhou, X.F., Chie, E.T., Deng, Y.S., Zhong, J.H., Xue, Q., Rush, R.A. & Xian, C.J.
(1999). Injured primary sensory neurons switch phenotype for brain-derived
neurotrophic factor in the rat. Neuroscience, 92, 841-53.
Zimmer, A., Zimmer, A.M., Hohmann, A.G., Herkenham, M. & Bonner, T.I. (1999).
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1
receptor knockout mice. Proc NatlAcad Sci USA, 96, 5780-5.
Zotterman, Y. (1933). Studies in the peripheral nervous mechanism of pain. Acta
Medica Scandinavica, 80, 185-242.
Zygmunt, P.M., Julius, I., Di Marzo, I. & Hogestatt, E.D. (2000). Anandamide - the
other side of the coin. Trends in Pharmacological Sciences, 21, 43-4.
Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H., Sorgard, M., Di Marzo,
V., Julius, D. & Hogestatt, E.D. (1999). Vanilloid receptors on sensory nerves
mediate the vasodilator action of anandamide. Nature, 400, 452-7.
260
Index ofFigures and Tables
Index of Figures and Tables
261
Index of Figures and Tables
Figure 2.1 - Experimental set-up for neuronal recording from rat MAN 56
Figure 2.2 - Schematic of signal processing of neural recording 1
Figure 3.1 - Proportion of afferent nerves showing spontaneous firing in recordings
from normal and arthritic rat knee joints 77
Figure 3.2 - Basal spontaneous activity in fibres of the MAN in normal and arthritic
rat knee joints 78
Figure 3.3 - Typical responses evoked by capsaicin, bradykinin and ATP in a multi-
unit recording from the MAN in a normal rat knee joint 79
Figure 4.1 - Structure of somatostatin and synthetic analog octreotide 85
Figure 4.2 - Effect of octreotide on spontaneous discharge in afferents innervating
normal and arthritic rat knee joints 98
Figure 4.3 - Evoked responses to capsaicin, bradykinin, and aPmeATP following
octreotide in normal rat knee joints 99
Figure 4.4 - Blood pressure response evoked by octreotide and somatostatin-14 in a
normal rat 100
Table 5.1 - Effect of anandamide on evoked excitation from nociceptive afferents by
ATP, bradykinin and capsaicin 116
Table 5.2 - Responses evoked by bradykinin and aPmeATP before and after
capsazepine 117
Figure 5.1 - Anandamide excites a population of sensory afferents in the normal rat
knee joint 118
Figure 5.2 - Proportion of C and AS fibres activated by anandamide 119
Figure 5.3 - Anandamide activates sensory afferents in a dose- dependent mannerl20
Figure 5.4 - Excitatory effects of anandamide on afferent discharge recorded from
normal and arthritic knee joints 121
Figure 5.5 - Comparison of the excitatory response recorded from nociceptive
afferents in normal and arthritic rat knee joints following injection of
anandamide 122
Figure 5.6 - Comparison of the excitation evoked by capsaicin and anandamide from
articular nociceptive afferents innervating normal rat knee joints 123
Figure 5.7 - Effect of capsazepine on afferent discharge evoked by capsaicin and
anandamide from nociceptive afferents innervating a normal rat knee joint... 124
262
Index of Figures and Tables
Table 6.2 - Explanation of pain scores for hyperalgesia from a joint squeeze 182
Figure 6.1 - Schematic of the experimental set up for recording from saphenous nerve
in mice 183
Figure 6.2 - Effect on joint diameter of a single sub-cutaneous injection of FCA in the
ankle ofDBA1 mice 184
Figure 6.3 - Effect on joint diameter of a single sub-cutaneous injection of FCA (or a
single plus a booster injection) in the knee of DBA/1 mice 185
Figure 6.4 - Effect on knee diameter of mBSA-induced inflammation in the knee of
C57BL6 mice 186
Figure 6.6 - Effect on joint diameter of repeated i.art. injections of FCA into the knee
of DBA/1 mice 188
Figure 6.7 - Schematic of inflammatory response to repeated intra-articular injections
of FCA 189
Figure 6.8 - Effect of repeated injections of FCA on body weight in DBA/1 mice 190
Figure 6.9 - Effect of repeated injections of FCA on mobility in DBA/1 mice 191
Figure 6.10 - Effect of FCA on pain evoked by noxious pressure applied to the knee
joint in DBA/1 mice 191
Figure 6.10 - Effect of FCA on pain evoked by noxious pressure applied to the knee
joint in DBA/1 mice 192
Figure 6.11 - Histopathology of DBA/1 mice receiving repeated intra-articular
injections ofFCA 193
Figure 6.12 - Histopathology of DBA/1 mice receiving repeated intra-articular
injections of FCA 194
Figure 6.13 - Effect on joint diameter of repeated injections of FCA in the knee of
C57BL6 mice 195
Figure 6.14 - Effect of repeated injections of FCA on body weight in C57BL6 mice
196
Figure 6.15 - Effect of repeated injections ofFCA on mobility in C57BL6 mice... 197
Figure 6.16 - Effect of FCA on pain evoked by noxious pressure applied to the knee
joint in C57BL6 mice 198
Figure 6.17 - Histopathology of DBA/1 mice receiving repeated intra-articular
injections ofFCA 199
Figure 6.18 - Histopathology of C57BL6 mice receiving repeated intra-articular
injections of FCA 200
263
Index of Figures and Tables
Figure 6.19 - Comparison of knee diameter during FCA-induced unilateral arthritis in
DBA/1 and C57BL6 mice 201
Figure 6.20 - Comparison of mobility during FCA-induced unilateral arthritis in
DBA/1 and C57BL6 mice 202
Figure 6.21 - Comparison of pain evoked by noxious pressure applied to the knee
joint in DBA/1 and C57BL6 mice 203
Figure 6.22 - Comparison of histological scores in DBA/1 and C57BL6 mice
receiving repeated intra-articular injections ofFCA 204
Figure 6.23 - Effect of prednisolone on knee diameter during established FCA
induced unilateral arthritis in DBA/1 mice 205
Figure 6.24 - Effect of prednisolone on body weight during established FCA-induced
unilateral arthritis in DBA/1 mice 206
Figure 6.25 - Effect of prednisolone on the mobility during established FCA-induced
unilateral arthritis in DBA/1 mice 207
Figure 6.26 - Effect of prednisolone on pain evoked by noxious pressure during
established FCA-induced unilateral arthritis in DBA/1 mice 207
Figure 6.26 - Effect of prednisolone on pain evoked by noxious pressure during
established FCA-induced unilateral arthritis in DBA/1 mice 208
Figure 6.27 - Effect of prednisolone on inflammation and joint destruction during
established FCA-induced unilateral arthritis in DBA/1 mice 209
Figure 6.28 - Effect of prednisolone on the histological score during established
FCA-induced unilateral arthritis in DBA/1 mice 210
Figure 6.29 - Effect of indomethacin on knee diameter during established FCA-
induced unilateral arthritis in C57BL6 mice 211
Figure 6.30 - Effect of indomethacin on body weight during established FCA-induced
unilateral arthritis in C57BL6 mice 212
Figure 6.31 - Effect of indomethacin on mobility during established FCA-induced
unilateral arthritis in C57BL6 mice 213
Figure 6.32 - Effect of indomethacin on pain evoked by noxious pressure during
established FCA-induced unilateral arthritis in C57BL6 mice 213
Figure 6.32 - Effect of indomethacin on pain evoked by noxious pressure during
established FCA-induced unilateral arthritis in C57BL6 mice 214
Figure 6.33 - Effect of indomethacin on inflammation and joint destruction in
established FCA-induced unilateral arthritis in C57BL6 mice 215
264
Index ofFigures and Tables
Figure 6.34 - Effect of indomethacin on the histological score in established FCA-
induced unilateral arthritis in C57BL6 mice 216
Figure 6.35 - Effect of FCA-induced unilateral arthritis on knee diameter in P2X7
knock out mice 217
Figure 6.36 - Effect of FCA on body weight in P2X7 KO and WT mice 218
Figure 6.37 - Effect of repeated injections of FCA on mobility in P2X7 KO and WT
mice 219
Figure 6.38 - Effect of repeated injections of FCA on pain evoked by noxious
pressure in P2X7 KO and WT mice 220
Figure 6.39 - Effect of FCA on the histological score in P2X7 KO and WT mice..221
Figure 6.40 - Activation of C-fibre polymodal nociceptors in the C57BL6 mouse
knee joint 222
Figure 6.41 - Capsaicin activates sensory afferents innervating the C57BL6 mouse
knee joint in a dose- dependent manner 223
Figure 6.42 - Bradykinin activates sensory afferents innervating the C57BL6 mouse
knee joint in a dose- dependent manner 224
Figure 6.43 - Typical responses to capsaicin and bradykinin in afferents of the MAN
in the C57BL6 mouse knee joint 225
Figure 6.44 - Comparison of the excitation of mouse knee joint afferents evoked by
capsaicin and bradykinin 226
265
Appendix I - Drugs and Solutions
Appendix I - Drugs and Solutions
266
Appendix I - Drugs and Solutions
Drugs used in this study






disodium salt 551.1 Sigma PBS
aPmeATP
a,P-methylene adenosine

























Sigma 10% ethanol, PBS
Octreotide
D-Phe-c[Cys-Phe-D-Trp-







Saline: 0.9 g NaCl in 100 ml distilled water
Phosphate Buffered Saline:
(PBS)
40.5 ml 0.2M Na2HP04.12H20 in saline
9.5 ml 0.2M Na2H2P04.2H20 in saline
50 ml saline
10% Formalin: 10 ml 40% formaldehyde (w/v)
0.9 g NaCl
90 ml distilled water
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SPECIAL REPORT
Anandamide activates peripheral nociceptors in normal and
arthritic rat knee joints
* 'S.D. Gauldie, 'D.S. McQueen, 2R. Pertwee & 3-4I.P. Chessell
'Sensory Pharmacology Unit, Department of Neuroscience, University of Edinburgh, Edinburgh, EH8 9JZ; :Department of
Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen AD25 2ZD and 'Department of
Pharmacology, Glaxo Institute of Applied Pharmacology, University of Cambridge, Cambridge, CB2 1QJ
The effects of the endogenous cannabinoid anandamide were studied on peripheral, polymodal
nociceptors recorded from normal and chronically inflamed (Freund's adjuvant) knee joint afferents
in rats anaesthetized with pentobarbitone. Anandamide (860 nmol) caused a rapid, short lasting
excitation of a sub-population of capsaicin-sensitive nociceptive afferents in normal knee joints
(7.2 + 2.3 impulses s_l; «= 15 units from five animals). In arthritic joints there were 9.7 + 3.0
impulses s_l (n= II from six animals), which was not significantly different from normal joints. The
excitation was dose dependent (8.6-2900 nmol) and mediated by activation of the vanilloid receptor
(VR|) as it was abolished by the VR1 antagonist capsazepine (1 mg kg '). Our results show that
anandamide, at high doses, can activate nociceptive afferents innervating the rat knee joints, in
contrast with its widely described analgesic actions.
British Journal of Pharmacology (2001) 132, 617-621
Keywords: Sensory nerves; anandamide; adjuvant arthritis; knee joint; afferent nociceptors; vanilloid receptor
Abbreviations: a/frneATP, a,/?-methyleneadenosine 5'-triphosphate; anandamide, arachidonylethanolamide; ATP, adenosine
triphosphate; capsaicin, 8-methyl-N-vanillyl-6-nonenamide; CGRP, calcitonin-gene-related peptide; PBS,
phosphate buffered saline; VR1, vanilloid receptor
Introduction Following the discovery of anandamide as an
endogenous ligand for the CB (cannabinoid) receptor, there
has been intense interest in its physiological function. An
important putative role for anandamide is as a modulator of
nociception, in part involving activation of the CB, receptors
on sensory neurones and the subsequent inhibition of the
release of CGRP (Richardson et al., 1998). Reports have also
linked anandamide with the recently cloned vanilloid receptor
subtype 1 (VR,) which is sensitive to capsaicin (Caterina et
al., 1997). The action of anandamide on the VR, receptor has
been demonstrated using transfected human receptors (Smart
et al., 2000), on sensory nerves controlling vasodilatation in
isolated arteries (Zygmunt et al., 1999), and the amplitude of
electrically-evoked contractions in the mouse isolated vas
deferens (Ross et al., 2001). The VR, agonist capsaicin is a
potent activator of C-fibre polymodal nociceptors in the
periphery. In view of the reported actions of anandamide,
and its structural relationship to capsaicin and other vanilloid
agonists, we hypothesized that anandamide can directly
activate capsaicin nociceptors and have investigated those
innervating the rat knee joint. Using a unilateral adjuvant-
induced arthritis model in the rat (Dowd et al., 1998) we have
also investigated the effects of anandamide to determine
whether the responsiveness of these joint nociceptors was
altered during experimental inflammation.
Methods Experiments were performed on five normal and
six arthritic male Wistar rats (body weight range 280-470 g;
mean ±s.e.mean 374+19 g).
Induction of arthritis Freund's Complete Adjuvant (FCA,
0.15-0.20 ml of I mg ml-1 heat killed Mycobacterium
tuberculosis in paraffin oil, Sigma) was introduced into the
left knee (stifle) joint by intra-articular injection under
transient halothane anaesthesia (3% in oxygen). The
animals were used for electrophysiological recording 14-35
days post-injection. Animals displayed mild but persistent
unilateral arthritis as characterized by a significant increase in
the diameter of the injected joint (injected 10.6 + 0.1 mm;
uninjected 9.8 + 0.1 mm; n = 6, /><0.05, Wilcoxon).
Surgical procedures Animals were anaesthetized with an
intra-peritoneal (i.p.) injection of pentobarbitone
(60 mg kg ') and the trachea was cannulated. Anaesthesia
was maintained with an intravenous (i.v.) infusion of
pentobarbitone (0.4-0.5 mg kg"1 min~') via a cannula
inserted in the right femoral vein and the right carotid
artery was cannulated for monitoring blood pressure. An
additional catheter was inserted into the right femoral artery
with its tip positioned in the lower abdominal aorta to allow
for close arterial injection of drugs to the left knee joint.
Animals were killed at the end of the experiment by an
overdose of anaesthetic.
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4Current address: Neurology and Rheumatology Systems. Glaxo-
1
Wellcome, Gunnels Wood Road, Stevenage, Herts SGI 2NY
Electrophysiology Extracellular recordings were performed
on filaments of the medial articular nerve (MAN) innervating
the left knee joint using previously described techniques
(Dowd et al., 1998). Briefly, the left leg was fixed to a support
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and an incision was made on the medial aspect of the limb
and the skin secured to form a pouch that was filled with
heavy liquid paraffin. Three branches of the medial articular
nerve (MAN) were exposed at the point where they leave the
saphenous nerve. The saphenous nerve was cut centrally to
prevent interference from efferent activity. One branch of the
MAN was dissected from surrounding tissue and electrical
activity was recorded from filaments, typically containing 1 -4
afferent fibres, using a Pt-Ir bipolar electrode connected to an
amplifier. Neural activity was viewed on an oscilloscope,
digitally recorded and analysed using a personal computer
running Spike 2 software (CED, Cambridge). Drugs were
administered by close intra-arterial injection (total volume:
0.1 ml drug+ 0.2 ml wash), completed within 2 s. The
minimum time interval between injections was 20 min to
minimize the possibility of desensitization.
Data analysis Drug effects were determined by comparing
the action potential discharge frequency or the absolute
number of events immediately following injection with that in
the 15 s period immediately prior to injection. Data are
expressed as either the mean change in action potential
frequency (impulses s^1) or the change in the absolute
number of action potentials evoked during the response
(impulses). The maximum possible dose for anandamide was
2900 nmol, the concentration of the stock solution.
Differences between means were analysed statistically using
the Mann-Whitney test for unpaired data and the Wilcoxon
matched-pairs test for paired data. The null-hypothesis was
rejected at T<0.05.
Drugs Anandamide and capsazepine were purchased from
Tocris (U.K.) and capsaicin, bradykinin, adenosine 5'-
triphosphate (ATP) and a,/l-methyleneadenosine 5'-
triphosphate (a/fmeATP) were purchased from Sigma
(U.K.). Capsaicin was dissolved in Tween 80 (10% v v-1),
ethanol (10% vv-1) and PBS. Capsazepine stock
(10 mg ml"') was dissolved in 20% cremophor EL (Sigma,
U.K.) in distilled water. All drugs were diluted in PBS for
injection.
Results In normal animals (n = 5) recordings were made
from five afferent fibres consisting of 15 units with receptive
fields in the knee joint. These units were identified as either
C-fibre polymodal nociceptors (14/15, 93%) or A<5-mechan-
onociceptors (1/15, 7%) according to their conduction
velocities, mechanosensitivity, and their response to capsaicin
(9 nmol, 18.2 + 5.4 impulses s_l). Basal discharge from these
afferents was 0.01 ±0.01 impulses s '. Recordings were also
made in arthritic animals (n = 6) from a total of six
mechanosensitive afferents consisting of 11 units, all of which
were C-fibre polymodal nociceptors and responded to
capsaicin (9 nmol i.a.: 11.6±2.0 impulses s"1). Basal dis¬
charge was 0.04 + 0.02 impulses s_1 which was not signifi¬
cantly different (P>0.05, Mann-Whitney) from the
untreated group.
Responses to anandamide in normal and arthritic knee
joints Anandamide (8.6-2900 nmol) evoked an increase in
afferent discharge in 64% (9/14) of C-fibre polymodal
nociceptors but not in the single Ac5-mechanonociceptor
recorded from normal knee joints. In arthritic joints
anandamide (8.6-2900 nmol) evoked a response in 72%
(8/11) of C-fibre polymodal nociceptors. Injection of vehicle
had no effect in these fibres (soya oil: water (1:4), —0.1+0.1
impulses s_l, n = 5).
The excitation evoked by anandamide in the sensory fibres
was dose dependent (Figure 1) and there was no shift in the
dose-response curve when comparing normal with arthritic
joints. It was not possible to determine a maximum response,
as the amount that could be administered was limited by the
solubility of anandamide. Figure 2 shows a typical response
to anandamide (860 nmol) recorded from normal and
arthritic knee joints. In normal joints the response to this
dose was rapid in onset (4.5 + 0.5 s) and of short duration
(4.8 + 1.0 s) and caused an average change in the discharge
frequency of 7.2 + 2.3 impulses s"' (w = 15 units from five
animals). A similar response was obtained from arthritic
joints with a response latency of 5.2 + 0.4 s, response duration
of 3.9 ± 1.1 s and a change in the discharge frequency of
9.7 + 3.0 impulses s_l (;;=11 units from six animals). Figure
3 shows there was no significant difference in the responses
when comparing normal and arthritic joints (P>0.05,
Mann-Whitney).
Other algogens that are capable of activating polymodal
nociceptors were also examined to ascertain whether or not
they were affected by the administration of anandamide
(860-2900 nmol). In normal joints the response to bradyki¬
nin (9 nmol) was 1.7 + 0.7 impulses s_l and after anandamide
it was not significantly different (P>0.05, Mann-Whitney)
with a response of 1.3 + 0.6 impulses s"1 (n = 8 units from two
animals). The response to ATP (2000 nmol) was unchanged
after the administration of anandamide (P>0.05, Mann-
Whitney) with a response of 14.8 + 6.0 impulses s_1 prior to
anandamide and 11.2 + 4.7 impulses s"1 following (» = 5 units
from two animals). In arthritic joints after anandamide, there
was no significant difference (P>0.05, Mann-Whitney) in
the response to bradykinin (9 nmol) or ATP (2000 nmol)
with responses of 2.2 + 0.6 impulses s~' and 1.3±0.5
impulses s~' (n = 6 units from three animals) before and after
bradykinin respectively and 2.3+1.5 impulses s~" and
6.5 + 2.5 impulses s_l (n = 4 units from three animals) before
and after ATP respectively.
The response to capsaicin (9 nmol) was also examined
before and after anandamide. In normal joints, the afferent
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Figure 1 Dose-related increase in absolute discharge (impulses)
evoked by close arterial injection of anandamide in a single C-fibre
polymodal nociceptor innervating both a normal and an arthritic
knee joint.
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Figure 2 Spike 2 traces showing the evoked discharge from an afferent fibre of the medial articular nerve innervating the (A)
normal and (B) arthritic rat knee joint evoked by close arterial injection of anandamide (860 nmol; arrow). The upper panel shows
the blood pressure and the lower panel is a bar graph representing the pooled discharge of the individual units recorded from the
afferent fibre. Pooled data are shown because the responses evoked are similar in all units. Discharge is displayed in 1 s bins. The
panels on the right show an overlay of the individual units (2) present in the pooled discharge.
impulses s~' after anandamide and this difference was not
found to be significant (P> 0.05, Wilcoxon, n=12 from four
animals). Similarly, no difference was seen in the arthritic
joints (P>0.05, Wilcoxon) with responses of 11.6±2.0
impulses s~' before and 8.1 ±2.2 impulses s_1 after ananda¬
mide (« = 11 from six animals).
Response to anandamide is abolished by VR1 antagonist
capsazepine In order to confirm the algogenic effects of
anandamide were attributable to activation of VRj receptors
the effects of both capsaicin (9 nmol) and anandamide
(2900 nmol) were examined in the presence of the VR1
antagonist capsazepine (1 mg kg '). In a normal rat knee
joint, capsazepine completely abolished the afferent response
to both capsaicin and anandamide (Figure 4). The effect was
short lasting and the response to both drugs recovered after
20 min. Furthermore the effect was specific to capsaicin and
anandamide, as responses to both bradykinin (9 nmol) and
a/fmeATP (60 nmol) were not altered by capsazepine (data
not shown).
Discussion The primary finding from this in vivo study is
that anandamide causes a rapid short-lasting excitation in a
sub-population of peripheral, polymodal nociceptors in
normal and arthritic rat knee joints in a dose dependent
manner, producing a rapid, short-lasting excitation.
Anandamide is an agonist at CB, and CB2 receptors; both
these receptors are present in the periphery, with CB|
I
receptors localized to the sensory nerves and the CB2
receptors expressed on immune cells such as B-cells and
natural killer cells. The ability of anandamide to activate
nociceptors seems inconsistent with previously reported anti¬
nociceptive actions of the CB[ receptor. Cannabinoids act
on the CB, receptor both centrally, in the brain and spinal
cord, and peripherally in the dorsal root ganglion to
produce their analgesia (reviewed in Walker et al., 1999
and Fuentes et al., 1999). However, our studies focus in
particular on the role of anandamide acting directly on
peripheral nerve terminals located in an articular joint and
its ability to initiate a nociceptive response. Analgesic effects
of the CB| receptor appear to result from relatively low
doses of cannabinoids, and the high doses of anandamide
required to activate peripheral nociceptors in our study are
likely to result from actions on a different pharmacological
receptor.
The rapid onset of the response to anandamide eliminates
a number of potential indirect mechanisms, such as activation
of the CB2 receptor on immune cells triggering the release of
algogenic mediators. Furthermore, even allowing for the
rapid metabolism of anandamide to arachadonic acid and
subsequent eicosanoids, the latency of onset of the response is
too short to be the result of a metabolite. The rapid response
is not characteristic of G-protein coupled receptor activation,
rather it is more representative of the response of a ligand
gated ion-channel such as the VR, receptor channel (Szallasi
& Blumberg, 1999).
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Figure 4 Afferent discharge from a single C-fibre evoked by (A)
capsaicin (9 nrnol) on (B) anandamide (2900 nmol) innervating a
normal knee joint before and after the bolus injection of capsazepine
1 mg kg-1. Capsaicin is administered at the arrows and capsazepine











Figure 3 Comparison of the (A) increase in nociceptive discharge,
(B) latency to onset, (C) duration of the response following a close
arterial injection of anandamide (860 nmol). Data shown is for
normal (15 units from five animals) and chronically arthritic (n= 11
units from six animals) joints. There is no significant difference in any
facet of the response between normal and arthritic joints (P>0.05,
Mann - Whitney).
Anandamide is a full agonist at the human VR, receptor
when expressed in HEK293 cells (Smart et al., 2000), and the
vasodilatory action of anandamide is a result of VR,
mediated release of CGRP (Zygmunt et al., 1999). The
afferents activated by anandamide were all sensitive to
capsaicin, however the corollary was untrue with 64 and
72% of capsaicin sensitive afferents being activated by
anandamide in normal arthritic joints respectively. The VR|
receptor is expressed on approximately 88% of small to
medium neurones in the dorsal root ganglion (Michael &
Priestley, 1999). These are the cell bodies for thinly
myelinated (A<5) or unmyelinated (C) fibres running from
the periphery. Although the VR| receptor is not present on
all sensory afferents our study did not demonstrate any
afferents that were sensitive to anandamide without showing
sensitivity to capsaicin. Furthermore, we have shown that
direct activation of capsaicin sensitive sensory nerves in vivo
by anandamide can be abolished by the VRj antagonist
capsazepine (1 mg kg '). Therefore, the activation of periph¬
eral nociceptors by high doses of anandamide appears to
involve a VR,-dependent mechanism. In addition, it can be
concluded that if cannabinoid receptors are present on
peripheral terminals they are not excitatory.
Capsaicin, even in small doses, causes desensitization of the
VR| receptor in our preparation. However, anandamide at
the doses tested did not produce desensitization either to
capsaicin or itself. Further experiments are required to
examine the afferent response to anandamide after a
desensitizing dose of capsaicin (>86 nmol).
As stated earlier, low doses of cannabinoids can produce
anti-hyperalgesia and anti-nociception when acting both
centrally and peripherally. We examined the effect of the
highest dose of anandamide on responses evoked by other
algogens commonly used to characterize primary nociceptive
afferents. Responses to three algogens (capsaicin, bradykinin,
and ATP) were not significantly different after anandamide
(860, 2900 nmol). Therefore anandamide did not reduce the
chemosensitivity of primary sensory afferents. More detailed
experiments are required to determine whether the high
threshold mechanosensitivity or thermosensitivity of these
afferents is affected by high doses of anandamide.
There has been recent debate in the literature that the
concentrations of anandamide required to activate VR, are
not physiologically relevant (Smart & Jerman, 2000;
Szolcsanyi, 2000a,b; Zygmunt et al., 2000). It is still not
clear at what concentration anandamide might be present at
peripheral nerve terminals, and it is possible that levels of
locally produced ligand are sufficient for activation of nearby
sensory nerve terminals. Similarly, it may be that there is an
unknown endogenous compound similar to anandamide in
structure with a higher affinity for the VR! receptor.
Regardless of whether the ability of anandamide to activate
the vanilloid receptor has any physiological significance, it
does have pharmacological relevance with regard both to the
pharmacological profile of anandamide and to the develop¬
ment of novel vanilloid receptor ligands.
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